MXPA06009290A

MXPA06009290A - Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein

Info

Publication number: MXPA06009290A
Application number: MXPA/A/2006/009290A
Authority: MX
Inventors: Honda Takahiro; Tajima Hisashi; Kawashima Kenji; Okamoto Kazuyoshi; Yamamoto Minoru; Inaba Takaaki; Takeno Yuriko
Original assignee: Santen Pharmaceutical Co Ltd
Priority date: 2004-02-17
Filing date: 2006-08-16
Publication date: 2006-12-13

Abstract

A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt of the compound. They are useful as a medicine. The cyclic compound is a compound represented by the following formula [I], which is useful for the treatment of diseases in which angiogenesis participates. In the following formula [I], ringA represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring;B represents alkylene;R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.;R3 and R4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.;R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.;X and Y each represents H, etc.;Z represents -CO-, -COO-, -CONR6-, -SO2-, etc.;R6 represents H, etc.;p is 0, 1, or 2;and q is 0 or 1.

Description

COMPOSITION CYCLIC NOVEDOSO THAT HAS A GROUP 4- PIRIDILALQUILTIO THAT HAS A A INO (NOT) SUBSTITUTED INTO THE SAME TECHNICAL FIELD The present invention relates to a novel cyclic compound having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced therein or a salt thereof, which is useful as a pharmaceutical substance. Said compound is useful as a therapeutic agent for a disease in which vascular angiogenesis or hyperpermeability is involved, particularly as a therapeutic agent for cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, premature retinopathy, occlusion of the retinal vein, polypoid choroidal angiopathy, diabetic macular edema, vulgar psoriasis, atherosclerosis or similar.

JANUARY OF THE TECHNIQUE Angiogenesis is a phenomenon in which a new vascular network is formed from an existing blood vessel and is observed mainly in a microvaso. Angiogenesis is originally a physiological phenomenon and is essential for the formation of blood vessels in embryogenesis, but it is usually observed only at a limited site such as the endometrium or the follicle or in a limited period, for example in a healing process. wounds in adults. However, pathological angiogenesis is observed in a disease such as cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, polypoid choroidal angiopathy, diabetic macular degeneration, psoriasis vulgaris and atherosclerosis and it is closely related to the paternal progress of these diseases. It is considered that angiogenesis or vascular hyperpermeability is regulated by an equilibrium between its promoter factor and an inhibiting factor, and angiogenesis or vascular hyperpermeability is caused by impaired balance (Molecular Medicine vol.35, special issue, "Molecular Mechanism of Symptoms and Pathologic conditions ", Nakayama Shoten, 73-74 (1988) and Protein, Nucleic Acid, Enzyme, extra number, "The Most Advanced Development of New Drugs", Kyoritsu Shuppan, 1182-1187 (2000)). A vascular endothelial growth factor (hereinafter abbreviated as "VEGF") is a factor which acts specifically on a receptor (Flt-1, KDR / Plk-1 or the like) present on the surface of vascular endothelial cells, and This way the proliferation and migration of vascular endothelial cells, the construction of a network of capillaries due to vaasculogénesi. VEGF plays a very important role in the presentation of vascular angiogenesis and hyperpermeability. Consequently, there have been many reports of attempts to treat a disease in which the angiogenesis of vascular hyperpermeability is involved by inhibiting VEGF to control angiogenesis and vascular hyperpermeability. Examples of medicaments to be used for the treatment include 2-indolinone derivatives (WO 98/50356), phthalazine derivatives (WO 98/35958), quinazoline derivatives (WO 97/30035), anthranilamide derivatives ( WO 00/27819), 2-aminonicotinic acid derivatives (WO 01/55114) and the like. However, there is no disclosure of cyclic compounds having a 4-pyridylalkylthio group in these patent documents. Still less, there is no description of compounds having a substituted or unsubstituted amino group introduced into the pyridine ring of a 4-pyridylalkylthio group. On the other hand, II Farmaco-Ed. Se, 18, 288 (1963) and WO 02/066470 reported compounds having relatively close chemical structures with those of the cyclic compounds having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced therein. The compound described in II Farmaco-Ed. Se, 18, 288 (1963) is an acid amide derivative benzoic having a 3-pyridylalkylthio group and an antibacterial action is mentioned in its use. WO 02/0066470 relates to substituted alkylamine derivatives and their pharmaceutical use and describes compounds that have enormous combinations of chemical structures. WO 02/066470 only describes a derivative having a 4-pyridylalkylamino group as an example among those compounds and does not disclose a cyclic compound having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced therein., in any way.

DESCRIPTION OF THE INVENTION It is a very interesting subject to study the synthesis of novel cyclic compounds having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced therein and to find a pharmacological action of the compounds. The present inventors have studied the synthesis of novel cyclic compounds having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced therein and have been successful in producing numerous novel compounds.

In addition, they studied the pharmacological actions of these compounds extensively and found that the compounds have an inhibitory effect on cell proliferation, an inhibitory effect of tumor growth, an inhibitory effect of edema on the paw's plant and / or an inhibitory effect of Choroidal neovascularization and are useful as a therapeutic agent for a disease in which angiogenesis or vascular hyperpermeability is involved, particularly as a therapeutic agent for cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, premature retinopathy, occlusion of the retinal vein, polypoid choroidal angiopathy, diabetic macular edema, vulgar psoriasis, atherosclerosis or the like, and in this manner carried out the present invention. The present invention provides a novel cyclic compound having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced therein, or a salt thereof which is useful as a pharmaceutical substance. The novel cyclic compound according to the present invention has an excellent inhibitory effect on cell proliferation, an inhibitory effect of tumor growth, an inhibitory effect of edema in the paw plant or an inhibitory effect of choroidal neovascularization, and is useful as a therapeutic agent for a disease in which angiogenesis or vascular hyperpermeability is involved, for example cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, prematurity retinopathy, retinal vein occlusion, polypoid choroidal angiopathy , diabetic macular edema, vulgar psoriasis, atherosclerosis or similar. The present invention relates to a compound represented by the general formula (I) or a salt thereof (hereinafter referred to as "the compound of the present invention" unless otherwise specified) and a pharmaceutical composition containing The compound of the present invention The compound of the present invention has a chemical structural feature in which a substituted or unsubstituted amino group has been introduced into the pyridine ring portion of the 4-pyridylalkylthio group. of the present invention in more detail, relates to a therapeutic agent containing the compound of the present invention as an active ingredient for a disease in which angiogenesis or vascular hyperpermeability is involved, for example, it is related to a therapeutic agent for cancer, rheumatoid arthritis, age-related macular degeneration, ret Diabetic inopathy, retinopathy of prematurity, occlusion of the retinal vein, polypoid choroidal angiopathy, diabetic macular edema, vulgar psoriasis, atherosclerosis or similar.

(In the formula, ring A represents a benzene ring or an aromatic five-membered heterocyclic ring or an aromatic six-membered heterocyclic ring which may be fused to a cycloalkane ring; R1 and R2, which are the same or different, represent a hydrogen atom, a hydroxy group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, an amino group, a substituted or unsubstituted alkylamino group, a substituted or unsubstituted arylamino group or a substituted or unsubstituted acyl group; R1 and R2 can be joined to form a substituted or unsubstituted heterocyclic ring; R3 and R4, which are the same or different, represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a hydrocarbonyl group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted arylcarbonyl group or Z-R5, - R3 and R4 together may form a substituted or unsubstituted heterocyclic ring; Z represents CO, CS, COB20, CSB20, CONBR6, CSBNR6, CONB2R6S02, CSB2NReS02 or S02; R5 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a heterocyclic ring substituted or unsubstituted, a carboxy group or an ester thereof or an amide thereof, a hydrocarbonyl group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted arylcarbonyl group, or a substituted or unsubstituted heterocyclic carbonyl group; Rs and Re together can form a substituted or unsubstituted heterocyclic ring; R6 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; X and Y, which are the same or different, represent one or a plurality of groups which are selected from a hydrogen atom, a halogen atom, a hydroxy group, a substituted or unsubstituted alkoxy group, a substituted aryloxy group or substituted, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylamino group, a substituted or unsubstituted arylamino group, a mercapto group, a substituted alkylthio group or unsubstituted, a substituted or unsubstituted arylthio group, a carboxy group or an ester thereof, or an amide thereof, a cyano group and a nitro group; B1 represents an alkylene group; B2 represents a single bond or an alkylene group; p represents 0, 1 or 2; and q represents 0 or 1. The same definitions apply in the following). The respective atoms, rings or groups defined in the above are defined to have the following meanings in this specification. The term "cycloalkane ring" refers to a cycloalkane ring having 3 to 8 carbon atoms. Specific examples thereof include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a. cycloheptane ring, a cyclooctane ring and the like. The term "aromatic five-membered heterocyclic ring" refers to a monocyclic aromatic five-membered heterocyclic ring that "has one or a plurality of heteroatoms that are selected from a nitrogen atom, an oxygen atom and a sulfur atom in the The specific examples thereof include a pyrrole ring, a pyrazole ring, an imidazole ring and a [1, 2, 3] triazole ring, each of which has a nitrogen atom in the ring, a furan ring, which has an oxygen atom in the ring, a thiophene ring, which has a sulfur atom in the ring, an oxazole ring and an isoxazole ring, each of which has a nitrogen atom and an oxygen atom in the ring. the ring, and a thiazole ring and an isothiazole ring, each of which has a nitrogen atom and a sulfur atom in the ring, a pyrazole ring, a furan ring or a thiophene ring is preferred, and a thiophene ring.

The term "aromatic five-membered heterocyclic ring fused to a cycloalkane ring" refers to a bicyclic ring in which a five-membered heterocyclic ring is fused to a cycloalkane ring. The term "aromatic six-membered heterocyclic ring" refers to a monocyclic aromatic six-membered heterocyclic ring having one or a plurality of nitrogen atoms in the ring. Specific examples thereof include a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a [1, 2, 3] triazine ring, a ring [1,2,4] triazine and a ring [1, 2, 3, 4] tetrazine. • A pyridine ring or a pyrazine ring is preferred, and a pyridine ring is particularly preferred. The term "aromatic six-membered heterocyclic ring fused to a cycloalkane ring" refers to a bicyclic ring in which the aromatic six-membered heterocyclic ring is fused to a cycloalkane ring. The term "alkylene" refers to a straight or branched chain alkylene having 1 to 8 carbon atoms. Specific examples thereof include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, methylmethylene, dimethylmethylene, propylene, 2-methyltrimethylene and the like. The term "alkoxy" refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms. Specific examples thereof include methoxy, ethoxy, n-propoxy, n-butoxy, n-pentoxy, n-hexyloxy, isopropoxy, isobutoxy, secbutoxy, terbutoxy, isopentoxy and the like. The term "alkyl" refers to a straight or branched chain alkyl having 1-6 carbon atoms. Specific examples thereof include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and the like. The term "cycloalkyl" refers to a cycloalkyl having 3 to 8 carbon atoms. In addition, a saturated polycyclic hydrocarbon formed by the fusion of two or three cycloalkane rings is also included in the term "cycloalkyl" of the present invention. Specific examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Specific examples of a saturated polycyclic hydrocarbon include adamantyl and the like. The term "aryl" refers to a monocyclic aromatic hydrocarbon or a fused polycyclic, bicyclic or tricyclic aromatic hydrocarbon having 6 to 14 carbon atoms. In addition, a fused polycyclic hydrocarbon which is formed by fusion thereof with a cycloalkane ring is also included in the term "aryl" of the present invention. A specific example of the monocyclic aromatic hydrocarbon is phenyl, specific examples of fused polycyclic aromatic hydrocarbon include naphthyl, anthryl, phenanthryl, and the like, and specific examples of the fused polycyclic hydrocarbon include indanyl, tetrahydronaphthyl, tetrahydroanthranyl, and the like. The term "aryloxy" refers to a monocyclic aromatic hydrocarbonoxy or a fused polycyclic aromatic hydrobonoxy having 6 to 14 carbon atoms, or a fused polycyclic hydrocarbonoxy which is formed by fusion thereof with a cycloalkane ring. A specific example of the monocyclic aromatic hydrocarbonoxy is phenoxy, specific examples of the fused polycyclic aromatic hydrobonoxy include naphthyloxy, anthryloxy, phenanthryloxy and the like, and specific examples of the fused polycyclic hydrocarbonoxy include indanyloxy, tetrahydronaphthyloxy, tetrahydroantranyloxy and the like. The term "heterocyclic ring" refers to a saturated or unsaturated monocyclic heterocyclic ring, or a fused, bicyclic or tricyclic polycyclic heterocyclic ring, having one or a plurality of heteroatoms that are selected from a nitrogen atom, an oxygen atom and a sulfur atom in the ring. Specific examples of the saturated monocyclic heterocyclic ring include aziridine, acetidine, pyrrolidine, pyrazolidine, imidazolidine, triazolidine, piperidine, hexahydropyridazine, hexahydropyrimidine, piperazine, homopiperidine, homopiperazine and the like, each of which has a nitrogen atom in the ring; oxirane, tetrahydrofuran, tetrahydropyran and the like, each of which has an oxygen atom in the ring; tetrahydrothiophene, tetrahydrothiopyran and the like, each of which has a sulfur atom in the ring; oxazilidine, isoxazolidine, morpholine and the like, each of which has a nitrogen atom and an oxygen atom in the ring, and thiazolidine, isothiazolidine, thiomorpholine and the like, each of which has a nitrogen atom and an oxygen atom. Sulfur in the ring. In addition, such a saturated monocyclic heterocyclic ring can be fused with a benzene ring or the like to form a fused polycyclic heterocyclic ring such as dihydroindole, dihydroindazole, dihydrobenzimidazole tetrahydroquinoline, tetrahydroisoquinoline, tetrahydrocinnoline, tetrahydrophthalazine, tetrahydroquinazoline, tetrahydroquinoxaline, dihydrobenzofuran, dihydroisobenzofuran, chroman, isochroman , dihydrobenzothiophene, dihydroisobenzothiophene, thiochroman, isothiochroman, dihydrobenzoxazole, dihydrobenzisoxazole, dihydrobenzoxazine, dihydrobenzothiazole, dihydrobenzoisothiazole, dihydrobenzothiazine, xanthene, 4a-carbazole or pyrimidine. Specific examples of the unsaturated monocyclic heterocyclic ring include dihydropyrrole, pyrrole, dihydropyrazole, pyrazole, dihydroimidazole, imidazole, dihydrotriazole, triazole, tetrahydropyridine, dihydropyridine, pyridine, tetrahydropyridazine, dihydropyridazine, pyridazine, tetrahydropyrimidine, dihydropyrimidine, pyrimidine, tetrahydropyrazine, dihydropyrazine, pyrazine and similar, each of which has a nitrogen atom in the ring; dihydrofuran, furan, dihydropyran, pyran and the like, each of which has an oxygen atom in the ring; dihydrothiophene, thiophene, dihydrothiopyran, thiopyran and the like, each of which has a sulfur atom in the ring; dihydrooxazole, oxazole, dihydroisoxazole, isoxazole, dihydrooxazine, oxazine and the like, each of which has a nitrogen atom and an oxygen atom in the ring; dihydrothiazole, thiazole, dihydroisothiazole, isothiazole, dihydrothiazine, thiazine and the like, each of which has a nitrogen atom and a sulfur atom in the ring. In addition, said unsaturated monocyclic heterocyclic ring may be fused to a benzene ring or the like to form a fused polycyclic heterocyclic ring such as indole, indazole "-, benzimidazole, benzotriazole, dihydroquinoline, quinoline, dihydroisoquinoline, isoquinoline, phenanthridine, dihydrocinnoline, cinnoline, dihydrophthalazine phthalazine, dihydroquinazoline, quinazoline, dihydroquinoxaline, quinoxaline, benzofuran, isobenzofuran, chromene, isocromen, benzothiophene, isobenzothiophene, thiochromen, isothiochromen, benzoxazole, benzisoxazole, benzoxazine, 'benzothiazole, benzoisothiazole, benzothiazine, phenoxanthin, carbazole, β-carboline, phenanthridine, acridine, phenanthroline, phenazine, phenothiazine or phenoxazine. The term "alkylamino" refers to a monoalkylamino having 1 to 6 carbon atoms or dialkylamino having 2 to 12 carbon atoms. Specific examples of the monoalkylamino include methylamino, ethylamino, hexylamino and the like, and specific examples of the dialkylamino include ethylmethylamino, dimethylamino, diethylamino, dihexylamino and the like. The term "arylamino" refers to a monoarylamino having 6 to 20 carbon atoms or diarylamino having 12 to 28 carbon atoms. Specific examples of the monoarylamino include phenylamino, naphthylamino, ethylphenylamino and the like, and specific examples of the diarylamino include diphenylamino, diantrilamino and the like. The term "acyl" refers to hydrocarbonyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl or heterocyclic carbonyl. Specific examples of hydrocarbon include formyl. Specific examples of alkylcarbonyl include acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, monochloroacetyl, trifluoroacetyl and the like, specific examples of cycloalkylcarbonyl include cyclopentanecarbonyl, cyclohexanecarbonyl and the like, the specific examples of arylcarbonyl include benzoyl, naphthoyl, toluoyl and the like and specific examples of heterocyclic carbonyl include furoyl, tenoyl, picolinoyl, nicotinoyl, isonicotinoyl and the like. The term "alkenyl" refers to a straight or branched chain alkenyl having 2 to 8 carbon atoms. Specific examples thereof include vinyl, allyl, 1-propenyl, 3-butenyl, 3-pentenyl, 4-hexenyl, 5-heptenyl, 7-octenyl, 1-methylvinyl and the like. The term "alkynyl" refers to a straight or branched chain alkynyl having 2 to 8 carbon atoms. Specific examples thereof include ethynyl, 2-propynyl, 2-butynyl, 3-pentynyl, 4-hexynyl, 5-heptynyl, 7-octynyl, 2-methylbutyl and the like. The term "halogen" refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. The term "ester of a carboxy group" refers to an ester with an alkyl alcohol, an aryl alcohol or the like. Specific examples of the alkyl alcohol include methanol, ethanol, propanol, butanol, benzyl alcohol, phenethyl alcohol and the like. Specific examples of the aryl alcohol include phenol, naphthol, antrol, cresol, xyleneol and the like. The term "amide of a carboxy group" refers to an amide with alkylamine, cycloalkylamine, arylamine, heterocyclic amine or the like. Specific examples of alkylamine include methylamine, ethylamine, ethylmethylamine, dimethylamine, diethylamine, benzylamine and the like, specific examples of cycloalkylamine include cyclopentylamine, cyclohexylamine, cyclohexylmethylamine and the like, specific examples of arylamine include aniline, naphthylamine, diphenylamine, ethylphenylamine, anisidine. , toluidine and the like, and specific examples of heterocyclic amine include benzofuranoamine, quinolyl amine and the like. The term "alkylcarbonyl" refers to straight or branched chain alkylcarbonyl having 2 to 7 carbon atoms. Specific examples thereof include methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbonyl, isopropylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, isopentylcarbonyl, and the like. The term "arylcarbonyl" refers to a monocyclic aromatic hydrocarbon carbonyl or a fused polycyclic aromatic hydrocarbon carbonyl having 7 to 15 carbon atoms, or a fused polycyclic hydrocarbon carbonyl formed by fusion thereof with a cycloalkane ring. A specific example of the monocyclic aromatic hydrocarboncarbonyl is phenylcarbonyl, specific examples of the fused polycyclic aromatic hydrocarbonyl include naphthylcarbonyl, anthrylcarbonyl, phenanthrylcarbonyl and the like, and specific examples of the fused polycyclic hydrocarbonyl include indanyl carbonyl, tetrahydronaphthylcarbonyl, tetrahydroantrylcarbonyl and the like. The term "heterocyclic carbonyl" refers to a monocyclic, saturated or unsaturated heterocyclic carbonyl, a fused, bicyclic or tricyclic polycyclic heterocyclic carbonyl, each of which has one or a plurality of heteroatoms that are selected from a nitrogen atom, a atom of oxygen and a sulfur atom in the ring. The term "alkylsulfonyl" refers to a straight or branched chain alkylsulfonyl having 1 to 6 carbon atoms. Specific examples thereof include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, n-butylsulfonyl, n-pentylsulfonyl, n-hexylsulfonyl, isopropylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, isopentylsulfonyl and the like. The term "arylsulfonyl" refers to a monocyclic aromatic hydrocarbon sulfonyl or a fused polycyclic aromatic hydrocarbon sulfonyl having 6 to 14 carbon atoms, or a fused polycyclic hydrocarbon sulfonyl which is formed by fusion thereof with a cycloalkane ring. A specific example of the monocyclic aromatic hydrocarbonsulfonyl is phenylsulfonyl, the specific examples of the fused polycyclic aromatic hydrocarbon sulfonyl include naphthylsulfonyl, anthrylsulfonyl, phenanthrylsulfonyl and the like, and the specific examples of fused polycyclic hydrocarbonsulfonyl include indanylsulfonyl, tetrahydronaphthylsulfonyl, tetrahydroantrysulfonyl and the like. The term "alkylthio" refers to a straight or branched chain alkylthio having 1 to 6 carbon atoms. Specific examples thereof include methylthio, ethylthio, n-propylthio, n-bourylthio, n-pentthio, n-hexylthio, isopropylthio, isobutylthio, sec-butylthio, tert-butylthio, isopentylthio and the like. A monocyclic aromatic hydrocarbon, or fused polycyclic, bicyclic or tricyclic aromatic hydrocarbon having 6 to 14 carbon atoms, further refers to a bicyclic to tetracyclic fused polycyclic hydrocarbon which is formed by fusing it with a cycloalkane ring. Specific examples of the monocyclic aromatic hydrocarbon are phenylthio, specific examples of the fused polycyclic aromatic hydrocarbon include naphthylthio, anthrylthio, phenanthylthio and the like, and specific examples of the fused polycyclic hydrocarbon include indanylthio, tetrahydronaphthylthio, tetrahydroanthylthio and the like, the term "haloalkoxy" refers to an alkoxy group having one or a plurality of atoms d and halogen identical or different, as substituents. The term "hydroxyalkoxy" refers to an alkoxy group having one or a plurality of hydroxy groups as substituents. The term "alkoxyalkoxy" refers to an alkoxy group having one or a plurality of the same or different alkoxy groups, as substituents. * The term "aryloxyalkoxy" refers to an alkoxy group having one or a plurality of the same or different aryloxy groups as substituents. The term "halogenoalkyl" refers to an alkyl group having one or a plurality of halogen atoms, the same or different, as substituents. The term "hydroxyalkyl" refers to an alkyl group having one or a plurality of hydroxy groups as substituents. The term "alkoxyalkyl" refers to an alkyl group having one or a plurality of alkoxy groups, the same or different, as substituents. The term "aryloxyalkyl" refers to an alkyl group having one or a plurality of aryloxy groups, the same or different, as substituents.

The term "hydroxyaryl" refers to an aryl group having one or a plurality of hydroxy groups as substituents. The term "alkoxyaryl" refers to an aryl group having one or a plurality of the same or different alkoxy groups, as substituents. The term "substituted alkoxy group" refers to an alkoxy group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an alkoxy group substituted with an aryl group, an aryloxy group, a cycloalkyl group, an aryl group, an aryl group substituted with an alkoxy group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group or a mercapto group, an alkylthio group, an arylthio group, a group carboxy or an ester thereof or an amide thereof, a cyano group and a nitro group. The term "substituted aryloxy group" refers to an aryloxy group having one, or a plurality of groups as substituents selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group or a cyano group and a nitro group. The term "substituted alkyl group" refers to an alkyl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a cycloalkyl group, a group alkenyl, an aryl group, an aryl group substituted with a halogen atom, a heterocyclic group, an amino group, an "alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or a ester of the same or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group The term "substituted cycloalkyl group" refers to a cycloalkyl group having one or a plurality of groups as substituents which are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkyl group amino, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, an Eiano group and a group nitro. The term "substituted aryl group" refers to an aryl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an alkoxy group substituted with a halogen atom , an aryloxy group, an alkyl group, an alkyl group substituted with a halogen atom, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group , an arylthio group, a carboxyl group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group or an aryl group having one or a plurality of groups carbonyl or thiocarbonyl groups in the ring. The term "substituted heterocyclic ring" refers to a heterocyclic ring having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an alkoxy group substituted with a halogen atom, an aryloxy group, an alkyl group, an alkyl group substituted with a halogen atom, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group, or a heterocyclic ring having one or a plurality of carbonyl groups or groups thiocarbonyl in the ring. The term "substituted alkylamino group" refers to an alkylamino group having one or a plurality of groups in its alkyl portion as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a group cycloalkyl, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide thereof, a group formyl, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group. The term "substituted arylamino group" refers to an arylamino group having one or a plurality of groups in its aryl moiety as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a group alkyl, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide of the same, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group, or an arylamino group having one or a plurality of carbonyl groups or thiocarbonyl groups in the ring. The term "substituted acyl group" refers to an acyl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a cycloalkyl group, a group aryl, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide thereof, a formyl group, a alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group. The term "substituted alkenyl group" refers to an alkenyl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a cycloalkyl group, a group aryl, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group.

The term "substituted alkynyl group" refers to an alkynyl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a cycloalkyl group, a group aryl, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a group nitro. The term "substituted alkylcarbonyl group" refers to an alkylcarbonyl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, a cycloalkyl group, a alkenyl group, an aryl group, an aryl group substituted with a halogen atom, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or a ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group. The term "substituted arylcarbonyl group" refers to an arylcarbonyl group having one or A plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an alkoxy group substituted with a halogen atom, an aryloxy group, an alkyl group, an alkyl group substituted with a halogen atom, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxyl group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group or an arylcarbonyl group having one or a plurality of groups carbonyl or thiocarbonyl groups in the ring. The term "substituted heterocyclic carbonyl group" refers to a heterocyclic carbonyl group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an alkoxy group substituted with an atom of halogen, an aryloxy group, an alkyl group, an alkyl group substituted with a halogen atom, a cycloalkyl group, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a mercapto group, an alkylthio group, an arylthio group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group, or a heterocyclic carbonyl group having one or a plurality of carbonyl groups or thiocarbonyl groups in the ring. The term "substituted alkylthio group" refers to an alkylthio group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an alkoxy group substituted with an aryl group, a aryloxy group, a cycloalkyl group, an aryl group, an aryl group substituted with an alkoxy group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a cyano group and a nitro group. The term "substituted arylthio group" refers to an arylthio group having one or a plurality of groups as substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, a group cycloalkyl, an aryl group, a heterocyclic group, an amino group, an alkylamino group, an arylamino group, a carboxy group or an ester thereof or an amide thereof, a formyl group, an alkylcarbonyl group, an arylcarbonyl group, a group cyano and a nitro group, or an arylthio group having one or a plurality of carbonyl groups or thiocarbonyl groups in the ring.

When the compound of the present invention has a free hydroxyl group, a free amino group, a free alkylamino group, a free arylamino group or a free mercapto group as a substituent, these substituents can be protected with a protecting group. When the heterocyclic group has a free nitrogen atom, the nitrogen atom can also be protected with a protecting group. The term "protecting group for the free hydroxy group" refers to one widely used as a protecting group such as a substituted or unsubstituted alkyl group or an unsubstituted alkenyl group such as a methyl group, a methoxymethyl group, a benzyl group , a 4-methoxyphenylmethyl group or an allyl group; a substituted or unsubstituted heterocyclic group such as a 3-bromotetrahydropyranyl group, a tetrahydropyranyl group or a tetrahydrofuranyl group; a substituted or unsubstituted alkylcarbonyl group or a substituted or unsubstituted arylcarbonyl group such as an acetyl group, a trifluoroacetyl group, a benzoyl group or a 4-chlorobenzoyl group; a substituted or unsubstituted alkyloxycarbonyl group, an unsubstituted alkenyloxycarbonyl group or a substituted or unsubstituted aryloxycarbonyl group such as a methoxycarbonyl group, an ethoxycarborbonyl group, an isobutoxycarbonyl group, a terbutoxycarbonyl group, a benzyloxycarbonyl group, a p-methoxybenzyloxycarbonyl group, a 9-fluorenylmethoxycarbonyl group, a vinyloxycarbonyl group, an aryloxycarbonyl group, a phenyloxycarbonyl group or a p-nitrophenyloxycarbonyl group, or a substituted silyl group such as a trimethylsilyl group, a triethylsilyl group, a triisopropylsilyl group, a tertbutyldimethylsilyl group or a tertbutyldiphenylsilyl group . The term "protecting group for the free amino group, the free alkylamino group, the free arylamino group or the free nitrogen atom in the case where the heterocyclic group has a nitrogen atom in its ring" refers to one widely used as a protecting group such as an unsubstituted alkenyl group such as an allyl group; a hydrocarbonyl group such as a formyl group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted arylcarbonyl group or an unsubstituted heterocyclic carbonyl group such as an acetyl group, a trichloroacetyl group, a trifluoroacetyl group, a benzoyl group, a 4-chlorobenzoyl group or a picolinoyl group; a substituted or unsubstituted alkyloxycarbonyl group; a substituted or unsubstituted aryloxycarbonyl group such as a methoxycarbonyl group, an isobutoxycarbonyl group, a tert-butoxycarbonyl group, a 2,2,2-trichloroethoxycarbonyl group, a benzyloxycarbonyl group, a diphenylmethoxycarbonyl group, a phenoxycarbonyl group or a m-nitrophenoxycarbonyl group; or a substituted or unsubstituted alkylsulfonyl group, or a substituted or unsubstituted arylsulfonyl group such as a methylsulfonyl group, a benzylsulfonyl group, a phenylsulfonyl group, a 4-chlorophenylsulfonyl group, a tolylsulfonyl group or a 2,4,6-trimethylphenylsulfonyl group . The term "protecting group for the free mercapto group" refers to one widely used as a protecting group such as a substituted or unsubstituted alkyl group or an unsubstituted alkenyl group such as a methyl group, a methoxymethyl group, a benzyl group , a 4-methoxyphenylmethyl group or an allyl group; a substituted or unsubstituted heterocyclic group such as a 3-bromotetrahydropyranyl group, a tetrahydropyranyl group or a tetrahydrofuranyl group; a substituted or unsubstituted alkylcarbonyl group or a substituted or unsubstituted arylcarbonyl group such as an acetyl group, a trifluoroacetyl group, a benzoyl group or a 4-chlorobenzoyl group; or a substituted or unsubstituted alkyloxycarbonyl group, an unsubstituted alkenyloxycarbonyl group or a substituted or unsubstituted aryloxycarbonyl group such as a methoxycarbonyl group, an ethoxycarbonyl group, an isobutoxycarbonyl group, a tert-butoxycarbonyl group, a benzyloxycarbonyl group, a p-methoxybenzyloxycarbonyl group, a 9-fluorenylmethoxycarbonyl group, a vinyloxycarbonyl group, an aryloxycarbonyl group, a phenyloxycarbonyl group or a p-nitrophenyloxycarbonyl group. The "plurality of groups," as used herein, may be the same or different, respectively. In addition, in the "group", as used herein, the respective atoms and rings are also included. The "salt" in the compound of the present invention is not particularly limited insofar as it is a pharmaceutically acceptable salt and examples thereof include salts with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid , sulfuric acid or phosphoric acid; salts with an organic acid such as acetic acid, fumaric acid, maleic acid, succinic acid, citric acid, tartaric acid, adipic acid, lactic acid, methanesulfonic acid, trifluoromethanesulfonic acid or p-toluenesulfonic acid; salts with an alkali metal such as lithium, sodium or potassium; salts with an alkaline earth metal such as calcium or magnesium; and quaternary salts with ammonia, methyl iodide and the like. In the case where there are geometric isomers or optical isomers in the compound of the present invention, these isomers are also included within the scope of the present invention. In addition, the compound of the present invention may be in the form of a hydrate or a solvate. In addition, in the case where there is a proton tautomerism in the compound of the present invention, the tautomeric isomers thereof are also included in the scope of the present invention. (a) The preferred examples of? The compounds of the present invention include compounds that satisfy the following definitions, and salts thereof. In general formula (1), (a) ring A represents a benzene ring, a thiophene ring or a pyridine ring; or (a2) R1 represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic ring; or (a3) in the case where R1 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from an aryl group, a hydroxyaryl group and an alkoxyaryl group; or (a4) in the case where R1 is an aryl group, the aryl group can have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, an alkoxy group, a halogenoalkoxy group, a hydrocarbonyloxy group , an alkylcarbonyloxy group, an arylcarbonyloxy group, an alkyl group, a halogenoalkyl group and an aryl group; or (a5) R2 represents a hydrogen atom, an alkyl group or an aryl group; or (a6) in the case where R2 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a carboxy group, an alkoxycarbonyl group and an aryloxycarbonyl group; or (a7) R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring or Z-R5; or (a8) in the case where R3 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a hydroxy group, an alkoxy group, an aryloxy group, an amino group, an alkylamino group and an arylamino group; or (a9) in the case where R3 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of cyano groups as substituents; or (alO) R3 and R4 can be joined to form a heterocyclic ring; or (all) in the case where R3 and R4 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group , a hydroxyalkyl group, an alkoxyalkyl group, an aryloxyalkyl group, an aryl group, an amino group, an alkylamino group, an arylamino group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a hydrocarbyl group, an alkylcarbonyl group, an arylcarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group and an arylaminocarbonyl group, furthermore, the heterocyclic ring may have a carbonyl group in the ring; or (al2) R4 represents a hydrogen atom, an alkyl group, an aryl group, a hydrocarbonyl group, an alkylcarbonyl group or an arylcarbonyl group; 'or (al3) in the case where R4 - is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of alkylcarbonyloxy groups as substituents; or (al4) Z represents CO, CS, CO-B2-0, CS-B2-0, CO-B2-NR6, CS-B2-? R6, CO-B2-? R6S02, CS-B2-? RsS02 or S02; or (al5) R5 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, a heterocyclic ring, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a hydrocarbonyl group , an alkylcarbonyl group, an arylcarbonyl group, a heterocyclic sarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group; or (al6) in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, an alkoxy group, a hydroxyalkoxy group, an alkoxyalkoxy group , an aryloxyalkoxy group, a cycloalkyl group, an aryl group, a heterocyclic ring, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a hydrocarbyl group, an alkylcarbonyl group, an arylcarbonyl group, an amino group, an alkylamino group, an arylamino group, an alkoxycarbonylamino group, an aryloxycarbonylamino group, a hydrocarbonylamino group, an alkylcarbonylamino group, an arylcarbonylamino group, a mercapto group, an alkylthio group, an arylthio group and a cyano group; or (al7) in the case where R5 is an aryl group, the aryl group may have one or a plurality of substituents of halogen atoms; or (ald) in the case where R5 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from an alkyl group and an aryl group; or (a9) in the case where R5 is an alkylcarbonyl group, the alkylcarbonyl group can have one or a plurality of substituents that are selected from a carboxy group, a hydrocarbonyloxy group, an alkylcarbonyloxy group, an arylcarbonyloxy group, an amino group, an alkylamino group and an arylamino group; or (a20) R5 and R6 can be joined to form a heterocyclic ring; or (a21) in the case where R5 and R6 join to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from a hydroxy group, a group-. alkoxy, an aryloxy group, an alkyl group, a hydroxyalkyl group, an alkoxyalkyl group, an aryloxyalkyl group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a carbonyl group, a hydrocarbonyl group, an alkylcarbonyl group and an arylcarbonyl group in addition, the heterocyclic ring may have a carbonyl group in the ring; or (a22) R6 represents a hydrogen atom, an alkyl group or an aryl group; or (a23) X and Y, which are the same or different, represent one or a plurality of groups that are selected from a hydrogen atom, a halogen atom and an alkyl group; or (a24) B1 represents an alkylene group; or (a25) B2 represents a single bond or an alkylene group; or (a26) p represents 0, 1 or 2; or (a27) q represents 0 or 1. That is, preferred examples thereof include in the compounds represented by the general formula (1) compounds that satisfy one or a combination of two or more of the above-selected subparagraphs ( al), (a2), (a3), (a4), (a5), (aß), (a7), (a8), (a9), (alO), (all), (al2), (al3) , (al4), (al5), (al6), (al7), (al8), (al9), (a20), (a21), (a22), (a23-;), (a24), (a25) , (a26) and (a27), and salts thereof. (b) The most preferred examples of the compound of the present invention include compounds which satisfy the following definitions, and salts thereof. In general formula (1), (bl) ring A represents a benzene ring, a thiophene ring or a pyridine ring; or (b2) R1 represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic ring; or (b3) in the case where R1 is an alkyl group, the alkyl group may have one or a plurality of alkoxyaryl groups as substituents; or (b4) in the case where R1 is an aryl group, the aryl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, an alkoxy group, a halogenoalkoxy group, an alkylcarbonyloxy group , an alkyl group and a halogenoalkyl group; or (b5) R2 represents a hydrogen atom or an alkyl group; or (b6) in the case where R2 is an alkyl group, the alkyl group may have one or a plurality of substituents that are selected from a carboxy group and an alkoxycarbonyl group; or (b7) R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring or Z-R5; or (b8) in the case where R3 is an alkyl group, the alkyl group may have one or a plurality of substituents that are selected from a hydroxy group and an alkylamino group; or (b9) in the case where R3 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of cyano groups as substituents; or (blO) R3 and R4 can be joined to form a heterocyclic ring; or (bll) in the case where R3 and R4 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from a hydroxy group, an alkyl group, a hydroxyalkyl group, an alkylamino group , an alkoxycarbonyl group, an alkylcarbonyl group and an alkylaminocarbonyl group, furthermore, the heterocyclic ring may have a carbonyl group in the ring; or (bl2) R4 represents a hydrogen atom, an alkyl group or an alkylcarbonyl group; or (bl3) in the case where R4 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of alkylcarbonyloxy groups as substituents; or (bl4) Z represents CO, C0-B2-0, C0-B2-NR6,. CS-B2-NR6, CO-B2-NRsS02 or S02; or (bl5) R5 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, a heterocyclic ring, an alkoxycarbonyl group, an alkylcarbonyl group, a heterocyclic carbonyl group or a group alkylaminocarbonyl; or (bl6) in the case where Rs is an alkyl group, the alkyl group may have one or a plurality of substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, a hydroxyalkoxy group, a group alkoxyalkoxy, a cycloalkyl group, a heterocyclic ring, a carboxy group, an alkoxycarbonyl group, an amino group, an alkylamino group, an alkoxycarbonylamino group, an alkylcarbonylamino group, an alkylthio group and a cyano group; or (bl7) in the case where R5 is an aryl group, the aryl group may have one or a plurality of halogen atoms as substituents; or (bl8) in the case where R5 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of alkyl groups -as substituents; or (bl9) in the case where Rs is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of substituents which are selected from a carboxy group, an alkylcarbonyloxy group and an alkylamino group; or (b20) R5 and R6 can be joined to form a heterocyclic ring; or (b21) in the case where R5 and R6 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from a hydroxy group, an alkyl group, a hydroxyalkyl group, an alkoxycarbonyl group and an alkylcarbonyl group, furthermore, the heterocyclic ring may have a carbonyl group in the ring; or (b22) R6 represents a. hydrogen atom, or an alkyl group; or (b23) X and Y represent a hydrogen atom, or (b24) B1 represents an alkylene group; or (b25) B2 represents a single bond or an alkylene group; or (b26) p represents 0 or 1; (b27) q represents 0. That is, the most preferred examples thereof included in the compounds represented by the general formula (1), compounds satisfying one or a combination of two or more of the entries that are selected from the above , (bl), (b2), (b3), (b4), (b5), (b6), (b7), (b8), (b9), (blO), (bll), (bl2), ( bl3), (bl4), (bl5), (bl6), (bl7), (bl8), (bl9), (b20), (b21), (b22), (b23), (b24), (b25) , (b26) and (b27) and salts thereof. (c) In addition, the most preferred examples of the compound of the present invention include compounds that satisfy the following definitions and salts thereof. In general formula (1), (cl) ring A represents a benzene ring, a thiophene ring or a pyridine ring; or (c2) R1 represents an aryl group or a heterocyclic ring; or (c3) in the case where R1 is an aryl group, the aryl group may have one or a plurality of substituents which are selected from a halogen atom, a halogenoalkoxy group, an alkyl group and a halogenoalkyl group; or (c4) R2 represents a hydrogen atom; or (c5) R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring or Z-R5; or (c6) in the case where R3 is a group, the alkyl group may have one or a plurality of alkylamino groups as substituents; or (c7) in the case where R3 * is a heterocyclic ring, the heterocyclic ring may have one or a plurality of cyano groups as substituents; or (c8) R3 and R4 can be joined to form a heterocyclic ring; or (c9) in the case where R3 and R4 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from an alkyl group and an alkylcarbonyl group; or (clO) R4 represents a hydrogen atom or an alkyl group; or (cll) Z represents CO, C0-B2.-0, CO-B2-NR6, CO-B2-NR6S02 or S02; or (cl 2) R 5 represents a hydrogen atom, an alkyl group, an aryl group, an alkylcarbonyl group or an alkylaminocarbonyl group; or (cl3) in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, a heterocyclic ring, an alkylamino group and an alkylcarbonylamino group; or (cl4) in the case where R5 is an aryl group, the aryl group may have one or a plurality of halogen atoms as substituents; or (cl5) in the case where XR5 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of carboxy groups as substituents; or (cl6) R5 and Rs can be joined together to form a heterocyclic ring; or (cl7) in the case where R5 and R6 join to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of hydroxyalkyl groups as substituents; or (cl8) R6 represents a hydrogen atom or an alkyl group; or (cl9) X and Y represent a hydrogen atom; or (c20) B1 represents an alkylene group; or (c21) B2 represents a single bond or a. alkylene group; or (c22) p represents 0; or (c23) q represents 0. That is, the further more preferred examples thereof include in the compounds represented by the general formula (1) compounds that satisfy one or a combination of two or more of the entries that are selected from the previous (cl), (c2), (c3), (c4), (c5), (c6), (c7), (c8), (c9), (CÍO), (cll), (cl2), ( cl3), (cl4), (cl5), (clß), (cl7), (Cl8), (cl9), (c20), (c21), (c22) and (c23) and salts thereof. (d) Preferred examples of the compound of the present invention in terms of pharmacological activity include compounds that satisfy the definitions described in any of the foregoing paragraphs (a) to (c) and in which in the general formula (1) the ring A is a pyridine ring or a thiophene ring or salts thereof, and compounds in which ring A is a pyridine ring and salts thereof are particularly preferred. (e) The most preferred examples of the compound of the present invention in terms of pharmacological activity include compounds that meet the definitions described in any of the foregoing paragraphs (a) to (d) and in which in the general formula (1), join a partial structure (C): and a partial structure (D) to adjacent carbon atoms in ring A, and salts thereof. (f) Additional, more preferred examples of the compound of the present invention in terms of pharmacological activity include compounds that meet the definition described in subparagraph (d) above and the definition described in subsection (e) above and in which the structure partial (C) or (D) is attached to the carbon atom that is located at position a with respect to a heteroatom in ring A, and salts thereof. (g) Particularly preferred examples of the compound of the present invention include compounds that satisfy the definitions described in any of the above (a) to (f) and that also satisfy the definitions described in the following, and salts thereof, In the general formula (1), (gl) R3 represents Z-R5; or (g2) Z represents CO, CO-B2-0, -CO-B2-NR6 or CO-B2- NRS02; or (g3) R5 represents a hydrogen atom, an alkyl group, an aryl group, an alkylcarbonyl group or an alkylaminocarbonyl group; or (g4) in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, a heterocyclic ring, an alkylamino group and an alkylcarbonylamino group; or (g5) in the case where R5 is an aryl group, the aryl group may have one or a plurality of halogen atoms as substituents; or (g6) in the case where R5 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of carboxy groups as substituents; or (g7) R5 and Rs can be joined to form a heterocyclic ring; or (g8) in the case where R5 and R6 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of hydroxyalkyl groups as substituents; or (g9) R6 represents a hydrogen atom or an alkyl group; or (glO) B2 represents a single bond or an alkylene group. That is, in the particularly preferred examples thereof they include in the compounds that satisfy the definitions described in any of the items (a) to (f) and are represented by the general formula (1), compounds that satisfy one or a combination of two or more selected- from the preceding paragraphs (gl), (g2), (g3), (g4), (g5), (gd), (g7), (g8), (g9) and (glO) and salts of them. Particularly preferred specific examples of the compound of the present invention are shown below: N- (3,5-dimethylphenyl) -2- [2- (4-methylpiperazin-1-yl) pyridin-4-ylmethylthio] iridin-3-carboxamide 2 (2-cyclopropylaminopyridin-4-ylmethylthio) -? (3,5-dimethylphenyl) pyridine-3-carboxamide 2- [2- (- (2-dimethylaminoethyl) -? - methylamino) -pyridin-4-ylmethylthio] -? - (3,5-dimethylphenyl) pyridin-3 -carboxa ida? - (3, 5-dimethylphenyl) -2- (2-morpholinopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3,5-dimethylphenyl) -2- [2- (piperidin-1-yl ) pyridin-4-ylmethylthio] pyridine-3-carboxamide 2 [2- [4-acetylpiperazin-1-yl) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridin-3-carboxamide N- (indan -5-yl) -2- (2-morpholinopyridin-4-ylmethylthio) pyridine-3-carboxamide 2 - [2- (4-acetylpiperazin-1-yl) pyridin-4-ylmethylthio] -N- (indan-5- il) pyridin-3-carboxamide N- (3,5-dimethylphenyl) -2- (2-n-pentylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -? - (3,5-dimethylphenyl) pyridin-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -? - (3-isopropylphenyl) pyridine-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) ) -? - (indan-5-yl) pyridine-3-carboxamide 2- (2-ter-but toxicarbonylaminopyridin-4-ylmethithio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -? - (4-tert-butylphenyl) pyridine-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -? - (lH-indazol-6) -yl) pyridin-3-carboxamide 2- [2- (β-tert-butoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -? - (3, 5-dimethylphenyl) pyridine-3-carboxamide 2- [2- (5-cyanothiazol-2-ylamino) pyridin-4-ylmethylthio] -? - (3, 5-dimethylphenyl) pyridine-3-carboxamide 2- (2- aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridine-3-carboxamide 2- (2- aminopyridin-4-ylmethylthio) -N- (indan-5-yl) pyridin-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) pyridine-3-carboxamide 2- ( 2-aminopyridin-4-ylmethylthio) -N- (1H-indazol-6-yl) pyridine-3-carboxamide, N- (3, 5-dimethylphenyl) -2- (2-methylaminopyridin-4-ylmethylthio) pyridin-3 -carboxamide N- (indan-5-yl) -2- (2-methylaminopyridin-1,4'-ylmethylthio) pyridin-3-carboxamide 2- (2-methylaminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine -3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridin-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine-3 -carboxamide 2- (2-aminopyridin-4-ylmethylthio) -N- (isoquinolin -3-yl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -N- (3, 5-dimethylphenyl) benzamide 2- (2-aminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) ) benzamide 3- (2-aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) thiophene-2-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine) -3-carboxamide N- (3,5-dimethylphenyl) -2- (2-propionylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-trifluoroacetylaminopyridin-4-ylmethylthio) ) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-isobutyrylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3,5-dimethylphenyl) -2- (2-pivaloilami? opyridin) -4-ylmethylthio) pyridine, 3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-trifluoromethanesulfonylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) pyridin-3-carboxamide 2- [2-acetylaminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- [α-acetyl-β-methylamino) p iridin-4-ylmethylthio] -? (3,5-dimethylphenyl) pyridine-3-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (1 H -indazol-6-yl) pyridine-3-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) ) -N- (3,5-dimethyl-4-hydroxyphenyl) pyridine-3-carboxamide 2-2-acetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) benzamide 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) benzamide 3- (2-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) thiophene-2-carboxamide 3- (2-acetylaminopyridin-4-ylmethylthio) -N - (4-chlorophenyl) thiophene-2-carboxamide N- (3, 5-dimethylphenyl) -2- [2- (N '-n-propylureido) pyridin-4-ylmethylthio] -pyridin-3-carboxamide 2- [2 - (N 1 -ter-butylureido) pyridin-4-ylmethylthio] -N- (3, 5-dimethylphenyl) -pyridin-3-carboxamide 2- [2- (N 1 -4-chlorophenyl) -pyridin-4-ylmethylthio] -N - (3,5-dimethylphenyl) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-formylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide N- (3,5-dimethylphenyl) -2 - (2-phenylaminopyridin-4-ylmethylthio) pyridine-3-carboxy gives N- (3,5-dimethylphenyl) -2- [2- (N 1 -methylureido) pyridin-4-ylmethylthio] pyridin-3-carboxamide 2- [2- (N 1 -methylureido) pyridin-4-ylmethylthio] -N - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (4-chlorophenyl) -2- [2- (N 1 -methylureido) pyridin-4-ylmethylthio] pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- [N '-methylureido) pyridin-4-ylmethylthio] pyridin-3-carboxamide 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N- (3, 5-dimethylphenyl) pyridin-3-carboxamide 2- (2 -acetoxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-aminoacetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide 2- (2 -hydroxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- ( 4-chlorophenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3,5-dimethyl-4-hydroxyphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide '2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (3-methylphenyl) pyridin-3-carboxamide 2- (2-hydroxyacetylaminopyridin-4) -ylmethylthio) -? - (4-trifluoromethylphenyl) pyridine-3-carboxamide 2- (2-Hydroxyacetylaminopyridin-4-ylmethylthio) -? - (isoquinolin-3-yl) pyridine-3-carboxamide N- (3-chlorophenyl) - 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (indan-5-yl) pyridine-3-carboxamide? - (3-chloro-4) -trifluoromethoxyphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- (2-hydroxylacetylaminopyridin-4-methylmethyl) -N- (3-isopropylphenyl) pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) ) -2- (2- Hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -? - (3-trifluoromethylphenyl) pyridine-3-carboxamide 2- [2- (3-hydroxycarbonylpropionyloxy) -acetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide? - (3, 5-dimethylphenyl) -2- (2-methanesulfonylamino-acetylaminopyridin-4-methylmethyl) pyridine-3-carboxamide 2- (2-dimethylaminocarbonyl-acetylaminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-isopropylaminoacetylaminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -? - (3,5-dimethyl-phenyl) pyridine-3-carboxamide 2- (2-dimethylaminoacetylamino-pyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-morpholineacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine- 3-carboxamide 2- [2- (2-morpholinyl) aminoacetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (3-hydroxypropyl) aminoacetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide ? - (4-chlorophenyl) -2- [2- (2-dimethylaminoethyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridin-3-carboxaromide 2- (2-Aminoacetylaminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxy-phenyl) -pyridine-3-carboxamide 2- [2- (- (2-dimethylaminoethyl) -? - methylamino) -acetylaminopyridin-4-ylmethylthio ] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (2-hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- (2-dimethylamino-acetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- [2- (2-acetylaminoethyl) minoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxy-ida N- (4-chlorophenyl) -2- [2- (piperazin-1-yl) acetyl-aminopyridin-4-ylmethyl-thio] pyridin-3-carboxamide 2- [2- (2-hydroxyethyl) ) minoacetylaminopyridin-4-ylthioethyl] -N- (3-methylphenyl) pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (2-hydroxyethyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide 2- [2- (2-acetylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -? - (4-difluoromethoxyphenyl) pyridine-3-carboxamide? - (4-difluoromethoxyphenyl) -2- [2- (N- (2-dimethylamino) ) -N-methylamino) acetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -? - (4-trifluoromethylphenyl) pyridine-3-carboxamide 2- [2 - (4- (2-hydroxyethyl) piperazin-1-yl) acetyl-aminopyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) -pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- (2-isopropylamino-acetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- [2- ( 2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridine-3-carboxamide N- (3,5-dimethylphenyl) -2- (2-isopropylaminoacetyl-aminopyridin-4-ylmethylthio) pyridine- 3 -carboxamide? - (3,5-dimethylphenyl) -2- [2- (3-hydroxypropyl) -aminoacetylaminopyridin- 4-ylmethylthio] pyridin-3-carboxamide ? - (3,5-dimethylphenyl) -2- [2, (2-morpholinyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide 2- (2-ethylaminoacetylaminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-aminoacetylaminopyridin-4-ylmethylthio) -? - (4-difluoromethoxyphenyl) pyridine-3 - carboxamide 2- (3-aminopyridin-4-ylmethylthio) -N- (3,5-dimethyl-phenyl) pyridine-3-carboxamide 2- (3-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine- 3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-morpholineacetylamino-pyridin-4-ylmethylthio) pyridine-3-carboxamide 2- [2- (3-dimethylaminopropyl) aminoacetylamino] pyridin-4-ylmethylthio ] -? - (4-trifluoromethoxyphenyl) -pyridin-3-carboxamide 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -? - (3-methylphenyl) pyridin-3-carboxamide 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridine -4-ylmethylthio] -N- (3-methylphenyl) pyridin-3-carboxamide N- (3-methylphenyl) -2- [2- (piperazin-1-yl) acetyl-aminopyridin-4-ylmethylthio] pyridin-3 - carboxamide 2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] -N, (4-trifluoromethylphenyl) pyridin-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (N- (2-hydroxyethyl) -? - methylamino) acetylaminopyridin-4-ylmethyl] pyridine-3-carboxamide The compounds of the present invention can be prepared by the following methods . Each specific procedure for preparing the present compounds will be described in detail in the following examples (under the heading of preparation examples). The term "Hal" used in the following synthesis routes represents a halogen atom, the term "Boc" represents a terbutoxycarbonyl group and the term "TBS" represents a terbutyldimethylsilyl group. When an oxygen atom, a nitrogen atom, a sulfur atom or the like are included in R1, R2, R3, R4, R5 or Re of the following formulas, protection and deprotection can be carried out according to the methods widely used. The methods for preparing the compounds of the present invention are generally divided into the methods described in the following and the suitable method can be selected according to the kind of substituent. 1) The compound of the present invention (the) (R3, R4, alkyl, aryl, hydrogen or the like) can be synthesized according to synthesis route 1.

Specifically, the compound of the present invention (Ia) can be provided by the reaction of the compound (lia) with the amine (III) without a solvent or in an organic solvent such as tributylamine at 100 D to 200 D for 1 hour to 12 hours. Synthesis Route 1 (I I a) (I a) The compound (II) (Hal; F, Cl, Br) which includes the compound (bundle), can be synthesized according to synthesis route 1-1. Specifically, the compound (II) can be administered by the reaction of the compound (IV) with an amine (V) in an organic solvent such as dichloromethane or N, N-dimethylformamide (hereinafter referred to as DMF) in the presence of an agent of condensation such as N, N '-dicyclohexylcarbodiimide (hereinafter referred to as DCC), O- (7-azabenzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate (hereinafter referred to as HATU) or polymer of N-benzyl-N'-cyclohexylcarbodiimide and in the presence of a base such as N, β-diisopropylethylamine at room temperature up to 50 D for 1 hour to 24 hours.

Synthesis Route 1-1 The compound (IV) can be synthesized according to synthesis route 1-2. Specifically, the compound (IV) can be provided by the reaction of the compound (VI) with the compound (VII) in an organic solvent such as DMF in the presence of a base such as triethylamine at OD up to room temperature for 1 hour to 12 hours. hours .

Synthesis Route 1-2 Hal "The compound (VII) can be synthesized according to the synthesis route 1-3, Specifically, the compound (VII) can be provided by the treatment of the compound (VIII) in an organic solvent such as acetonitrile and in the presence of an initiator of radicals such as benzoyl peroxide and a halogenating agent such as N-chlorosuccinimide or β-bromosuccinimide under reflux for 1 hour to 12 hours.R7 and R8 are used in the following synthesis route representing a hydrogen atom, a alkyl group or the like.

Synthesis Route 1-3 (VI I I) (VI I) (R7, R8 = H or alkyl, etc.) 2) The compound of the present invention (Ib) (R3) alkyl, aryl, hydrogen atom, R4, alkyl, aryl, hydrogen atom, COR5, CONR5R6 or the like is it can be synthesized according to the synthesis route 2. Specifically, it can be provided by the reaction of the compound (IIb), which is obtained according to synthesis route 1-1, with the compound (III) (amine, amide or urea) in the presence of a transition metal catalyst such as palladium acetate or tris (dibenzylideneacetone) -dipaladium (O) in the presence of a base such as cesium carbonate, in the presence of a catalytic ligand such as 4.5- bis (diphenylphosphino) -9,9-dimethylxanthene and in an organic solvent such as 1,4-dioxane at 80 D to 150 D for 1 hour to 12 hours.

Synthesis Route 2 3) The compound of the present invention (le) (Z; CO, S02 or similar) can be synthesized according to synthesis route 3. Specifically, the compound of the present invention (le) can be provided by the reaction of the compound of the present invention (Id) with an anhydride of acid (IX) such as acetic anhydride or acid halide (X) such as pivaloyl chloride in the presence of an organic solvent such as pyridine at OD at 80D for 1 hour to 12 hours.

Synthesis Route 3 (Id) (I c) 4) The compound of the present invention (le) (Z; CO, CS or the like) can be synthesized according to synthesis route 4. Specifically, the compound of the present invention (le) can be administered by the reaction of the compound of the present invention (Id) with isocyanate (XI) such as n-propyl isocyanate or isothiocyanate (XII) such as methyl isothiocyanate in an organic solvent such as DMF at room temperature up to 100D for 1 hour to 12 hours.

Synthesis route 4 - (I d) (I e) ) The compound of the present invention (Ib) (R3: alkyl, aryl, a hydrogen atom, R4, alkyl, aryl, a hydrogen atom, COR5, CONR5Rs or the like), can be synthesized according to synthesis route 5. Specifically, the compound of the present invention (Ib) can be provided by the reaction of the compound (XIII) with amine (V) in an organic solvent such as methylene chloride or DMF in the presence of a condensing agent such as DCC, HATU or N-benzyl-N '- cyclohexylcarbodiimide bound to polymer and in the presence of a base such as N, N-diisopropylethylamine at room temperature at 50 D for 1 hour at i2 'hours.

Synthesis Route 5 (XIII) < - 1 b > The compound (XIII) can be synthesized according to synthesis route 5-1. Specifically, the compound (XIII) can be provided by the reaction of the compound (VI) with the compound (XIV) (W; a leaving group such as a halogen atom, a methanesulfonyloxy group, a toluenesulfonyloxy group or the like) in a solvent organic such as DMF and in the presence of a base such as triethylamine at OD at room temperature for 1 hour to 12 hours.

Synthesis route 5-1 (IV) (XII or The compound (XlVa) can be synthesized according to synthesis route 5-2. Specifically, the compound (XlVa) can be provided by the reaction of the compound (XV) with a halogenating agent such as carbon tetrabromide-triphenylphosphine in an organic solvent such as methylene chloride at OD at room temperature for 1 hour to 4 hours.

Synthesis route 5-2 (XV) (XlVa) The compound (XlVb) can be synthesized according to synthesis route 5-3. Specifically, the compound (XlVb) can be provided by the reaction of the compound (XV) with methanesulfonyl chloride in an organic solvent such as methylene chloride and in the presence of a base such as N, N-diisopropylethylamine at OD at room temperature during 30 minutes to 3 hours.

Synthesis Route 5-3 (XV) (XlVb) 6) The compound of the present invention (If) can be synthesized according to synthesis route 6. Specifically, the compound of the present invention (If) can be provided by the reaction of the compound of the invention. present invention (Id) with a formylating agent such as N-formylbenzotriazole in an organic solvent such as tetrahydrofuran under reflux for 3 hours to 24 hours.

Synthesis Route 6 dd) < m 7) The compound of the present invention (Ig) (R2, alkyl or the like) can be synthesized according to synthesis route 7. Specifically, the compound of the present invention (Ig) can be provided by the reaction of the compound of the present invention (Ih) with R2-halide ( XVI) (R2, alkyl or the like) in an organic solvent such as tetrahydrofuran or DMF and in the presence of a base such as sodium hydride at OD at room temperature for 30 minutes to 3 hours.

Synthesis Route 7 (Ih) (le) 8) The compound of the present invention (Ii) can be synthesized according to the synthesis route 8. Specifically, the compound of the present invention (Ii) can be provided by the reaction of the compound of the invention. present invention (Id) with R3-halide (XVII) (R3; substituted or unsubstituted aryl and the like) in an organic solvent, such as tetrahydrofuran or 1,4-dioxane, in the presence of a transition metal catalyst such as acetate of palladium or tris (dibenzylideneacetone) dipalladium (0) in the presence of a catalytic ligand such as triphenylphosphine, 1,4-bis (diphenylphosphino) butane or 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene and in the presence of from a base such as cesium carbonate at 500 to 12 OD for 3 hours to 24 hours.

Synthesis Route 8 9) The compound of the present invention (Ij) (p = 0, 1 0 2, q = 0 or 1) can be synthesized according to the synthesis route 9. Specifically, the compound of the present invention (Ij) , wherein the sulfur atom or the nitrogen atom of the compound (Ib) (R3; alkyl, aryl or a hydrogen atom; R4; alkyl, aryl, a hydrogen atom, COR5, CONR5R6 or the like), is oxidized, it can be provided by treating the compound (Ib) in an organic solvent such as chloroform and in the presence of an oxidizing agent such as m-chloroperbenzoic acid or hydrogen peroxide at OD at room temperature for 1 hour to 12 hours.

Synthesis Route 9 * - (I b) (I j) ) The compound of the present invention (Ik) (B2, alkylene or the like, R7, R8, alkyl, a hydrogen atom or the like) can be synthesized according to synthesis route 10. Specifically, the compound of the present invention (Ik) can be provided by the reaction of the compound of the present invention (II) (B2; alkylene or the like: W; a halogen atom or the like) with amine (XVIII) without solvent or in an organic solvent such as DMF or methanol at room temperature at 100D for 10 minutes at 12 hours .

Synthesis Route 10 (I I) (I) 11) The compound of the present invention (11) (B2, alkylene or the like) can be synthesized according to synthesis route 11. Specifically, the compound of the present invention (II) can be provided by the reaction of the compound of the present invention '(Im) with a halogenating agent such as thionyl chloride in an organic solvent such as methylene chloride at OD at 50D for 10 minutes to 12 hours.

Synthesis Route 11 12) The compound of the present invention (In) (R3; alkyl, aryl, a hydrogen atom or the like; Realkyl, aryl, a hydrogen atom, COR5, CONR5R6 or the like) can be synthesized according to the synthetic route 12. Specifically, the compound of the present invention (In) can be provided by the reaction of the compound (XIX) with the compound (XIV) (W; a leaving group such as a bromine atom or a methanesulfonyloxy group) in a solvent organic such as DMF and in the presence of a base such as triethylamine at OD at 500 for 30 minutes at 24 hours.

Synthesis Route 12 The compound (XIX) can be synthesized according to synthesis route 12-1. Specifically, compound (XIX) can be provided by the amine reaction (V) with the compound (Via) in an organic solvent such as DMF and in the presence of a condensing agent such as DCC, HATU or carbonyldiimidazole and in the presence of a base such as N, N-diisopropylethylamine at 0D to 500 for 1 hour to 12 hours.

Synthesis Route 12-1 (Via) (XIX) The compound (XIVc) can be synthesized according to synthesis route 12-2. Specifically, the compound (XIVc) can be provided by the reaction of the compound (XV) with a halogenating agent such as an aqueous solution of hydrobromide in water or an organic solvent such as methylene chloride or DMF at OD at 10OD for 3 hours at 12 hours.

Synthesis Route 12-2 (XV) (XIVc) 13) The compound of the present invention (lo) (B2; alkylene or the like) can be synthesized according to synthesis route 13. Specifically, the compound of the present invention (lo) can be provided by the treatment of the compound of the present invention (Ip) in the presence of a base such as hydrazine monohydrate or an aqueous solution of sodium hydroxide and in an organic solvent such as methanol or 1,4-dioxane at room temperature at 1000 for 1 hour to 24 hours.

Synthesis Route 13 (Ip) (I o) In order to find the usefulness of the compounds of the present invention, the following pharmacological tests 1 to 4 are carried out and the pharmacological effects of the compounds of the present invention are evaluated. The details will be described in the following examples (under pharmacological testing). In the pharmacological test 1 (in vitro) the compounds of the present invention have an excellent cell proliferation inhibiting action and an inhibiting effect of angiogenesis is found and an inhibitory effect of vascular hyperpermeability is then suggested. In addition, the compounds of the present invention exhibit an excellent tumor growth inhibitory action, an inhibitory action of edema in the paw plant and an inhibitory effect of choroidal neovascularization in pharmacological tests 2 to 4 (in vivo) using animal models with specific disease, and it was found that the compounds of the present invention are useful as a therapeutic agent for a specific disease in which vascular angiogenesis or hyperpermeability is involved. 1. Evaluation test of the inhibitor of angiogenesis inhibitor An inhibitory action test of cell proliferation of the compounds of the present invention is performed using the HUVEC proliferation evaluation system induced by VEGF (HUVEC are the initials for human umbilical vein endothelial cells) , which is one of the widely used methods. to evaluate the inhibitory effects of in vitro angiogenesis of drugs. 2. Anticancer Effect Evaluation Test A tumor growth inhibitory action test of the compounds of the present invention is performed using a tumor growth model in mice, which is one of the methods widely used to evaluate anticancer effects in vivo. of the medicines. 3. Antiarthritic Effect Evaluation Test A test of the paw plant edema inhibitory action of the compounds of the present invention is performed using an arthritis model with adjuvant in rats, which is one of the methods widely used to evaluate the in vivo antiarthritic effects of medications. 4. Choroidal neovascularization inhibitory effect evaluation test The neovascularization incidence test of the compounds of the present invention is performed using a choroidal neovascularization model in rats, which is one of the widely used methods to evaluate the inhibitory effects of choroidal neovascularization in vivo of medications. As shown in tests 1 to 4, the compounds of the present invention are useful as a therapeutic agent for a disease in which angiogenesis or vascular hyperpermeability is involved, specifically they are very useful as a therapeutic agent to treat cancer, rheumatoid arthritis. , age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, polypoid choroidal angiopathy, diabetic macular edema, vulgar psoriasis or atherosclerosis. The compound of the present invention can be administered orally or parenterally. Examples of the dosage form for administration include a tablet, a capsule, a granule, a powder, an injection, an ophthalmic solution and the like. Such preparation can be made by a widely used technique. For example, oral preparations such as a tablet, a capsule, a granule and a powder can be prepared by optionally adding an excipient such as lactose, mannitol, starch, crystalline cellulose, light silicic anhydride, calcium carbonate or calcium acid phosphate. , a lubricant such as stearic acid, magnesium stearate or talc, a binder such as starch, hydroxypropylcellulose, hydroxypropylmethylcellulose or polyvinylpyrrolidone, a disintegrator such as carboxymethylcellulose, low substituted hydroxypropylmethylcellulose or calcium citrate, a coating agent such as hydroxypropylmethylcellulose, macrogol or a silicone resin, a stabilizer such as ethyl p-hydroxybenzoate or benzyl alcohol, a concealer such as a sweetener, an anti-bitter agent, or a flavor or the like. Parenteral preparations such as an injection and an ophthalmic solution can optionally be prepared by adding a tonicity agent such as sodium chloride, concentrated glycerin, propylene glycol, polyethylene glycol, potassium chloride, sorbitol or mannitol, a buffer such as sodium phosphate, sodium acid phosphate, sodium acetate, citric acid, glacial acetic acid or trometamol, a surfactant such as polyoxyethylene sorbitan monooleate, polyoxyl 40 stearate or hydrogenated polyoxyethylene castor oil, a stabilizer such as sodium citrate or disodium edetate, a preservative such as benzalkonium chloride, paraben, benzethonium chloride, p-hydroxybenzoate, sodium benzoate or chlorobutanol, a pH adjusting agent such as hydrochloric acid, citric acid, phosphoric acid, glacial acetic acid, sodium hydroxide, sodium carbonate or sodium acid carbonate, a fluidizing agent such as benzyl alcohol or the like. The dosage of the compound of the present invention can be appropriately selected depending on the symptoms, age of the patients, dosage form and the like. For example, in the case of an oral preparation, the compound of the present invention may be administered in an amount generally of 0.01 to 1000 mg, preferably 1 to 100 mg per day, which may be administered in a single dose or in several divided doses. Furthermore, in the case of an ophthalmic solution, one containing the compound of the present invention in a concentration of 0.0001 to 10% (w / v), preferably 0.01 to 5%, (w / v) can be administered once a several times a day.

BEST MODE FOR CARRYING OUT THE INVENTION: The following are examples of preparation, formulation examples and the results of pharmacological tests of the compounds of the present invention: These examples are intended to make the present invention more clearly understood and that it does not limit later the scope of the present invention.

[Preparation Examples] Reference Example 1 4-chloromethyl-2-fluoropyridine (Reference Compound No. 1-1) N-chlorosuccinimide (8.8 g, 66 mmol) is added, 0.15 ml of acetic acid and benzoyl peroxide '(220 mg, 0. 91 mmol) was added to a solution of 2-fluoro-4-picoline (5.0 g, 45 mmol) in 25 ml of acetonitrile at room temperature, and the mixture was refluxed for 2 hours. The reaction mixture is cooled to room temperature, added 200 ml of water to it and then the mixture is extracted with 300 ml of ethyl acetate). The organic layer was washed with 200 ml of brine and dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure, hexane / ethyl acetate (1: 1) is added to the resulting residue, then the insoluble material is filtered off. The filtrate is evaporated under reduced pressure to provide 6.5 g of the title reference compound, as a crude product. 2 H-NMR (500 MHz, DMSO-ds) d 4.83 (s, 2 H), 7.26 (s, 1 H), 7.43 (d, J = 5.2 Hz, 1 H), 8.27 (d, J = 5.2 Hz, 1 H). described in the following, the reference compounds (No. 1-2) are obtained using the corresponding compounds that are selected from commercially available compounds or known compounds, according to the method of synthesis of the reference compound (No. 1-1 ). 2-bromo-4-chloromethylpyridine (reference compound No. 1-2) XH NMR (500 MHz, DMSO-dg) d 4.51 (s, 2H), 7.28 (s, 1H), 7.52 (d, J = 5.2 Hz , 1H), 8.36 (d, J = 5.2 Hz, 1H) Reference example 2 2- (2-fluoropyridin-4-ylmethylthio) pyridin-3-carboxylic acid (reference compound No. 2-1) A solution of triethylamine (7.0 ml, 50 mmol) in 20 ml of N, N-dimethylformamide is added to a solution of 4-chloromethyl-2-fluoropyridine (reference compound No. 1-1, 5.5 g, 38 mmol) and 2-mercaptonicotinic acid (6.2 g, 40 mmol) in 40 ml of N, N-dimethylformamide under cooling with ice, then the mixture is stirred for 12 hours at room temperature. 50 ml of ethyl acetate are added to the reaction mixture, the whole is extracted with 100 ml of a 0.1 N aqueous solution of. sodium hydroxide. 1 N hydrochloric acid is added to the aqueous layer to adjust to pH 5 and the precipitating crystal is filtered off. The crystal is dried at 80 D under reduced pressure to provide 5.3 g of the title compound of reference as a brown solid. (Yield 53%) NMR XH (500 MHz, DMSO-d6) d 4.43 (s, 2H), 7.20 (s, 1H), 7.23 (dd, J = 7.9, 4.9 Hz, 1H), 7.39 (d, J = 5.2 Hz, 1H) , 8.13 (d, J = 5.2 Hz, 1H), 8.24 (dd, J = 7.9, 1.8 Hz, 1H), 8.64 (dd, J = 4.9, 1.8 Hz, 1H), 14.60 (s broad, 1H) As described in the following, the reference compound (No. 2-2) is obtained by using the corresponding compounds that are selected from the reference compound (No. 1-2), from commercially available compounds or from known compounds according to the method of synthesis of the reference compound (No. 2-1). 2- (2-Bromopyridin-4-methylmethyl) pyridine-3-carboxylic acid (Reference Compound No. 2-2) XH NMR (500 MHz, DMSO, d6) d 4.37 (s, 2H), 7.28 (dd, J) = 7.8, 4.7 Hz, 1H), 7.48 (dd, J = 4.9, 1.4 Hz, 1H), 7.69 (dd, J = 1.4, 0.4 Hz, 1H), 8.23 (dd, J = 7.8, 1.7 Hz, 1H) , 8.27 (dd, J = 4.9, 0.4 Hz, 1H), 8.63 (dd, J = 4.7, 1.7 Hz, 1H), 13.55 (s, 1H) Reference Example 3 N- (3,5-dimethylphenyl) -2 - (2-fluoropyridin-4-ylmethylthio) pyridine-3-carboxamide (reference compound No. 3-1) O- (7-azabenzotriazol-1-yl) -N, N, N ', N' hexafluorophosphate is added -tetramethyluronium (3.0 g, 7.9 mmol) to a solution of 2- (2-fluoropyridin-4-ylmethylthio) pyridin-3-carboxylic acid (reference compound No. 2-1, 1.5 g, 5.7 mmol), 3,5-xylidine (0.90 g, 7.4 mmol) and N, N-diisopropylethylamine (2.0 ml, 11 mmol) in 20 ml of N, N-dimethylformamide at room temperature, and the mixture Stir for 12 hours. To the reaction mixture is added 30 ml of ethyl acetate, the whole is washed with 50 ml of brine and then the organic layer is dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure and the resulting residue is purified by silica gel column chromatography to provide 0.91 g of the title compound of reference as a colorless solid. (Performance 44%) NMR XH (500 MHz, DMSO-d6) d 2.26 (s, 6H), 4.46 (s, 2H), 6.76 (s, 1H), 7.18 (s, 1H), 7.29 (dd, J = 7.3, 4.6 Hz, 1H), 7.32 (s, 2H), 7.38 (d, J = 5.2 Hz, 1H), 7.94 (dd, J = 7.3, 1.5 Hz, 1H), 8.13 (d, J = 5.2 Hz, 1H), 8.58 ( dd, J = 4.6, 1.5 Hz, 1H), 10.32 (s, 1H) As described in the following, the reference compounds (No. 3-2-7) are obtained using the compounds that are selected from the reference compound (No. 2-1), The reference compound (No. 2-2), commercially available compounds or known compounds, according to the method of synthesis of the reference kit (No. 3-1). 2- (2-fluoropyridin-4-ylmethylthio) -N- (indan-5-yl) pyridine-3-ca-rboxamide (reference compound No. 3-2) 2 H NMR (500 MHz, DMS0-d6) d 1.98 -2.06 (m, 2H), 2.79-2.90 (m, 4H), 4.46 (s, 2H), 7.16-7.20 (m, 2H), 7.29 (dd, J = 7.3, 4.9 Hz, 1H), 7.38 (dd) , J = 4.6, 1.5 Hz, 2H), 7.61 (s, 1H), 7.95 (dd, J = 7.3, 1.5 Hz, 1H), 8.13 (d, J = 5.2 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.35 (s, 1H) 2- (2-fluoropyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (reference compound No. 3-3) XH NMR (500 MHz, DMS0-d6) d 4.47 (s, 2H), 7.18 (s, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.35-7.40 (m, 3H), 7.81 (d, J = 8.2 Hz, 2H), 8.00 (dd, J = 7.6, 1.8 Hz, 1H), 8.13 (d, J = 5.2 Hz, 1H), 8.61 (dd, J = 4.9, 1.8 Hz, 1H), 10.67 ( s, 1 H) 2- (2-bromopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (reference compound No. 3-4) XH NMR (400 MHz, DMS0-d6) d 2.26 (s, 6H), 4.41 (s, 2H), 6.76 (s, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H ), 7.32 (s, 2H), 7.47 (dd, J = 5.1, 1.5 Hz, 1H), 7.67 (d, J = 0.7 Hz, 1H), 7.94 (dd, J = 7.6, 1.7 Hz, 1H), 8.27 (dd, J = 5.1, 0.7 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.32 (s, 1H) 2- (2-bromopyridin-4-ylmethylthio) -N- (4- trifluoromethoxyphenyl) pyridine-3-carboxamide (reference compound No. 3-5) XH NMR (500 MHz, DMSO-d6) d 4.42 (s, 2H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 5.1 Hz, 1H), 7.67 (s, 1H), 7.80 (d, J = 8.7 Hz, 2H), 8.00 (dd, J = 7.6, 1.7 Hz, 1H), 8.27"(dd, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.68 (s, 1H) 2- (2-bromopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridine-3-carboxamide (reference compound No. 3-6) XH NMR (400 MHz, DMSO-d5) d 4.41 (s, 2H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.42 (d, J = 9.0 Hz, 2H), 7.47 (dd, J = 5.0, 1.5 Hz, 1H), 7.67 (d, J = 0.7 Hz, 1H), 7.73 (d, J = 9.0 Hz, 2H) , 8.00 (dd, J = 7.6, 1.7 Hz, 1H), 8.27 (dd, J = 5.0, 0.7 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.61 (s, 1H) 2 - (2-bromopyridin-4-ylmethylthio) -N- (4-difluoromethoxyphenyl) pyridine-3-carboxamide (reference compound No. 3-7) • XH NMR (400 MHz, DMSO-d6) d 4.41 (s, 2H) ), 7.16 (t, J = 74.2 Hz, 1H), 7.19 (d, J = 8.8 Hz, 2H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.47 (dd, J = 5.1, 1.5 Hz , 1H), 7.67 (s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.27 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.56 (s, 1H) Reference Example 4 (2-tert-butoxycarbonylaminopyridin-4-yl) methanol (reference compound No. 4-1) Diterbutyl dicarbonate is added (7.1 g, 32 mmol) was added to a solution of (2-aminopyridin-4-yl) methanol (3.0 g, 24 mmol) in 60 ml of tert.-butanol at room temperature and the mixture was stirred for 12 hours. The reaction mixture is evaporated under reduced pressure, 20 ml of ethyl acetate are added to the resulting residue and the insoluble material is then filtered off. The filtrate is evaporated under reduced pressure and the resulting residue is purified by silica gel column chromatography to provide 3.6 g of the title compound of reference as colorless crystal urine. (Yield 60%) H NMR aH (500 MHz, CDCl 3) d 1.56 (s, 9H), 1.86 (t, J = 6.1 Hz, 1H), 4.73 (d, J = 6.1 Hz, 2H), 7.00 (d, 'J = 5.2 Hz, 1H), 7.53 (broad s, 1H), 7.92 (s, 1H), 8.21 (d, J = 5.2 Hz, 1H) Reference Example 5 2-tert-butoxycarbonylamino-4- (tert-butyldimethylsilyloxymethyl) pyridine (reference compound No. 5 -1) Imidazole (2.1 g) is added, 31 mmol) and tert-butyldimethylsilyl chloride (4.4 g, 29 mmol) to a solution of (2-tert-butoxycarbonylaminopyridin-4-yl) methanol (reference compound No. 4-1, 6.2 g, 28 mmol) in 120 ml N , N-dimethylformamide at room temperature and the mixture is stirred for 2 hours. 300 ml of ethyl acetate are added to the reaction mixture, then the mixture is separated 750 ml of water and 200 ml of brine and then the mixture is dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure to provide 9.0 g of the title reference compound as a colorless solid. (Yield 96%) H NMR XH (400 MHz, DMSO-ds) d 0.09 (s, 6H), 0.92 (s, 9H), 1.46 (s, 9H), 4.72 (s, 2H), 6.93 (dd, J = 4.9, 0.9 Hz, 1H), 7.78 (s, 1H), 8.16 (d, J = 4.9 Hz, 1 H), 9.67 (s, 1 H) Reference Example 6 2- (N-terbutoxycarbonyl-N-methylamino) -4- (tert-butyldimethylsilyloxymethyl) ) pyridine (reference compound No. 6-1) Washed with 5.0 ml of hexane 60% sodium hydride (310 mg, 7.6 mmol) and the residue is suspended in 20 ml of N, N-dimethylformamide. 2-tert-butoxycarbonylamino-4- (tert-butyldimethylsilyloxymethyl) pyridine (reference compound? Or 5-1, 1.3 g, 3.7 mmol) are added dropwise to the suspension, for 15 minutes under ice-cooling, and iodide is added thereto. of methyl (2.4 ml, 39 mmol) and then the mixture is stirred overnight at room temperature. 70 ml of water are added to the reaction suspension and the whole is extracted with 100 ml of ethyl acetate. The organic is washed with 50 ml of a saturated aqueous solution of sodium hydrogencarbonate and 100 ml of brine, and dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure to provide 1.4 g of the mixture including the title reference compound as an orange-red oil.

RM? XH (500 MHz, CDC13) d 0.11 (s, 6H), 0.95 (s, 9H), 1.51 (s, 9H), 3.39 (s, 3H), 4.73 (s, 2H), 7.01 (d, J = 5.2 Hz, 1H), 7.57 (s, 1H), 8.31 (d, J = 5.-2 Hz, 1H) Reference Example 7 [2- (γ-tert-Butyloxycarbonyl-β-methylamino) pyridin-4-yl] methanol (Reference compound ○ 7-1) A solution of tetra-n-butylammonium fluoride trihydrate (1.3 g) is added , 4.2 mmol) in 20 ml of tetrahydrofuran to a solution of 2- (β-tert-butyloxycarbonyl-β-methylamino) -4- (tert-butyldimethylsilyloxymethyl) pyridine (reference compound ○ 6-1, 1.4 g, 3.7 mmol) in 20 ml of tetrahydrofuran. ml of tetrahydrofuran, for 5 minutes at room temperature and the mixture is stirred for 15 minutes. 50 ml of ethyl acetate and 100 ml of water are added to the reaction mixture, the whole is separated and then the aqueous layer is extracted with 50 ml of ethyl acetate. These organic layers are combined, then washed with 100 ml of brine and dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure, then the resulting residue is purified by silica gel column chromatography to provide 450 mg of the title reference compound as a reddish brown oil. (Yield 50%) NMR XH (500 MHz, CDC13) d 1.53 (s, 9H), 1.93 (t, J = 5.6 Hz, 1H), 3.40 (s, 3H), 4.73 (d, J = 5.6 Efz, 2H), 7.02 (d , J = 5.1 Hz, 1H), 7.70 (s, 1H), 8.34 (d, J = 5.1 Hz, 1H) Reference Example 8 4-bromomethyl-2-terbutoxycarbonylaminopyridine (reference compound No. 8-1) triphenylphosphine (970 mg, 3.7 mmol) and carbon tetrabromide 1.5 g, 4.6 mmol) to a solution of (2-tert-butoxycarbonylaminopyridin-4-yl) methanol (reference compound No. 4-1, 690 mg, 3.1 mmol) in 20 g. ml of methylene chloride under cooling with ice and the mixture is stirred for 2 hours at room temperature. 30 ml of ethyl acetate are added to the reaction mixture, the whole is washed with 20 ml of a saturated aqueous solution of sodium acid carbonate and 20 ml of brine, and then dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure and the resulting solid is filtered off with ethyl acetate to provide 550 mg of the reference compound as a colorless solid. (Yield 62%) H NMR XH (400 MHz, CDC13) d 1.54 (s, 9H), 4.38 (s, 2H), 6.99 (d, J = 5.1 Hz, 1H), 7.61 (broad s, 1H), 7.98 (s, 1H), 8.22 (d, J = 5.1 Hz, 1H) As described in the following, reference compounds (No. 8-2-3) are obtained using the corresponding compounds selected from the reference compound (No 7-1), commercially available compounds or known compounds, according to the method of synthesis of the reference compound (? O. 8-1). 4-bromomethyl-2- (β-tert-butyloxycarbonyl-β-methylamino) pyridine (reference compound No. 8-2) XH-NMR (500 MHz, DMS0-d6) d 1.48 (s, 9H), "3.29 (s, 3H), 4.67 (s, 2H), 7.17 (d, J = 5.1 Hz, 1H), 7.70 (s, 1H), 8.35 (d , J = 5.1 Hz, 1H) 4-bromomethyl-2-phthaloylaminopyridine (reference compound No. 8-3) XH NMR (500 MHz, CDC13) d 4.48 (s, 2H), 7.39 (dd, J = 5.2, 1.5 Hz, 1H), 7.48 (s, 1H), 7.80-7.84 (m, 2H), 7.96-8.00 (m, 2H), 8.67 (d, J = 5.2 Hz, 1H) Reference Example 9 2- (2-Acid -terthoxycarbonylaminopyridin-4-ylmethylthio) pyridine-3-carboxylic acid (reference compound No. 9-1) A solution of triethylamine (0.75 ml, . 4 mmole) in 2.0 ml of N, N-dimethylformamide to a solution of 4-bromomethyl-2-terbutoxycarbonylaminopyridine (reference compound No. 8-1, 500 mg, 1 .7 mmole) and 2-mercaptonicotinic acid (270 mg, 1.7 mmol) 3.0 ml of N, N-dimethylformamide, under ice-cooling and the mixture is stirred for 12 hours at room temperature, 20 ml of ethyl acetate are added to the reaction mixture and the whole is extracted with 50 ml. ml of a 0.1 N aqueous solution of sodium hydroxide, 1 N hydrochloric acid is added to the aqueous layer until pH 5 is adjusted and the precipitating crystal is filtered off.The crystal is dried under reduced pressure at 60 ° C to give 560 mg of the reference title compound as a colorless crystal (Yield 88%) H-NMR (500 MHz, DMSO-d6) d 1.46 (s, 9H), 4.35 (s, 2H), 7.05 (d, J = 5.2 Hz, 1H), 7.26 (dd, J = 7.9, 4.9 Hz, 1H), 7.87 (s, 1H), 8.12 (d, J = 5.2 Hz,? H), 8.23 (dd, J = 7. 9, 1.8 Hz, 1H), 8.63 (dd, J = 4.9, 1.8 Hz, 1H), 9.67 (s, 1H), 13.50 (s broad, 1H) As described in the following, reference compounds (No. 9-2-6) are obtained using the corresponding compounds selected from the reference compound (No. 8-2), reference compound (No. 8-3), commercially available compounds or compounds known in accordance with the method of synthesis of the reference compound (No. 9-1). 2- [2- (N-Terbutoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] pyridin-3-carboxylic acid (reference compound) No. 9-2) XH NMR (500 MHz, DMSO-ds) d 1.40 (s, 9H), 3.25 (s, 3H), 4.38 (s, 2H), 7.17 (dd, J = 5.2, 1.5 Hz, 1H), 7.27 (dd, J = 7.6, 4.9 Hz, 1H), 7.61 (s, 1H), 8.21-8.26 (m , 2H), 8.63 (dd, J = 4.9, 1.8 Hz, 1H), 13.49 (broad s, 1H) 2- (2-phthaloylaminopyridin-4-ylmethylthio) pyridine-3-carboxylic acid (reference compound No. 9- 3) XH NMR (400 MHz, DMSO-ds) d 4.46 (s, 2H), 7.27 (dd, J = 7.7, 4.8 Hz, 1H), 7.56 (d, J = 5.1 Hz, 1H), 7.61 (s, 1H), 7.91-8.00 (m, 4H), 8.23 (dd, J = 7.7, 1.8 Hz, 1H), 8. 52 (d, J = 5.1 Hz, 1H), 8.63 (dd, J = 4.8, 1.8 Hz, 1H), 13. 55 (s broad, 1H) 2- [2- (5-Cyanothiazol-2-ylamino) pyridin-4-ylmethylthio] pyridine-3-carboxylic acid (Reference compound No. 9-4) XH NMR (400 MHz, DMSO-d6) d 4.39 (s, 2H), 7.12 (d, J = 5.1 Hz, 1H), 7.21 (s, 1H), 7.27 (dd, J = '7.8, 4.6 Hz, 1H), 8.23 (dd, J = 7.8, 1.7 Hz, 1H), 8.25 (s, 1H), 8.29 (d, J = 5.1 Hz, 1H), 8.62 (dd, J = 4.6, 1.7 Hz, 1H) , 12.19 (s, 1H), 13.52 (broad s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) benzoic acid (reference compound No. 9-5) XH NMR (500 MHz, DMSO-d6) d 1.47 (s, 9H) , 4.22 (s, 2H), 7.09 (d, J = 5.2 Hz, 1H), 7.22 (t, J = 7, 6 Hz, 1H), 7. 42 (d, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.88 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 8.16 (d, J = 5.2 Hz, 1H), 9.74 (s, 1H), 13.10 (broad s, 1H) 3- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) thiophene-2-carboxylic acid (reference compound X H NMR (400 MHz, DMSO-dg) d 1.47 (s, 9H), 4.33 (s, 2H), 7.09 (d, J = 5.1 Hz, 1H), 7.17 (d, J = 5.1 Hz, 1H), 7.85 (d, J = 5.1 Hz, 1H), 7.90 (s, 1H), 8.17 (d, J = 5.1 Hz, 1H), 9.76 (s, 1H), 13.04 (s broad, 1H) Reference Example 10 N- (3,5-dimethylphenyl) -2-thioxo- 1, 2-dihydropyridine-3-carboxamide (reference compound No. 10-1) 2-mercaptonicotinic acid (90 g, 0.58 mol) is suspended in 660 ml of N, N-dimethylformamide and carbonyldiimidazole is added thereto (110 g, 0.70 mol) under ice-cooling and then the mixture is stirred at room temperature for 2 hours, 5.4 ml of water are added thereto, the whole is stirred for 40 minutes, 3,5-xylidine is added thereto. (76 ml, 0.61 mol) and the mixture is stirred for 16 hours at 6 ° D. The mixture is allowed to settle, 1.3 1 of water is added thereto and then The precipitated solid is filtered off. The solid is dried under reduced pressure at 45 D to provide 130 g of the title reference compound as a yellow solid. (Performance 89%) NMR XH (500 MHz, DMSO-dg) d 2.27 (s, 6H), 6.77 (s, 1H), 7.10 (dd, J = 7.6, 6.0 Hz, 1H), 7.34 (s, 2H), 8.03 (dd, J = 6.0, 1.8 Hz, 1H), 8.55 (dd, J = 7.6, 1.8 Hz, 1H), 12.90 (s, 1H), 14.18 (s, 1H) As described in the following, reference compounds are obtained (No. 10-2-10) using the corresponding compounds that are selected from commercially available compounds or known compounds, in accordance with the method of synthesis of the reference compound (No. 10-1). 2-thioxo-N- (4-trifluoromethoxyphenyl) -1,2-dihydropyridine-3-carboxamide (reference compound No. 10-2) XH NMR (500 MHz, DMSO-dg) d 7.08 (dd, '"j = 7.5, 5.8 Hz, 1H), 7.39 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.8 Hz, 2H), 8.03 (dd, J = 5.8, 1.8 Hz, 1H), 8.48 (dd, J = 7.5, 1.8 Hz, 1H), 12.91 (s, 1H), 14.19 (s, 1H) N- (4-chlorophenyl) -2-thioxo-1,2-dihydropyridine-3-carboxamide (reference compound No. 10-3) XH NMR (400 MHz, DMSO-dg) d 7.08 (dd, J = 7.6, 6.1 Hz, 1H), 7.43 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 8.7 Hz, 2H), 8.03 (dd, J = 6.1, 1.8 Hz, 1H), 8.48 (dd, J = 7.6, 1.8 Hz, 1H), 12.90 (s, 1H), 14.19 (s, 1H) N- (indan-5 -yl) -2-thioxo-l, 2-dihydropyridin-3-carboxamide (reference compound 10-4) XH NMR (400 MHz, DMSO-dg) d 1.98-2.06 (m, 2H), 2.82.81-2.89 ( m, 4H), 7.09 (dd, J = 7.6, 4.8 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.43 (dd, J = 8.1, 2.0 Hz, 1H), 7.62 (s, 1H) ), 8.03 (dd, J = 4.8, 1.7 Hz, 1H), 8.55 (dd, J = 7.6, 1.7 Hz, 1H), 12.93 (s, 1H), 14.18 (s, 1 H) N- (4-tert-butylphenyl) -2-thioxo-1,2-dihydropyridine-3-carboxamide (reference compound No. 10-5) XH NMR (400 MHz, DMSO-dg) d 1.28 (s, 9H), 7.09 ( dd, J = 7.6, 5.9 Hz, 1H), 7.39 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H), 8.03 (dd, J = 5.9, 1.9 Hz, 1H), 8.55 (dd, J = 7.6, 1.9 Hz, 1H), 12.90 (s, 1H), '- 14.19 (s, 1H) N- (3-methylphenyl) -2-thioxo-1,2-dihydropyridine-3-carboxamide (reference compound No. 10-6) XH NMR (400 MHz, DMSO-dg) d 2.32 (s, 3H), 6.95 (d, J = 7.6 Hz, 1H), 7.10 (dd, J = 7.6, 5.9 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.52-7.55 (m, 2H), 8.03 (dd, J = 5.9, 2.0 Hz, 1H), 8.54 (dd, J = 7.6, 2.0 Hz, 1H), 12.91 (s, 1H), 14.19 (s, 1H) 2-thioxo-N- (4-trifluoromethylphenyl) -1 , 2-dihydropyridine-3-carboxamide (reference compound No. 10-7) XH NMR (500 MHz, DMSO-dg) d 7.09 (dd, J = 7.6, 5.8 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.92 (d, J = 8.4 Hz, 2H), 8.04 (dd, J = '5.8, 1.8 Hz, 1H), 8.47 (dd, J = 7.6, 1.8 Hz, 1H), 13.04 (s, 1H), 14.20 (s broad, 1H) N- (3-chlorophenyl) -2-thioxo-1,2-dihydropyridin-3-carboxamide (reference compound No. 10 -8) XH NMR (500 MHz, DMSO-dg) d 7.08 (dd, J = 7.6, 5.8 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.96 (t, J = 2.0 Hz, 1H), 8. 03 (dd, J = 5.8, 1.8 Hz, 1H), 8.46 (dd, J = 7.6, 1.8 Hz, 1H), 12.90 (s, 1H), 14.19 (broad s, 1H) N- (4-difluoromethoxyphenyl) - 2-thioxo-l, 2-dihydropyridine-3-carboxamide (reference compound No. 10-9) XH NMR (500 MHz, DMSO-dg) d 7.09 (dd, J = 7.5, 4.8 Hz, 1H), 7.18 ( t, J = 74.6 Hz, 1H), 7.20 (d, J = 9.1 Hz, 2H), 7.75 (d, J = 9.1 Hz, 2H), 8.03 (dd, J = '.8, 1.9 Hz, 1H), 8.51 (dd, J = 7.5, 1.9 Hz, 1H), 12.90 (s, 1H), 14.18 (s, 1H) N- (isoquinolin-3-yl) -2-thioxo-1,2-dihydropyridine-3-carboxamide (reference compound No. 10-10) XH NMR (400 MHz, DMSO-dg) d 7.15 (dd, J = 7.8, 6.1 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.75 (t, J = 7.0 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 8.08-8.10 (m, 2H), 8.69-8.72 (m, 2H), 9.19 (s, 1H), 13.71 (s, 1H), 14, 24 (s, 1H) Reference Example 11 4-acetoxymethyl-2-acetylaminopyridine (reference compound No. 11- 1) Suspend (2-aminopyridin-4-yl) methanol (5.0 g, 40 mmol) in 20 ml of pyridine, add thereto, under ice-cooling, acetic anhydride (11 ml, 120 mmol) and mix it is stirred for 5 hours at room temperature. To the reaction mixture is added 150 ml of ethyl acetate and then the mixture is washed with 150 ml of water, 150 ml of a saturated aqueous solution of sodium acid carbonate and 150 ml of brine, successively. The organic layer is dried over anhydrous magnesium sulfate and the solvent is evaporated under reduced pressure. The resulting solid is filtered off with hexane, then dried under reduced pressure at 4 [deg.] D to provide 6.7 g of the title reference compound as a colorless solid. (Performance 79%) H H NMR XH (500 MHz, DMSO-d6) d 2.09 (s, 3H), 2.11 (s, 3H), 5.11 (s, 2H), 7.04 (d, J = 5.2 Hz, 1H), 8.05 (s, 1H), 8. 27 (d, J = 5.2 Hz, 1H), 10.51 (s, 1H) Reference Compound No. 12 (2-acetylaminopyridin-4-yl) methanol (reference compound No. 12-1) 4-acetoxymethyl- is dissolved 2-acetylaminopyridine (Reference compound No. 11-1, 6.6 g, 32 mmol) in 20 ml of tetrahydrofuran and dropwise thereto, under ice-cooling, a 2 N aqueous solution of sodium hydroxide (19 ml, 38 mmol) ). The mixture is stirred for 40 minutes at room temperature and 100 ml of water are added thereto. The whole is extracted with 80 ml of ethyl acetate six times, and then the organic layer is dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and the resulting solid is filtered off with the mixed solvent of ethyl acetate and hexane and then the solid is dried under reduced pressure at 4 [deg.] D to provide 4.5 g of the title reference compound as a solvent. colorless solid. (Yield 86%) H NMR XH (400 MHz, DMSO-d6) d 2.08 (s, 3H), 4.50 (d, J = 5.9 Hz, 2H), 5.40 (t, J = 5.9 Hz, 1H), 7.01 (d, J = 4.9 Hz , 1H), 8.05 (s, 1H), 8.20 (d, J = 4.9 Hz, 1H), 10.38 (s, 1H) Reference Example 13 2-Acetylamino-4-methanesulfonyloxymethylpyridine (reference compound No. 13-1) A solution of triethylamine (1.7 ml, 12 mmol) and methanesulfonyl chloride (0.70 ml, 9.0 mmol) in 3.0 ml of anhydrous tetrahydrofuran is added to a solution of (2-acetylaminopyridin-4-yl) methanol (reference compound No. 12-1, 1.0 g, 6.0 mmol) in 9.0 ml of anhydrous tetrahydrofuran under cooling with ice, and the mixture is stirred for 20 minutes. 30 ml of water are added to the reaction mixture, the whole is extracted with 40 ml of ethyl acetate three times and then the organic layer is dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and the resulting solid is filtered off with hexane. The solid is dried under reduced pressure at 4? D to provide 1.3 g? of the title reference compound as a light yellow solid.

(Performance 87%) H NMR XH (400 MHz, CDC13) d 2.22 (s, 3H), 3.08 (s, 3H), 5.25 (s, 2H), 7.10 (dd, J = 5.2, 1.8 Hz, 1H), 8.18 (s, 1H) , 8.23 (s, 1H), 8.30 (d, J = 5.2 Hz, 1H) Reference Example 14 2-Amino-4-bromomethylpyridine Bromhydrate (reference compound No. 14-1) Suspended (2-aminopyridin-4 -yl) methanol (15 g, 12 mmol) in a 47% aqueous solution of hydrobromic acid (120 ml, 72 mmol) at room temperature, and the mixture is stirred for 6 hours at outdoor temperature of 12 OD. The mixture is stirred for 15 hours at room temperature, then the precipitated solid is filtered off and washed with ethyl acetate. The solid is dried under reduced pressure to provide 23 g of the title reference compound as a gray solid. (Yield 71%) HBr NMR XH (400 MHz, DMSO-dg) d 4.69 (s, 2H), 6.88 (dd, J = 6.8, 1.7 Hz, 1H), 7.04 (s, 1H), 7.94 (d, J = 6.8 Hz, 1H) , 8.13 (broad s, 2H), 13.28 (broad s, 1H) Example 1 N- (3,5-dimethylphenyl) -2- [2- (4-methylpiperazin-1-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 1-1) 2.0 ml of N-methylpiperazine to N- (3,5-dimethylphenyl) -2- (2-fluoropyridin-4-ylmethylthio) pyridine-3-carboxamide (reference compound No. 3-1, 100 mg, 0.27 mmol) at room temperature, and then the vessel is sealed and the reaction mixture is stirred for 3 hours at 150D. The mixture is cooled to room temperature, 20 ml of ethyl acetate are added to the reaction mixture and then the whole is washed with 20 ml of brine and dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure and the resulting solid is filtered off with ethyl acetate to provide 39 mg of a target compound as a colorless crystal. (Yield 32%) XH NMR (500 MHz, DMSO-dg) d 2.19 (s, 3H), 2.25 (s, 6H), 2.35 (t, J = 5.0 Hz, 4H), 3.42 (t, J = 5.0 Hz, 4H), 4.31 (s, 2H), 6.64 (dd, J = 5.2, 1.2 Hz, 1H), 6.76 (s, 1H), 6.84 (s, 1H), 7.28 (dd, J = 7.5, 4.9 Hz, 1H), 7.32 (s, 2H) ), 7.91 (dd, J = 7.5, 1.8 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 8.59 (dd, J = 4.9, 1.8 Hz, 1H), 10.30 (s, 1H). described in the following, the compounds are obtained (No. 1-2-21) using the corresponding compounds which are selected from the reference compounds (No. 3-1-3), commercially available compounds or compounds known in accordance with Synthesis method of the compound (No. 1-1). 2- (2-cyclopropylaminopyridin-4-ylmethylthio), N- (3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 1-2) XH NMR (500 MHz, CDCl3) d 0.48-0.53 (m, 2H) ), .0.73-0.77 (m, 2H), 2.32 (s, 6H), 2.46 (m, 1H), 4.41 (s, 2H), 5.20 (s broad, 1H), 6.67 (d, J = 5.2 Hz, 1H), 6.79 (s, 1H), 6.81 (s, 1H), 7.13 (dd, J = 7.6, 4.9 Hz, 1H), 7.24 (s, 2H), 7.88-7.91 (m, 2H), 7.93 (d , J = 5.2 Hz, 1H), 8.91 (dd, J = 4.9, 1.8 Hz, 1H) 2- [2- (N- (2-dimethylaminoethyl) -N-methylamino) pyridin-4-ylmethylthiol-N- (3 , 5-dimethylphenyl) pyridin-3-carboxamide (compound No. 1-3) XH NMR (500 MHz, DMSO-dg) d 2.13 (s, 6H), 2.25 (s, 6H), 2.33 (t, J = 7.0 Hz, 2H), 2.94 (s, 3H), 3.56 (t, J = 7.0 Hz, 2H), 4.30 (s, 2H), 6.53 (d, J = 5.2 Hz, 1H), 6.60 (s, 1H), 6.76 (s, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.31 (s, 2H), 7.90 (dd, J = 7.6, 1.5 Hz, 1H ), 7.93 (d, J = 5.2 Hz, 1H), 8.59 (dd, J = 4.9, 1.5 Hz, 1H), 10.30 (s, 1H) N- (3,5-dimethylphenyl) -2- (2-morpholinopyridine) -4-ylmethylthio) pyridine-3-carboxamide (compound No. 1-4) XH NMR (500 MHz, CDCl3) d 2.32 (s, 6H), 3.47 (t, J = 4.9 Hz, 4H), 3.80 (t, J = 4.9 Hz, 4H), 4.40 (s, 2H), 6.70 (s, 1H), 6.72 (d, J = 5.2 Hz, 1H), 6.82 (s, 1H), 7.15 (dd, J = 7.6, 4.8 Hz, 1H), 7.24 (s, 2H), 7.76 (s, 1H), 7.90 (dd, J = 7.6, 1.5 Hz, 1H), 8.10 (d, J = 5.2 Hz, 1H), 8.54 (dd, J = 4-8, 1.5 Hz, 1H) N- (3, 5-dimethylphenyl) -2- [2- (piperidin-1-yl) pyridin-4-ylmethylthio] pyridin-3-carboxamide (Compound No. 1-5 ) NMR XH (500 MHz, DMSO-dg) d 1.46-1.60 (m, 6H), 2.25 (s, 6H), 3.46 (t, J = 5.2 Hz, 4H), 4.30 (s, 2H), 6.58 (d) , J = 6.1 Hz, 1H), 6.76 (s, 1H), 6.82 (s, 1H) ), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.91 (m, 1H), 7.96 (m, 1H), 8.58 (dd, J = 4.9, 1.8 Hz, 1H) , 10.30 (s, 1H) 2- [2- (4-acetylpiperazin-1-yl) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (compound No. 1-6) NMR XH (500 MHz, CDCl 3) d 2.13 (s, 3H), ¿32 (s, 6H), 3.46-3.49 (m, 2H), 3.54-3.56 (m, 2H), 3.59-3.61 (m, 2H) ), 3.70-3.73 (m, 2H), 4.39 (s, 2H), 6.72 (m, 1H), 6.82 (s, 1H), 7.00 (s, 1H), 7.15 (dd, J = 7.6, 4.8 Hz, 1H), 7.24 (s, 2H), 7.75 (s, 1H), 7.89 (dd, J = 7.6, 1.7 Hz, 1H), 8.09 (dd, J = 4.6, 1.2 Hz, 1H), 8.54 (dd, J = 4.8, 1.7 Hz, 1H) 2- [2- (4-terthoxycarbonylpiperazin-1-yl) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 1-7 ) NMR XH (400 MHz, CDC13) d 1.47 (s, 9H), 2.29 (s, 6H), 3.49 (s broad, 8H), 4.36 (s, 2H), 6.68 (d, J = 5.3 Hz, 1H) , 6.70 (s, 1H), 6.80 (s, 1H), 7.08 (dd, J = 7.6, 4.9 Hz, 1H), 7.29 (s, 2H), 7.85 (dd, J = 7.6, 1.7 Hz, 1H), 8.05, (s, 1H), .8.07 (d, J = 5.3 Hz, 1H), 8.51 (dd, J = 4.9, 1.7 Hz, 1H) N- (3,5-dimethylphenyl) -2- [2- (N- (2-hydroxyethyl) -N-methylamino) pyridin-4 ~ ilmethylthio] pyridin-3-carboxamide (compound No. 1-8) XH NMR (500 MHz, CDC13) d 2.17 (s, 1H), 2.32 (s, 6H), 3.02 (s, 3H), 3.66 (t, J = 5.0 Hz, 2H), 3.79 (t, J = 5.0 Hz, 2H), 4.38 (s, 2H), 6.59 (s, 1H), 6.63 (dd, J = 5.2, 1.8 Hz, 1H), 6.81 ( s, 1H), 7, 13 (dd, J = 7.6, 4.9 Hz, 1H), 7.24 (s, 2H), 7.87 (s, 1H), 7.89 (dd, J = -7.6, 1.5 Hz, 1H), 7.94 (d, J = 5.2 Hz, 1H), 8.53 (dd, J = 4.9, 1.5 Hz, 1H) N- (3, 5-dimethylphenyl) -2- [2- (4-hydroxypiperidin-1-yl) pyridine -4-ylmethylthio] pyridine-3-carboxamide (compound No. 1-9) XH NMR (500 MHz, CDC13) d 1.43 (s, 1H), 1.48-1.61 (m, 2H), 1.92-1.98 (m, 2H ), 2.32 (s, 6H), 3.09-3.14 (m, 2H), 3.90 (m, 1H), 4.01-4.06 (m, 2H), 4.38 (s, 2H), 6.64 (dd, J = 5.1, 1.1 Hz, 1H), 6.73 (s, 1H), 6.82 (s, 1H), 7.14 (dd, J = 7.6, 4.8 Hz, 1H), 7.24 (s, 2H), 7.79 (s, 1H), 7.90 (d , J = 4.8 Hz, 1H), 8.08 (d, J = 5.1 Hz, 1 H), 8.55 (dd, J = 4.8, 1.8 Hz, 1H) N- (indan-5-yl) -2- (2-morpholinopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 1-10) NMR XH (500 MHz, CDCl3) d 2.03-2.13 (m, 2H), 2.85, 2.94 (m, 4H), 3.47 (t, J = 4.9 Hz, 4H), 3.80 (t, J = 4.9 Hz, 4H) , 4.39 (s, 2H), 6.68-6.72 (m, 2H), 7.15 (dd, J = 7.6, 4.8 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 7.24 (s, 1H), 7.58 (s, 1H), 7.81 (s, 1H), 7.91 (d, J = 7.6 Hz, 1H), 8.10 (d, J = 5.2 Hz, 1H), 8.54 (dd, J = 4.8, 1.8 Hz, 1H ) 2- [2- (4-acetylpiperazin-1-yl) pyridin-4-ylmethylthio] -N- (indan-5-yl) -pyridine-3-carboxamide (Compound No. 1-11) XH-NMR (500 MHz , CDC13) d 2.09 (t, J = 7.3 Hz, 2H), 2.13 (s, 3H), 2.87-2.94 (m, 4H), 3.47 (t, J = 5.2 Hz, 2H), 3.53-3.58 (m, 2H), 3.59-3.62 (m, 2H), 3.72 (t, J = 5.2 Hz, 2H), 4.39 (s, 2H), 6.72 (m, 2H), 7.15 (dd, J = 7.6, 4.8 Hz, 1H ), 7.19 (d, J = 8.9 Hz, 1H), 7.24 - (s, 1H), 7.58 (s, 1H), 7.80 (s, 1H), 7.91 (d, J = 6.7 Hz, 1H), 8.09 ( m, 1H), 8.54 (dd, J = 4.8, 1.8 Hz, 1H) 2- (2-morpholine) pyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 1-12) XH NMR (500 MHz, DMSO-dg) d 3.38 (t, J = 4.8 Hz, 4H), 3.66 (t, J = 4.8 Hz, 4H), 4.33 (s, 2H), 6, 70 (dd, J = 5.2, 1.2 Hz, 1H), 6.86 (s, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.97 ( dd, J = 7.6, 1.8 Hz, 1H), 8.01 (d, J = 5.2 Hz, 1H), 8.62 (dd, J = 4.9, 1.8 Hz, 1H), 10.66 (s, 1H) 2- [2- ( 4-acetylpiperazin-1-yl) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxy-phenyl) -pyridinium-3-carboxamide (Compound No. 1-13) XH-NMR (400 MHz, CDC13) d 2.05 (s, 3H) , 3.44-3.49 (m, 2H), 3.52-3.57 (m, 2H), 3.59-3.63 (m, 2H), 3.68-3.73 (m, 2H), 4.40 (s, 2H), 6.70-6.73 (m, 2H), 7.17 (dd, J = 7. 6, 4.9 Hz, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.64 (d, J = 8. 3 Hz, 2H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 7.98 (s, 1H), 8.10 (dd, J = 5.1, 0.7 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H) N- (3,5-dimethylphenyl) -2- [2- (4-ethoxycarbonylpiperazin-1-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 1-14) XH NMR (400 MHz, DMSO-ds) d 1 * 15-1.21 (m, 3H), 2. 25 (s, 6H), 3.18-3.40 (m, 2H), 3.41-3.48 (m, 6H), 4.03-4.09 (m, 2H), 4.32 (s, 2H), 6.68 (d, J = 5.0 Hz, 1H), 6.76 (s, 1H), 6.88 (s, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.91 (dd, J = 7.6, 1.7 Hz, 1H ), 8.00 (d, J = 5.0 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.31 (s, 1H) N- (3,5-dimethylphenyl) -2- (2-thiomorpholinopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 1-15) XH NMR (400 MHz, DMSO-d6) d 2.25 '(s, 6H), 2.49- 2.56 (m, 4H), 3.84-3.87 (m, 4H), 4.30 (s, 2H), 6.62 (d, J = 5.3 Hz, 1H), 6.76 (S, 1H), 6.86 (s) , 1H), 7.28 (dd, J = 7.6, 4. 9 Hz, 1H), 7.32 (s, 2H), 7.91 (dd, J = 7.6, 1.7 Hz, 1H), 7. 98 (d, J = 5.3 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), . 31 (s, 1H) N- (3, 5-dimethylphenyl) -2- [2- (3-hydroxymethylpiperidin-1-yl) pyridin-4-ylmethylthio] pyridin-3-carboxamide (Compound No. 1-16) NMR XH (500 MHz, DMSO-dg) d 1.14 (m, 1H), 1.37-1.74 (m, 4H), 2.25 (s, 6H), 2.71-2.77 (m, 2H), 3.24-3.35 (m, 2H) , 4.12 (d, J = 13.1 Hz, 1H), 4.24 (d, J = 13.1 Hz, 1H), 4.29 (s, 2H), 4.54 (t, J = 5.2 Hz, 1H), 6.58 (d, J = 5.2 Hz, 1H), 6.76 (s, 1H), 6.82 (s, 1H), 7.27 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.91 (dd, J = 7.6, 1.6 Hz, 1H), 7.95 (d, J = 5.2 Hz, 1H), 8.59 (dd, J = 4.9, 1.6 Hz, 1H), 10.30 (s, 1H) 2- [2- ((2S) -dimethylaminocarbonylpyrrolidin-il -yl) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (compound No. 1-17) XH-NMR (400 MHz, DMSO-dg) d 1.90-2: 00 (m , 2H), 2.25 (s, 6H), 2.76 (s, 3H), 3.08 (s, 3H), 3.20, 3.45 (m, 4H), 4.27 (d, J = 13.6 Hz, 1H), 4.33 (d, J = 13.6 Hz, 1H), 4.87 (m, 1H), 6.41 (s, 1H), 6.53 (dd, J = 5.4, 1.3 Hz, 1H), 6. 75 (s, 1H), 7.27 (dd, J = 7.5, 4.9 Hz, 1H), 7.32 (s, 2H), 7.87 (d, J = 5.4 Hz, 1H), 7.89 (dd, J = 7.5, 1.7 Hz , 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.32 (s, 1H) 2- [2- (3-dimethylaminopyrrolidin-1-yl) pyridin-4-ylmethylthio -N- (3, 5 -dimethylphenyl) pyridin-3-carboxamide (compound No. 1-18) XH NMR (400 MHz, DMSO-dg) d 1.75 (m, 1H), '2.11 (m, 1H), 2.17 (s, 6H), 2.25 (s, 6H), 2.74 (m, 1H), 3.04 (m, 1H), 3.28 (m, 1H), 3.50 (t, J = 8.5 Hz, 1H), 3.60 (dd, J = 9.8, 7.1 Hz, 1H), 4.30 (s, 2H), 6.48 (s, 1H), 6.54 (dd, J = 5.1, 1.2 Hz, 1H), 6.76 (s, 1H), 7.27 (dd, J = 7.8, 5.0 Hz, 1H ), 7.32 (s, 2H), 7.89-7.93 (m, 2H), 8.59 (dd, J = 5.0, 1.7 Hz, 1H), 10.30 (s, 1H) N- (3, 5-dimethylphenyl) -2- [2- (2-hydroxyethylamino) pyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 1-19) XH NMR (400 MHz, CDC13) d 2.32 (s, 6H), 2.88 (s, 1H), 3.43 (t, J = 4.6 Hz, 2H), 3.74 (t, J = 4.6 Hz, 2H), 4.34 (s, 2H), 5.08 (s, 1H), 6.52 (s, 1H), 6.63 (dd, J = 5.4, 1.2 Hz, 1H), 6.81 (d, J = 0.8 Hz, 1H), 7.11 (dd, J = 7.8, 4.8 Hz, 1H), 7.24 (s, 2H), 7.83-7.93 (m, 3H), 8.51 (dd, J = 4.8, 1.7 Hz, 1H ) N- (3,5-dimethylphenyl) -2- (2-n-pentylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (Compound No. 1-20) XH NMR (500 MHz, CDC13) d 0.86-0.92 ( , 3H), 1.20- 1.38 (m, 4H), 1.55-1.60 (m, 2H), 2.31 (s, 6H), 3.18-3.20 (m, 2H), 4.35 (s, 2H), 4.57 (s, 1H) ), 6.41 (s, 1H), 6.58 (dd, J = 5.2, 1.5 Hz, 1H), 6.80 (s, 1H), 7.09 (dd, J = 7.6, 4.9 Hz, 1H), 7.24 (s, 2H) , 7.86 (dd, J = 7.6, 1.7 Hz, 1H), 7.94 (d, J = 5.2 Hz, 1H), 8.02 (s, 1H), 8.51 (dd, J = 4.9, 1.7 Hz, 1H) N- ( 3,5-dimethylphenyl) -2- [2- (4-ethoxycarbonylpiperidin-1-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 1-21) XH-NMR (500 MHz, DMSO-dg) d 1.18 (t, J = 7.0 Hz, 3H), 1.48-1.51 (m, 2H), 1.82-1.86 (m, 2H), 2.25 (s, 6H), 2.57 (m, 1H), 2.86-2.93 (m , 2H), 4.06 (c, J = 7.0 Hz, 2H), 4.13-4.16 (m, 2H), 4.30 (s, 2H), 6.62 (dd, J = 5.2, 1.1 Hz, 1H), 6.76 (s, 1H), 6.87 (s, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.91 (dd, J = 7.6, 1.7 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.31 (s, 1H) Example 2 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- ( 3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 2-1) O- (7-azabenzotriazol-1-yl) -N, N, NXN '-tetramethyluronium hexafluorophosphate (630 mg, 1.7 mmol) is added to a solution of 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) pyridine-3-carboxylic acid (reference compound No. 9-1, 500 mg, 1.4 mmol), 3,5-xylidine (180 mg, 1.5 mmol) ) and N, N-diisopropylethylamine (0.72 ml, 4.1 mmol) in 7 ml of N, N-dimethylformamide at room temperature, and the mixture is stirred for 12 hours. 30 ml of ethyl acetate are added to the reaction mixture, then the whole is washed with 50 ml of brine and dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure, then the resulting residue is purified by silica gel column chromatography to provide 670 mg of the objective compound quantitatively, as a colorless solid, NMR XH (500 MHz, DMSO-ds) d 1.45 (s, 9H), 2.25 (s, 6H), 4.38 (s, 2H), 6.76 (s, 1H), 7.03 (d, J = 5.2 Hz, 1H) , 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.87 (s, 1H), 7.92 (dd, J = 7.6, 1.8 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.57 (dd, J = 4.9, 1.8 Hz, 1H), 9.66 (s, 1H), 10.30 (s broad, 1H) As described in the following, the compounds are obtained (No. 2-2 -36) using the corresponding compounds that are selected from the reference compounds (No. 9-1-6), commercially available compounds or known compounds, according to the method of synthesis of the compound (No. 2-1). 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridine-3-carboxamide (Compound No. 2-2) XH NMR (500 MHz, DMSO-dg) d 1.20 (d, J = 7.0 Hz, 6H), 1.45 (s, 9H), 2.86 (m, 1H), 4.39 (s, 2H), 7.00 (d, J = 7.6 Hz, 1H), 7.04 (dd, J = 4.9, 1.5 Hz, 1H ), 7.24-7.30 (m, 2H), 7.51 (d, J = 7.6 Hz, 1H), 7.59 (s, 1H), 7.87 (s, 1H), 7.96 (dd, J = 7.6, 1.5 Hz, 1H) , 8.11 (m, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 9.66 (s, 1H), 10.39 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- ( indan-5-yl) pyridin-3-carboxamide (compound No. 2-3) XH NMR (500 MHz, DMSO-dg) d 1.45 (s, 9H), 1.98-2.04 (m, 2H), 2.80-2.89 ( m, 4H), 4.38 (s, 2H), 7.03 (dd, J = 4.9, 1.5 Hz, 1H), 7.17 (d, J = 8.2 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H ), 7.38 (d, J = 8.2 Hz, 1H), 7.61 (s, 1H), 7.87 (s, 1H), 7.93 (d, J = 7.6, 1.5 Hz, 1H), 8.11 (d, J = 4.9 Hz , 1H), 8.57 (dd, J = 4.9, 1.5 Hz, 1?), 9.67 (s, 1H), 10.33 (s, 1H) 2- (2-terbutoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridin-3-carboxamide (Compound No. 2-4) XH NMR (500 MHz, DMSO-dg) d 1.45 (s, 9H), 4.39 (s, 2H), 7.03 (d, J = 5.2 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.81 (d, J = 8.2 Hz, 2H), 7.87 (s, 1H), 7.98 (dd, J = 7.6, 1.8 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.9, '1.8 Hz, 1H) , 9.67 (s, 1H), 10.66 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) pyridine-3-carboxamide (Compound No. 2-5) XH-NMR (500 MHz, DMSO-d6) d 1.27 (s, 9H), 1.45 (s, 9H), 4.38 (s, 2H), 7.03 (d, J = 5.2 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz , 1H), 7.36 (d, J = 8.8 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.87 (s, 1H), 7.94 (dd, J = 7.6, 1.5 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 9.67 (s, 1H), 10.39 (s, 1H) 2- (2-terbutoxycarbonylaminopyridin-4-ylmethylthio) - N- (1H-indazol-6-yl) pyridine-3-carboxamide (Compound No. 2-6) XH-NMR (500 MHz, DMSO-dg) d 1.45 (s, 9H), 4.40 (s, 2H), 7.04 (d, J = 5.2 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.87 (s, 1H) , 7.97-8.00 (m, 2H), 8.11 (d, J = 5.2 Hz, 1H) 8.21 (s, 1H), 8.60 (d, J = 4.9, 1.6 Hz, 1H), 9.68 (s, 1H), 10.60 (s, 1H), 12.95 (s, 1H) 2- [2- (N-terbutoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridine-3-carboxamide ( Compound No. 2-7) XH NMR (500 MHz, DMSO, d6) d 1.41 (s, 9H), 2.25 (s, 6H), 3.24 (s, 3H), 4.41 (s, 2H), 6.76 (s, 1H), 7.15 (d, J = 5.2 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.31 (s, 2H), 7.64 (s, 1H), 7.93 (dd, J = 7, 6, 1.5 Hz, 1H), 8.25 (d, J = 5.2 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.29 (s, 1H) 2- [2- (N-terbutoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -N- (indan-5-yl) pyridin-3-carboxamide (compound No. 2-8) XH NMR (500 MHz, DMSO-dg) d 1.41 (s, 9H), 2.01 (t, J = 7.3 Hz, 2H), 2.80-2.86 (m, 4H), 3.24 (s) , 3H), 4.41 (s, 2H), 7.14-7.18 (m, 2H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 8.6 Hz, 1H), 7.61 (s, 1H), 7.64 (s, 1H), 7.92 (dd, J = 7.6, 1.8 Hz, 1H), 8.24 (d, J = 4.9 Hz, 1H), 8.58 (dd, J = 4.9, 1.8 Hz, 1H), 10.33 (s, 1H) 2- [2- (N-tert-butoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 2-9) XH NMR ( 500 MHz, DMSO-d6) d 1.40 (s, 9H), 3.24 (s, 3H), 4.43 (s, 2H), 7.15 (dd, J = 5.2, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = "8.6 Hz, 2H) 7.63 (s, 1H), 7.80 (d, J = 9.2 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.23 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.65 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridine-3-carboxamide (Compound No. 2-10) XH NMR (500 MHz, DMSO -dg) d 1.45 (s, 9H), 4.39 (s, 2H), 7.03 (d, J = 5.2 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.87 (s, 1H), 7.98 (dd, J = 7.6, 1.5 Hz, 1H), 8.10 (d, J = 5.2 Hz, 1H) , 8.59 (dd, J = 4.9, 1.5 Hz, 1H), 9.66 (s, 1H), 10.60 (s, 1H) 2- [2- (N-terbutoxycarbonyl-N-ethylamino) pyridin-4-ylmethylthio] -N - (3,5-dimethylphenyl) pyridin-3-carboxy ida- (compound No. 2-11) XH NMR (400 MHz, CDCl 3) d 1.19 (t, J = 6.9 Hz, 3H), 1.47 (s, 9H) , 2.31 (s, 6H), 3.94 (c, J = 6.9 Hz, 2H), 4.45 (s, 2H), 6.79 (s, 1H), 7.04 (dd, J = 5.1, 1.4 Hz, 1H), 7.14 ( dd, J = 7.6, 4.9 Hz, 1H), 7.22 (s, 2H), 7.56 (s, 1H), 7.86 (dd, J = 7.6, 1.8 Hz, 1H), 7.97 (s, 1H), 8.25 (d , J = 5.1 Hz, 1H), 8.55 (dd, J = 4.9, 1.8 Hz, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3-chlorophenyl) pyridin-3 -carboxamide (compound No. 2-12) XH NMR (500 MHz, DMSO-dg) d 1.45 (s, 9H), 4.39 (s, 2H), 7.03 (d, J = 5.2 Hz, 1H), 7.19 (d , J = 8.2 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (t, - J = 8.1 Hz, 1H), 7.59 (d, J = 8.2 Hz, 1H), 7.87 ( s, 1H), 7.89 (s, 1H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H ), 9.67 (s, 1H), 10.64 '(s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) pyridine-3-carboxamide (Compound No. 2-13) NMR XH (400 MHz, DMSO-dg) d 1.45 (s, 9H), 4.40 (s, 2H), 7.05 (dd, J = 5.2, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (ddd, J = 7.1, 6.8, 1.0 Hz, 1H), 7.75 (ddd, J = 7.1, 6.8, 1.0 Hz, 1H), 7.88 (broad s, 1H), 7.98 (d, J = 7.1 Hz, 1H), 8.06 (dd, J = 7.6, 1.7 Hz, 1H), 8.08 (broad s, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 8.59 (d, J = 1.0 Hz, 1H), 9.19 (s, ÍH), 9.68 (s, 1H), 11.16 (s, 1H) 2- [2- (N-terbutoxycarbonyl-N-methylamino) pyridine -4-ilmeti lthio] -N- (4-chlorophenyl) pyridin-3-carboxamide (Compound No. 2-14) XH NMR (400 MHz, DMSO-dg) d 1.40 (s, 9H), 3.24 (s, 3H), 4.42 ( s, 2H), 7.15 (dd, J = 5-2, 1.7 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.63 (s) , 1H), 7.72 (d, J = 8.9 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.24 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.58 (s, 1H) 2- [2- (N-tert-butoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -N- (3-chlorophenyl) pyridine-3-carboxamide (Compound No. 2 -15) XH NMR (400 MHz, DMSO-dg) d 1.40 (s, 9H), 3.24 (s, 3H), 4.43 (s, 2H), 7.16-7.18 (m, 2H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (t, J = 8.1 Hz, 1H), 7.58 (d, J = 9.3 Hz, 1H), 7.63 (s, 1H), 7.88 (t, J = 2.0 Hz, 1H) , 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.24 (dd, J = 5.0, 0.6 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.63 (s, 1H) 2 - [2- (N-terbutoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -N- (4-tert-butylphenyl) pyridine-3-carboxamide (Compound No. 2-16) XH NMR (400 MHz, DMSO -ds) d 1.27 (s, 9H), 1.40 (s, 9H), 3.24 (s, 3H), 4.41 (s, 2H), 7.15 (dd, J = 5.2, 1.6 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (d, J = 8.8 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.63 (s, 1H), 7.94 (dd, J = 7.6, 1.7 Hz, 1H), 8.24 (d, J = 5.1 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.37 (s, 1H) 2- [2- (N-terbutoxycarbonyl-N-methylamino ) pyridin-4-ylmethylthiol-N- (isoquinolin-3-yl) pyridine-3-carboxamide (Compound No. 2-17) XH NMR (500 MHz, DMSO-de) d 1.39 (s, 9H), 3.24 (s) , 3H), 4.43 (s, 2H), 7.16 (dd, J = 5.2, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.64 (s, 1H), 7.75 (t, J = 8.1 Hz, 1H), 7.97 (d, J = 8.1 Hz, 1H), 8.05-8.10 (m, 2H), 8.25 (d, J = 5.2 Hz, 1H ), 8.59-8.60 (m, 2H), 9.19 (s, 1H), 11.15 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- [2- (4-methoxyphenyl) eti] pyridine 3 -carboxamide (compound No. 2-18) NMR XH (500 MHz, DMS0-d6) d 1.46 (s, 9H), 2.75 (t, J = 7.3 Hz, 2H), 3.35-3.41 (m, 2H), 3.71 (s, 3H), 4.33 (s, 2H), 6.83 (d, J = 8.5 Hz, 2H), 7.02 (dd, J = 4.9, 1.2 Hz, 1H), 7.15 (d, J = 8.5 Hz, 2H), 7.21 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (dd, J = 7.6, 1.7 Hz, 1H), 7.87 (broad s, 1H), 8.11 (d, J = 4.9 Hz, 1H), 8.52 (dd, J = 4.9, 1.7 Hz, 1H), 8.58 (t, J = 5.4 Hz, 1H), 9.68 (s, 1H) N- (adamantan-1-yl) -2- (2-terbutoxycarbonylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (compound No 2-19) XH NMR (400 MHz, DMSO-dg) d 1.47 (s, 9H), 1.64 (s broad, 6H), 2.03 (s broad, 9H), 4.35 (s, 2H), 7.03 (dd, J = 5.4, 1.5 Hz, 1H), 7.17 (dd, J = 7.6, 4.9 Hz, 1H), 7.67 (dd, J = 7.6, 1.7 Hz, 1H), 7.85-7.92 (m, 2H), 8, 11 ( d, J = 5.4 Hz, 1H), 8.48 (dd, J = 4.9, 1.7 Hz, 1H), 9.68 (s, 1H) 2- [2- (N-terbutoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -? - (3,5-dimethylphenyl) -? - methylpyridine-3-carboxamide (compound? O. 2-20) RM? XH (400 MHz, DMSO-dg) d 1.44 (s, 9H), 2.04 (s, 6H), 3.25 (s, 3H), 3.32 (s, 3H), 4.43 (s, 2H), 6.73-6.78 (m, 3H), 6.98 (m, 1H), 7.10 (d, J = 5.1 Hz, 1H ), 7.41 (m, 1H), 7.67 (s, 1H), 8.25 (d, J = 5.1 Hz, 1H), 8.33 (m, 1H) - (3,5-dimethylphenyl) -2- (2-phthaloylaminopyridine) -4-ylmethylthio) pyridine-3-carboxamide (compound? O. 2-21) RM? XH (400 MHz, DMSO-dg) d 2.25 (s, 6H), 4.50 (s, 2H), 6.76 (s, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H) ), 7.56 (d, J = 5.1 Hz, 1H), 7.61 (s, 1H), 7.94-8.00 (m, 5H), 8.52 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.32 (s, 1H)? - (4-chlorophenyl) -2- [2- (5-cyanothiazol-2-ylamino) pyridin-4-ylmethylthiolpyridine-3-carboxamide (compound? 22) RM? XH (400 MHz, DMSO-dg), d 4.43 (s, 2H), 7.11 (d, J = 5.1 Hz, 1H), 7.21 (s, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H) , 7.42 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.25 (s, 1H), 8.28 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.60 (s, 1H), 12.20 (s, 1H) 2- [2- (5-cyanothiazol-2-ylamino) pyridine -4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound? O. 2-23) XH NMR (400 MHz, DMSO-dg) d 4.43 (s, 2H), 7.11 (d, J = 5.1 Hz, 1H), 7.22 (s, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 8.3 Hz, 2H), 7.81 (d, J = 8.3 Hz, 2H), 8.00 (dd, J = 7.6, 1.7 Hz, 1H), 8.25 (s, 1H), 8.28 (d, J = 5.1 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.67 (s, 1H), 12, 21 (s, 1H) 2- [2- (5-cyanothiazole -2-ylamino) pyridin-4-ylmethylthiol-N- (3,5-dimethylphenyl) pyridin-3-carboxamide (compound No. 2-24) XH-NMR (500 MHz, DMSO-ds) d 2.25- (s, 6H) ), 4.42 (s, 2H), 6.76 (s, 1H), 7.11 (d, J = 5.2 Hz, 1H), 7.21 (s, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.94 (dd, J = 7.6, 1.5 Hz, 1H), 8.25 (s, 1H), 8.28 (d, J = 5.2 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.31 (s) , 1H), 12.21 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-chlorofenyl) benzamide (Compound No. 2-25) XH NMR (500 MHz, DMSO-dg) d 1.45 (s, 9H), 4.22 (s, 2H), 6.99 (d, J = 5.2 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 8.6 Hz, 2H), 7.42 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 8.6 Hz, 2H), 7.83 ( s, 1H), 8.11 (d, J = 5.2 Hz, 1H), 9.68 (s, 1H), 10.48 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) benzamide (compound No. 2-26) XH NMR (500 MHz, DMSO-dg) d 1.27 (s, 9H), 1.45 (s, 9H), 4.22 (s, 2H), 7.00 (d, J = 5.2 Hz, 1H), 7.28 (t, J = 7. 6 Hz, 1H), 7.34 (d, J = 8.6 Hz, 2H), 7.40 (t, J = 7, 6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 8.6 Hz, 2H), 7.84 (s, 1H), 8.11 ( d, J = . 2 Hz, 1H), 9.70 (s, 1H), 10.27 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) benzamide (Compound No. 2-27) XH NMR ( 500 MHz, DMSO-dg) d 1.45 (s, 9H), 4.23 (s, 2H), 6.99 (d, J = 5.2 Hz, 1H), 7.30 (t,? J = 7.6 Hz, 1H), 7.35 (d , J = 8.6 Hz, 2H), 7.43 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 8.6 Hz, 2H), 7.84 (s, 1H), 8.11 (d, J = 5.2 Hz, 1H), 9.68 (s, 1H), 10.55 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) benzamide (compound No. 2-28) XH NMR (400 MHz, DMSO-dg) d 1.44 (s, 9H), 4.24 (s, 2H), 7.01 (d, J = 5.1 Hz, 1H), 7.30 (d, J = 7.3 Hz, 1H), 7.43 (t, J = 8.3 Hz, 1H), 7.47 (d, J = 7.1 Hz, 1H), 7.57 (t, J = 8.3 Hz , 1H), 7.61 (d, J = 7.3 Hz, 1H), 7.74 (t, J = 8. 3 Hz, 1H), 7.84 (broad s, 1H), 7.97 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.3 Hz, 1H), 8.11 (d, J = 5.1 Hz, 1H), 8.60 (s, 1H), 9.18 (s, 1H), 9.71 (s, 1H), 10.96 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) benzamide (Compound No 2-29) XH NMR (500 MHz, DMSO-dg) d 1.20 (d, J = 6.7 Hz, 6H), 1.45 (s, 9H), 2.86 (m, 1H), 4.23 (s, 2H), 6.98 (d, J = 7.6 Hz, 1H), 7.01 (d, J = 5.2 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.41 (t , J = 7.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.50-7.55 (m, 2H), 7.62 (s broad, 1H), 7.84 (s, 1H), 8.12 (d, J = 5.2 Hz, 1H), 9.70 (s, 1H), 10.28 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-chloro-3-methylphenyl) benzamide (Compound No. 2- 30) XH NMR (500 MHz, DMSO-dg) d 1.45"(s, 9H), 2.32 (s, 3H), 4.25 (s, 2H), 6.99 (d, J = 5.2 Hz, 1H), 7.29 (t, J = 7.3 Hz, 1H), 7.36 (t, J = 8.6 Hz, 1H), 7.45 (m, 1H), 7.51 (d, J = 7.3 Hz, 1H), 7.54 (d, J = 8.6 Hz, lH ', 7.72-7.80 (m, 2H), 7.84 (broad s, 1H), 8.11 (d, J = 5.2 Hz, 1H), 9.70 (s, 1H), 10.41 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (1H-indazol-6-yl) benzamide (Compound No. 2-31 ) NMR XH (500 MHz, DMSO-dg) d 1.44 (s, 9H), 4.24 (s, 2H), 7.00 (d, J = 5.2 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 7.30 (t, J = 8.6 Hz, 1H), 7.43 (t, J = 8.6 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.54 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 8. 6 Hz, 1H), 7.84 (s, 1H), 7.99 (broad s, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.25 (s, 1H), 9.69 (s, 1H), 10.49 (s, 1H), 12. 93 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) benzamide (Compound No. 2-32) XH-NMR (500 MHz, DMSO-dg) d 1.45 (s) , 9H), 2.25 (s, 6H), 4.22 (s, 2H), 6.74 (s, 1H), 7.00 (dd, J = 4.9 1.2 Hz, 1H), 7.28 (t, J = 7.3 Hz, 1H), 7.35 (s, 2H), 7.41 (m, 1H), 7.45 (s, 1H), 7.48 (t, J = 7.3 Hz, 1H), 7.84 (s, 1H), 8.12 (d, J = 4.9 Hz, 1H ), 9.69 (s, 1H), 10.18 (s, 1H) 3- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) thiophene-2-carboxamide (Compound No. 2-33) NMR XH (400 MHz, DMSO-dg) d 1.45 (s, 9H), 2.25 (s, 6H), 4.26 (s, 2H), 6.74 (s, 1H), 6.95 (d, - J = 5.1 Hz, 1H) , 7. 24 (s, 2H), 7.24 (d, J = 5.1 Hz, 1H), 7.82 (s, 1H), 7.83 (s, 1H), 8.11 (d, J = 5.1 Hz, 1H), 9.71 (s, 1H), 9.82 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3,5-dimethyl-4-hydroxyphenyl) pyridine-3-carboxamide (Compound No. 2-34) XH-NMR (400 MHz, DMSO-dg) d 1.46 (s, 9H), 2.15 (s, 6H), 4.37 (s, 2H), 7.03 (dd, J = 5.0, 1.3 Hz, 1H), 7.23 (s, 2H), 7.26 (dd, J = 7.6 , 4, 9 Hz, 1H), 7.87 (s, 1H), 7.90 (dd, J = 7.6, 1.6 Hz, 1H), 8.10-8.12 (m, 2H), 8.56 (dd, J = 4.9, 1.6 Hz, 1H), 9.68 (s, 1H), 10.09 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3-chloro-4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 2- 35) XH NMR (500 MHz, DMSO-d6) d 1.45 (s, 9H), 4.40 (s,, 2H), 7.03 (dd, J = 5.2, 1.5 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (dd, J = 8.9, 1.2 Hz, 1H), 7.71 (dd, J = 8.9, 2.4 Hz, 1H), 7.87 (s, 1H), 8.01 (dd, J = 7.6, 1.8 Hz, 1H), 8.08 (d, J = 2.4 Hz, 1H), 8.10 (d, J = 5.2 Hz, 1H), 8.61 (dd, J = 4.9, 1.8 Hz, 1H), 9.67 (s, 1H), 10.81 (s, 1H) 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3-trifluoromethylphenyl) pyridine-3-carbox amide (compound No. 2-36) XH NMR (500 MHz, DMSO-dg) d 1.45 (s, 9H), 4.40 (s, 2H), 7.04 (d, J = 5.2 Hz, 1H), 7.32 (dd, '-J = 7.6, 4.9 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.88 (s, 1H), 7.91 (d, J = 7.9 Hz, 1H), 8.03 (dd, J = 7.6, 1.8 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 8.18 ('s, 1H), 8.61 (dd, J = 4.9, 1.8 Hz, 1H), 9.67 (s, 1H), 10.79 (s, 1H) Example 3 2- (2-Aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide monochloride (Compound No. 3-1) A solution of 4 N hydrochloric acid in 5.0 ml is added of 1,4-dioxane to a solution of 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (Compound No. 2-1, 420 mg, 0.90. mmoles) in 5.0 ml of 1,4-dioxane at room temperature and the mixture is stirred for 12 hours. 6.0 ml of ethanol are added to the reaction mixture and the precipitated solid is filtered off. The solid is dried under reduced pressure at 6 [deg.] D to provide 320 mg of the objective compound as a colorless crystal. (Yield 88%)KNO Or as described in the following, a free base of compound No. 3-1 is synthesized. N- (3,5-dimethylphenyl) -2-thioxo-1,2-dihydropyridine-3-carboxamide (reference compound No. 10-1, 100 g, 0.39 mol) and 2-amino-4-hydrobromide are dissolved. bromomethylpyridine (reference compound No. 14-1, 110 g, 0.40 moles) in 840 ml of N, N-dimethylformamide, under ice-cooling, then triethylamine (160 ml, 1.2 moles) is added dropwise to the mixture. it is stirred for 6 hours at room temperature. The reaction mixture is poured into 2.5 1 of water and then the precipitated solid is filtered off and dried under reduced pressure at 45 D to provide 140 g of the free base of the objective compound, quantitatively, as a light yellow solid. NMR XH (500 MHz, DMSO-ds) d 2.26 (s, 6H), 4.44 (s, 2H), 6.77 (s, 1H), 6.89 (d, J = 6.7 Hz, 1H), 7.03 (s, 1H) , 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.34 (s, 2H), 7.84 (d, J = 6.7 Hz, 1H), 7.97 (s broad, 2H), 8.00 (dd, J = 7.6, 1.8 Hz, 1H), 8.56 (dd, J = 4.9, 1.8 Hz, 1H), 10.35 (s, 1H), 13.40 (s broad, 1H) As described in the following, the compounds are obtained (? O. -2-37) using the corresponding compounds that are selected from the reference compounds (γ or γ 2-1-36), commercially available compounds or n compounds, according to the method of synthesis of the compound (γ-3). 1) . 2- (2-Aminopyridin-4-ylmethylthio) -? - (3-isopropylphenyl) pyridine-3-carboxamide monochlorohydrate (compound? O. 3-2) RM? XH (500 MHz, DMSO-dg) d 1.21 (d, J = 6.7 Hz, 6H), 2.87 (m, 1H), 4.41 (s, 2H), 6.89 (d, J = 6.7 Hz, 1H), 7.00- 7.03 (m, 2H), 7.27 (m, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.53 (d, J = 7.3 Hz, 1H), 7.60 (s, 1H), 7.84 (d , J = 6.7 Hz, 1H), 7.95 (s, 2H), 8..04 (d, J = 7.6 Hz, 1H), 8.56 (d, J = '4.9 Hz, 1H), 10.44 (s, 1H) 13.33 (s broad, 1H) 2- (2-aminopyridin-4-ylmethylthio) -? - (indan-5-yl) pyridin-3-carboxyamide (compound? 3-3) RM monochlorohydrate? XH (500 MHz, DMSO-dg) d 1.91-2.05 '(m, 2H), 2.81-2.90 (m, 4H), 4.40 (s, 2H), 6.89 (m, 1H), 7.03 (s, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.31 (dd J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.63 (s, 1H), 7.84 (d, J = 6.7 Hz, 1H), 8.00-8.05 (m, 3H), 8.56 (dd, J = 4.9, 1.5 Hz, 1H), 10.40 (s, 1H), 13.50 (s broad, 1H) 2- (2-) monohydrochloride aminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) pyridine-3-carboxamide (Compound No. 3-4) XH-NMR (500 MHz, DMSO-dg) d 1.28 (s, 9H), 4.40 (s, 2H ), 6.89 (dd, J = 7.7, 1.5 Hz, 1H), 7.03 (S, 1H), 7.32 (dd, J = 7.7, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.62 (dlj = 8.8 Hz, 2H), 7.84 (d, J = 6.4 Hz, 1H), 7.97 (s, 2H), 8.02 (dd, J = 7.7, 1.5 Mz, 1H), 8.56 (dd, J = 4.9, 1.5 Hz, 1H), 10.44 (s, 1H), 13.42 (broad s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (1H-indazol-6-yl) pyridine-3-carboxamide monochlorohydrate (compound No. 3-5) XH NMR (500 MHz, DMSO-dg) d 4.42 (s, 2H), 6.39 (broad s, 1H), 6.89 (d, J = 6.4 Hz, 1H), 7.06 (s,1H), 7.29-7.36 (m, 2H), 7.70 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 6.4 Hz, 1H), 8.02 (s, 1H), 8.02-8.16 (m, 3H) ), 8.23 (s, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.70 (s, 1H), 13.71 (s broad, 1H) N- (3,5-dimethylphenyl) -2 monohydrochloride - (2-methylaminopyridin-4'-ylmethylthio) pyridin-3-carboxamide (Compound No. 3-6) XH NMR (500 MHz, DMSO-dg) d 2.26 (s, 6H), 2.91 (d, J = 4.9 Hz , 3H), 4.41 (s, 2H), 5.98 (broad s, 1H), 6.77 ,, (s, 1H), 6.87 (dd, J = 7.7, 1.5 Hz, 1H), 7.10 (s, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.35 (s, 2H), 7.81 (d, J = 7.7 Hz, 1H), 8.00 (dd, J = 7.6, 1.5 Hz, 1H), 8.57 (dd, J = 4.9, 1. 5 Hz, 1H), 10.39 (s, 1H), 13.48 (broad s, 1H) N- (indan-5-yl) -2- (2-methylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide monochlorohydrate (compound No. 3-7) XH NMR (400 MHz, DMSO-dg) d 1.98-2.06 (m, 2H), 2.81-2.87 (m, 4H), 2.91 (d, J = 4.9 Hz, 3H), 4.40 (s) , 2H), 6.87 (dd, J = 6.8, 1.5 Hz, 1H), 7.10 (s, 1H), 7.18 (d, J = 8.3 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, XH) , 7.42 (d, J = 8. 8 Hz, 1H), 7.63 (s, 1H), 7.80 (d, J = 6.6 Hz, 1H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 8. 97 (broad s, 1H), 10.44 (s, 1H), 13.43 (broad s, 1H) 2- (2-Methylaminopyridin-4-methylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide monochloride (Compound No. 3-8) XH NMR (500 MHz, DMSO-dg) d 2.91 (d, J = 4.9 Hz, 3H), 4.42 (s, 2H), 6.87 (dd, J = 6.7, 1.5 Hz, 1H), 7, 09 (s, 1H), 7.33 (dd, J = 7.6, 4, 9 Hz, 1H), 7.38 (d, J = 8.2 Hz, 2H), 7.80-7.85 (m, 3H), 8.07 (dd, J = 7.6, 1.8 Hz, 1H), 8.59 (dd, J = 4.9, 1.8 Hz, 1H ), 8.90 (broad s, 1H), 10.77 (s, 1H), 13.32 (s broad, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridin-3-carboxamide monohydrochloride (compound No. 3-9) XH NMR (500 MHz, DMSO-d6) d 4.41 (s, 2H), 6.89 (d, J = 6.4 Hz, 1H), 7.03 (s, 1H), 7.33 (dd, J = 7.6, 4.9 Hz, 1H), 7.43 (d, J = 8.6 Hz, 2H), 7.75 (d, J = 8.6 Hz, 2H), 7.84 (d, J = 6.4 Hz, 1H), 7.96 (s, 2H) ), 8.06 (dd, J = 7.6, 1.5 Hz, 1H), 8.57 (dd, J = 4.9, 1.5 Hz, 1H), 10.66 (s, 1H), 13.40 (broad s, 1H) 2- (2-aminopyridine) -4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 3-10) XH NMR (500 MHz, DMSO-dg) d 4.25 (s, 2H), 5.83 (s, 2H), 6.45 (s, 1H), 6.48 (dd, J = 5.2, 1.3 Hz, 1H), 7.30 (dd, J = 7.8, 4.8 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.77 (dd, J = 5.2 Hz, 1H), 7.81 (d, J = 8.2 Hz, 2H), 7.97 (d, J = 7.8, 1.8 Hz, 1H), 8.60 (dd, J = 4.8, 1.8 Hz ', 1H), 10.67 (s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N-monochlorohydrate - (3-chlorophenyl) pyridine-3-carboxamide (Compound No. 3-11) XH NMR (400 MHz, DMSO-d6) d 4.41 (s, 2H), 6.88 (d, J = 6.6 Hz, 1H), 7.05 (s, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.33 (dd, J = 7.6, 4.9 Hz, 1H), 7.40 (t, J = 8, 1 Hz, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.85 (d, J = 6.6 Hz, 1H), 7.93 (s, 1H), 8.04 (broad s, 2H), 8.08 (dd, J = 7.6, 1.7 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.78 (s, 1H), 13.64 (broad s, 1H) N- (3,5-dimethylphenyl) -2- (2-ethylaminopyridin-4-ylmethylthio) pyridine- 3-carboxamide (compound No. 3-12) XH NMR (400 MHz, DMSO-dg) d 1.08 (t, J = 7.2 Hz, 3H), 2.25 (s, 6H), 3.15.3.22 (m, 2H), 4.24 (s, 2H), 6.39 (t, J = 5.5 Hz, 1H), 6.42-6.46 (m, 2H), 6.76 (s, 1H), 7.27 (dd, J = 7.4, 4.8 Hz, 1H), 7.32 (s, 2H), 7.83 (d, J = 5.4 Hz, 1H), 7.90 (dd, J = 7.4, 1.5 Hz, 1H), 8.57 (dd, J = 4.8, 1.5 Hz, 1H), 10.30 (s, 1H) 2- (2- aminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) pyridine-3-carboxamide (Compound No. 3-13) XH-NMR (500 MHz, DMSO-dg) -d 4.25 (s, 2H), 5.83 ( s, 2H), 6.46 (s, 1H), 6.49 (dd, J = 5.2, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (ddd, J = 7.9, 7.9, 1.2 Hz, 1H), 7.75 (ddd, J = 7.9, 7.9, 1.2 Hz, 1H), 7.78 (d, J = 5.2 Hz, 1H), 7.98 (d, J = 7.9 Hz, 1H), 8.04 (dd, ¡T = 7.6, 1.8 Hz, 1H), 8.09 (d, J = 7.9 Hz, 1H), 8.59 (dd, J = 5.2, 1.5 Hz, 1H), 8.59 (broad s, 1H), 9.19 (broad s, 1H), 11.15 (s , 1H) N- (4-chlorophenyl) -2- (2-methylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 3-14) XH NMR (400 MHz, DMSO-dg) d 2.71 (d, J = 4.9 Hz, 3H), 4.26 (s, 2H), 6.46-6.49 (m, 3H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (dd, J = 6.7, 2.1 Hz, 2H ), 7.73 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 5.1 Hz, 1H), 7.96 (dd, J = 7.6, 1.7 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz , 1H), 10.60 '(s, 1H) N- (3-chlorophenyl) -2- (2-methylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 3-15) XH NMR (400 MHz, DMSO -dg) d 2.71 (d, J = 4.9 Hz, 3H), 4.26 (s, 2H), 6.42-6.49 (m, 3H), 7.18 (ddd, J = 8.1, 2.0, 0.9 Hz, 1H), 7.30 ( dd, J = 7.6, 4.9 Hz, 1H), 7.39 (t, J = 8.1 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.85 (d, J = 5.1 Hz, 1H), 7.89 ( t, J = 2.0 Hz, 1H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.65 (s, 1H) N- (4-tert-butylphenyl) -2- (2-m) ethylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 3-16) XH NMR (400 MHz, DMSO-dg) d 1.27 (s, 9H), 2.71 (d, J = 4.9 Hz, 3H), 4.25 (s, 2H), 6.40-6.49"(m, 3H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (d, J = 8.8 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 4.9 Hz, 1H), 7.92 (dd, J = 7.6, 1. 7 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), l? 'S39 (s, 1H) N- (isoquinolin-3-yl) -2- (2-methylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (compound No. 3-17) XH NMR (400 MHz, DMSO-dg) d 2.71 (d, J = 4.9 Hz, 3H), 4.27 (s, 2H), 6.39-6.50 (m, 3H) ), 7.27 (dd, J = 7.6, 4. 8 Hz, 1H), 7.58 (m, 1H), 7.75 (m, 1H), 7.85 (d, J = 5.4 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 8.04 (dd, J = 7.6, 1.7 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 8.58-8.60 (m, 2H), 9.19 (s, 1H), 11.16 (s, 1H) N- (adamantan-1) monohydrochloride -yl) -2- (2-aminopyridin-4-ylmethylthio) pyridin-3-carboxamide (Compound No. 3-18) - XH NMR (400 MHz, DMSO, d6) d 1.65 (broad s, 6H), 2.04 ( broad, 9H), 4.36. (s, 2H), 6.87 (d, J = 6.7 Hz,, 1H), 6.99 (s, 1H), 7.21 (dd, J = 7.6, 4.9 Hz, 1H), 7.74 (dd, J = 7.6, 1.2 Hz, 1H), 7.84 (d, J = 6.7 Hz, 1H), 7.87 (s broad, 2H), 7.92 (s, 1H), 8.47 (dd, J = 4.9, 1.2 Hz, 1H), 13.34 (s, 1H) N- (3,5-dimethylphenyl) -2- [2- (piperazin-1-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide dihydrochloride (compound No. 3.19) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 3.50-4.30 (m, 8H), 4.39 (s, 2H), 6.76 (s, 1H), 6.92 (s, 1H) ), 7.23 (s, 1H), 7.30 (dd, J = 7.7, 4.8 Hz, iH), 7.33 (s, 2H), 7.41 (s, 1H), 7.98 (d, J = 5.8 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 8.60 (dd, J = 4.8, 1.8 Hz, 1H), 9.20 (s, 2H), 10.35 (s, 1H) '' 2- (2-aminopyridin-4) monochlorohydrate -ylmethylthio) -N ~ (3, 5-dimethylphenyl) benzamide (compound No. 3-20) XH NMR (400 MHz, DMSO-dg) d 2.26 (s, 6H), 4.25 (s, 2H), 6.75 (s, 1H), 6.82 (m, 1H), 6.85 (s, 1H), 7.28-7.35 (m, 3H), 7.40-7.45 (m, 2H), 7.52 (d, J = 7.3 Hz, 1H), 7.84 (d, J = 6.6 Hz, 1H), 7.95 (broad s, 2H), 10.21 (s, 1H), 13.43 (s broad, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- ( 4-chlorophenyl) benzamide (compound No. 3-21) XH NMR (500 MHz, DMSO-dg) d 4.25 (s, 2H), 6.81 (dd, J = 6.7, 1.5 Hz, 1H), 6.85 (s, 1H), 7.35 (t, J = 8.6 Hz, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.45 (t, J = 8.6 Hz, 1H), 7.46 (d, J = 1.5 Hz, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7. 75 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 6.7 Hz, 1H), 7.92 (broad s, 2H), 10.51 (s, 1H), 13.33 (broad s, 1H) Monohydrochloride 2- (2-aminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) benzamide (Compound No. 3-22) XH NMR (400 MHz, DMSO-dg) d 1.28 (s, 9H), 4.25 (s, 2H) , 6.82 (d, J = 6.6 Hz, 1H), 6.84 (s, 1H), 7.33 (t, J = 6.6 Hz, 1H), 7.35 (d, J = 8.8 Hz, 2H), 7.40-7.47 (m, 2H), 7.53 (d, J = 6.6 Hz, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.83 (d, J = 6.6 Hz, 1H), 7.90 (broad s, 2H "), 10.29 (s, 1H), 13.36 (s broad, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) benzamide monochlorohydrate (compound No. 3'-23) RM? XH (400 MHz, DMSO-d6) d 4.25 (s, 2H), 6.81 (d, J = 6.7 Hz, 1H), 6.84 (s, 1H), 7.35 (m, 1H), 7.37 (d, J = 8. 9 Hz, 2H), 7.43-7.49 (m, 2H), 7.57 (d, J = 6.7 Hz, 1H), 7. 83 (s, 1H), 7.83 (d, J = 8.9 Hz, 2H), 7.88 (s broad, 2H), 10.57 (s, 1H), 13.41 (s broad, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) benzamide monochlorohydrate (Compound? 3-24) RM? XH (400 MHz, DMSO-dg) d 4.27 (s, 2H), 6.83 (d, J = 6.7 Hz, 1H), 6.87 (s, 1H), 7.35 (m, 1H), 7.44-7.46 (m, 2H) ), 7.58 (d, J = 8.2 Hz, 1H), 7.64 (d, J = 7.0 Hz, 1H), 7. 76 (t, J = 7.0 Hz, 1H), 7.84 (d, J = 6.7 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H), 8.00 (broad s, 2H), 8.09 (d, J = 8.2 Hz, 1H), 8.59 (S, 1H), 9.20 (s, 1H), 10.99 (s, 1H), 13.51 (broad s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (3 -isopropylphenyl) benzamide (compound No. 3-25) XH NMR (500 MHz, DMSO, d6) d 1.20 (d, J = 7.0 Hz, 6H), 2.86 (m, 1H), 4.06 (s, 2H), 5.86 (s, 2H), 6.43 (s, 1H), 6.49 (d, J = 5.2 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.42 (t, J = 8.2 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.64 (broad s, 1H), 7.79 (d, J = 5.2 Hz, 1H), 10.28 (s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-chloro-3-methylphenyl) benzamide (Compound No. 3-26) XH NMR (500 MHz, DMSO- dg) d 2.32 (s, 3H), 4.06 '(s, 2H), 5.87 (s, 2H), 6.42 (s, 1H), 6.48 (d, J = 5.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz , 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.75 (broad s, 1H), 7.79 (d, J = 5.2 Hz, 1H), 10.42 (s, 1H) 2- (2-aminopyridin-4) -iltmethylthio) -? - (lH-indazol-6-yl) benzamide (compound? o. 3-27) RM? XH (500 MHz, DMSO-d6) d 4.08 (s, 2H), 5.86 (s, 2H), 6.43 (s, 1H), 6.49 (d, J = 5.2 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 7.30 (t, J = 7.3 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), .7.68 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 5.2 Hz, 1H), 7.99 (s broad, 1H), 8.26 (broad s, 1H), 10.50 (s, 1H) , 12.93 (s, 1H) 3- (2-aminopyridin-4-methylmethyl) -N- (3,5-dimethylphenyl) thiophene-2-carboxamide (compound No. 3-28) XH NMR (400 MHz, DMSO-dg ) d 2.25 (s, 6H), 4.10 (s, 2H), 5.88 (s, 2H), 6.40 (s, 1H), 6.46 (s, J = 5.1 Hz, 1H), 6.74 (s, 1H), 7.20 (d, J = 5.1 Hz, 1H), 7.26 (s, 2H), 7.79 (d, J = 5.1 Hz, 1H), 7.82 (d, J = 5.1 Hz, 1H), 9.83 (s, 1H) 2- (3-Aminopyridin-4-methylmethyl) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 3-29) XH NMR (500 MHz, CDCl3) d 2.30 (s, 6H), 4.15- 4.60 (broad s, 2H), 4.38 (s, 2H), 6.81 (s, 1H), 7.09 (d, J = 4.9 Hz, 1H), 7.13 (dd, J = 7.6, 4.9 Hz, 1H), 7.24 ( s, 2H), 7.86-7.88 (m, 2H), 7. 97 (s, 1H), 8.13 (s, 1H), 8.53 (dd, J = 4.9, 1.8 Hz, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (3, 5-dimethyl-4-) hydroxyphenyl) pyridine-3-carboxamide (compound No. 3-30) XH NMR (500 MHz, DMSO-dg) d 2.15 (s, 6H), 4.23 (s, 2H), 5.85 (s, 2H), 6.45 (s) , 1H), 6.48 (dd, J = 5.2, 1.2 Hz, 1H), 7.23-7.27 (m, 3H), 7.77 (d, J = 5.2 Hz, 1H), 7.88 (dd, J = 7.6, 1.5 Hz, 1H), 8.09 (s, 1H), 8.55 (dd, J = 4.9, 1.5 Hz, 1H), 10.09 (S, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-difluoromethoxyphenyl) pyridine -3-carboxamide (compound No. 3-31) XH NMR (500 MHz, DMSO-dg) d 4.24 (s, 2H), 5.83 (s, 2H), 6.45 (d, J = 0.6 Hz, 1H), 6.48 (dd, J = 5.2 , 1.5 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.18 (t, J = 74.1 Hz, 1H), 7.29 (dd, J = 7.6, 4.8 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.77 (dd, J = 5.2, 0.6 Hz, 1H), 7.96 (dd, J = 7.6, 1.7 Hz, 1H), 8.59 (dd, J = 4.8, 1.7 Hz, 1H), 10.55 (s, 1 H) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) pyridin-3-carboxamide (Compound No. 3-32) XH-NMR (400 MHz, DMSO-dg) d 1.27" (s, 9H), 4.24 (s, 2H), 5.83 (s, 2H), 6.45 (s, 1H), 6.48 (dd, J = 5.2, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.77 (d, J = 5.2 Hz, 1H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.40 (s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (3-methylphenyl) pyridine-3-carboxamide (Compound No. 3-33) XH NMR ( 400 MHz, DMSO-dg) d 2.30 (s, 3H), 4.24 (s, 2H), 5.84 (s, 2H), 6.45 (s, 1H), 6.48 (dd, J = 5.2, 1.6 Hz, 1H), 6.93 (d, J = 7.8 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.77 (d, J = 5.2 Hz, 1H), 7.93 (dd, J = 7.6, 1.7 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.39 '( s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-trifluoromethylphenyl) pyridine-3-carboxamide (compound No. 3-34) XH NMR (400 MHz, DMSO-dg) d 4.25 (s, 2H), 5.84 (s, 2H), 6.45 (s, 1H), 6.48 (dd, J = 5.4, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 5.4 Hz, 1H), 7.92 (d, J = 8.3 Hz, 2H), 8.00 (dd, J = 7.6, 1.7 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.83 (s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (3 -chloro-4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 3-35) XH NMR (500 MHz, DMSO-dg) d 4.25 (s, 2H), 5.83 (s, 2H), 6.45 (s, 1H ), 6.48 (d, J = 5.1 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.59 (d, J = 8.9 Hz, 1H), 7 '.' 72 (dd, J = 8.9, 2.4 Hz, 1H), 7.77 (d, J = 5.1 Hz, 1H), 8.00 (dd, J = 7.6, 1.8 Hz, 1H), 8.09 (d, J = 2.4 Hz, 1H ), 8.61 (dd, J = 4.9, 1.8 Hz, 1H), 10.82 (s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (3-trifluoromethylphenyl) pyridin-3-carboxamide (Compound No. 3-36) XH NMR (400 MHz, DMSO-dg) d 4.25 (s, 2H), 5.84 (s, 2H), 6.45 (s, 1H), 6.48 (d, J = 5.1 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.48 (d, J = 7.1 Hz, 1H), 7.61 ( dd, J = 8.1, 7.1 Hz, 1H), 7.77 (d, J = 5.1 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 8.02 (dd, J = 7.6, 1.7 Hz, 1H), 8.19 (s, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.80 (s, 1H) 2- (2-aminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridin-3 carboxamide (compound No. 3-37) XH NMR (500 MHz, DMSO-dg) d 1.20 (d, J = 7.0 Hz, 6H), 2.87 (m, 1H), 4.24 (s, 2H), 5.83 (s, 2H), 6.45 (s broad, 1H), 6.48 (d, J = 5.2 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.60 (s, 1H), 7.77 (d, J = . 2 Hz, 1H), 7.94 (dd, J = 7.6, 1.5 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.40 (s, 1H).

Example 4 2- (2-Acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (Compound No. 4-1) Acetic anhydride (1.0 ml-, 10 mmol) is added to a 2- (2-aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxyamide monohydrochloride solution (Compounds 3-1, 1.0 g, 2.5 mmol) in 10 ml pyridine at room temperature, and the mixture is stirred for 4 hours. 30 ml of ethyl acetate are added to the reaction mixture, then the whole is washed with 20 ml of water and 20 ml of brine and then the organic layer is dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure and the resulting solid is filtered off with hexane / ethyl acetate (1: 1) to provide 770 mg of the objective compound as a colorless crystal (yield 76%) Or the compound is also synthesized in the following method N- (3,5-dimethylphenyl) -2-thioxo-1,2-dihydropyridine-3-carboxamide (reference compound No. 10-1) is suspended., 200 mg, 0.77 mmol) and 2-acetylamino-4-methanesulfonyloxymethylpyridine (reference compound No. 13-1, 190 mg, 0.77 mmol) in 2.0 ml of N, N-dimethylformamide under ice cooling and under a nitrogen atmosphere , then triethylamine (0.22 ml, 1.5 mmol) is added thereto and subsequently the mixture is stirred for 2 hours at room temperature. 40 ml of ethyl acetate are added to the reaction mixture and then the whole is washed with 30 ml of water and 20 ml of brine. The organic layer is dried over anhydrous magnesium sulfate and the solvent is evaporated under reduced pressure. The resulting solid is filtered off with the solvent mixture consisting of diisopropyl ether and ethyl acetate and dried under reduced pressure at 400 to provide 250 mg of the objective compound as a light yellow solid (yield, 81%) XH NMR (500 MHz, DMSO-dg) d 2.05 (s, 3H), 2.25 (s, 6H), 4.39 (s, 2H), 6.76 (s, 1H), 7.09 (dd, J = 5.2, 1.5 Hz, 1H), 7.28 (m, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1.8 Hz, 1H), 8.15-8.18 (m, 2H), 8.57 (dd, J = 5.2, 1.5 Hz, 1H), . 29 (s, 1H), 10.40 (s, 1H) 'As described in the following, compounds numbers 4-2-68 are obtained using the corresponding compounds which are selected from compounds numbers 3-1-37), commercially available compounds or compounds known in accordance with the method of synthesis of compound number 4-1). N- (3,5-dimethylphenyl) -2- (2-propionylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 4-2) XH NMR (500 MHz, DMSO-dg) d 1.05 (t, J = 7.3 Hz, 3H), 2.25 (s, 6H), 2.36 (c, J = 7.3 Hz, 2H), 4.39 (s, 2H), 6.76 (s, 1H), 7.09 (d, J = 5.1 Hz, 1H ), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.93 (dd, J = 7.6, 1.5 Hz, 1H), 8.16 (s, 1H), 8.17 (s, 1H) , 8.58 (dd, J = 4.9, 1.5 Hz, 1H), . 30 (s, 1H), 10.35 (s, 1H) N- (3,5-dimethylphenyl) -2- (2-trifluoroacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 4-3) XH NMR ( 400 MHz, DMSO-dg) d 2.25 (s, 6H), 4.45 (s, 2H), 6.76 (s, 1H), 7.27-7.32 (m, 4H), 7.93 (dd, J = 7.6, 1. 7 Hz, 1H), 8.03 (s, 1H), 8.31 (d, J = 4.9 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.30 (s, 1H), 11.97 (broad s, 1H) N- (3, 5-dimethylphenyl) -2- (2-isobutyrylaminopyridin-4-ylmethylthio) pyridine- 3-carboxamide (Compound No. 4-4) XH NMR (500 MHz, DMSO, d. {D) d 1.06 (d, J = 6.7 Hz, 6H), 2.25 (S, 6H), 2.72 (m, 1H) , 4.40 (s, 2H), 6.76 (s, 1H), 7.10 (dd, J = 4, 9, 1.8 Hz, 1H), 7X28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H) ), 7.93 (dd, J = 7.6, 1.8 Hz, 1H), 8.17, 8.19 (m, 2H), 8.58 (dd, J = 4.9, 1.8 Hz, 1H), 10.30 (s, 1H), 10.34 (s, 1 H) N- (3,5-dimethylphenyl) -2- (2-pivaloylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 4-5) XH NMR (400 MHz, CDC13) d 1.30 (s, 9H ), 2.32 (s, 6H), 4.49 (s, 2H), 6.80 (d, J = 0.7 Hz, 1H), 7.07-7.13 (m, 2H), 7.29 (s, 2H), 7.86 (dd, J = 7.6, 1.7 Hz, 1H), 8.00 (s broad, 1H), 8.11-8.15 (m, 2H), 8.31 (d, J = 0.7 Hz, 1H), 8.51 (dd, J = 4.9, 1.7 Hz, 1H) N- (3,5-dimethylphenyl) -2- (2-trifluoromethanesulfonylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 4-6) XH NMR ( 400 MHz, DMSO-dg) d 2.26 (s, 6H), 4.43 (s, 2H), 6.77 (s, 1H), 7.14 (d, J = 6.3 Hz, 1H), 7.28-7.32 (m, 3H), 7.72 (s, 1H), 7.95-7.99 (m, 2H), 8.53 (dd, J = 4.9, 1.7 Hz, 1H), 10.29 (s, 1H), 13.99 (broad s, 1H) N- (3, 5 dimethylphenyl) -2- (2-methanesulphonylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 4-7) XH NMR (500 MHz, CDC13) d 2.32 (s, 6H), 2.94 (s, 3H), 4.42 (s, 2H), 6.81 (s, 1H), 6.85 (dd, J = 6.1, 1.5 Hz, 1H), 7.13 (dd, J = 7.6, 4.9 Hz, 1H), 7.28 (s, 2H) ), 7.46 (s, 1H), 7.83 (dd, J = 7.6, 1.5 Hz, 1H), 7.91 (s, 1H), 8.03 (d, J = 6.1 Hz, 1H), 8.51 (dd, J = 4.9, 1.5 Hz, 1H), 11.80 (broad s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridine-3-carboxamide (Compound No. 4-8) XH NMR (400 MHz , DMSO-dg) d 1.20 (d, O = 6.8 Hz, 6H), 2.06 (s, 3H), 2.87 (m, 1H), 4.39 (s, 2H), 7.00 (d, J = 7.6 Hz, 1H) , 7.10 (dd, J = 5.1, 1.7 Hz, 1H), 7.23-7.30 (m, 2H), 7.51 (d, J = 7.8 Hz, 1H), 7.59 (s, 1H), 7.96 (d, J = 5.9 Hz, 1H), 8.15-8.18 (m, 2H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.39 (s, 1H), 10.40 (s, 1H) 2- (2-acetylaminopyridin-4-) ylmethylthio) -N- (indan-5-yl) pyridin-3-carboxamide (Compound No. 4-9) XH NMR (400 MHz, DMSO-dg) d 1.97-2.06 (m, 2H), 2.06 (s, 3H ), 2.79-2.87 (m, 4H), 4.39 (s, 2H), 7.09 (d, J = 5.1, 1.5 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.61 (s, 1H), 7.93 (d, J = 5.9 Hz, 1H), 8.15-8.18 (m, 2H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.33 ( s, 1H), 10.40 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridin-3-carboxamide (Compound No-4-10) XH NMR (500 MHz, DMSO -dg) d 2.06 (s, 3H), 4.40 (s, 2H), 7.09 (d, J = 5.2 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 Hz, 2H), 7.98 (dd, J = 7.6, 1.8 Hz, 1H), 8.16 (s, 1H), 8.17 (d, J = 5.2 Hz , 1H), 8.59 (dd, J = 4.9, 1.8 Hz, 1H), 10.40 (s, 1H), 10.59 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridin-3-carboxamide (compound? o. 4-11) RM? XH (400 MHz, DMSO-dg) d 2.06 (s, 3'H), 4.40 (s, 2H), 7.10 (dd, J = 5.2, 1.6 Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz , 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.14-8.18 (m, 2H) , 8.60 (dd, J = 4.8, 1.7 Hz, 1H), 10.41 (s, 1H), 10.66 (s, 1H) 2- [2- (N-acetyl-β-methylamino) pyridin-4-methylmethyl] -N - (3,5-dimethylphenyl) pyridine-3-carboxamide (compound? O. 4-12) RM? XH (500 MHz, DMSO-dg) d 1.96 (s, 3H), 2.25 (s, 6H), 3.22 (s, 3H), '4.43 (s, 2H), 6.76 (s, 1H), 7.27-7.30 (m, 2H), 7.32 (s, 2H), 7.52 (s, 1H), 7.93 (dd, J = 7.6, 1.5 Hz, 1H), 8.34 (d, J = 4.9 Hz, 1H), 8.58 (dd, J = 4.9, 1.8 Hz, 1H), 10.31 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N - (quinolin-6-yl) pyridin-3-carboxamide (Compound No. 4-13) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 4.42 (s, 2H), 7.11 (d, J = 5.2 Hz, 1H), 7.33 (dd, J = 7.6, 4.9 Hz, 1H), 7.51 (dd, J = 8.2, 4.3 Hz, 1H), 7.89 (dd, J = 9.2 , 2.4 Hz, 1H), 8.00 (d, J = 9.2 Hz, 1H), 8.05 (dd, J = 7.6, 1.5 Hz, 1H), 8.15-8.20 (m, 2H), 8.34 (d, J = 7.6 Hz, 1H), 8.51 (d, J = 2.4 Hz, 1H), 8.62 (dd, J = 4.9, 1.5 Hz, 1H), 8.81 (dd, J = 4.3, 1.5 Hz, 1H), 10.40 (s, 1H), 10.80 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3-chloro-4-trifluoromethoxyphenyl) pyridine -3-carboxamide (Compound No. 4-14) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3'H), 4.41 (s, 2H), 7.10 (d, J = 4.9 Hz, 1H) , 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.08 (s, 1H), 8.16 (s, 1H), 8.17 (d, J = 4.9 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.80 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) pyridin-3-carboxamide (Compound No. 4-15) XH NMR (400 MHz, DMSO-dg) d 2.05 (s, 3H), 4.40 (s, 2H), 7.11 (dd, J = 5.1, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (m, 1H), 7.75 (, 1H), 7.97 (d, J = 8.0 Hz, 1H), 8.06 (dd, J = 7.6, 1.7 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.15-8.20 (m, 2H), 8.58-8.60 (m, 2H), 9.19 (s) , 1H), 10.42 (s, 1H), 11.16 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3-chlorophenyl) pyridine-3-carboxamide (Compound No. 4-16) NMR XH (500 MHz, DMSO-dg) d 2.06 (s, 3H), 4.40 (s, 2H), 7.10 (dd, J = 5.1, 1.5 Hz, 1H), 7.18 (dd, J = 8.1, 1.1 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (t, J = 8.1 Hz, 1H), 7.58 (dd, J = 8.1, 1.1 Hz, 1H), 7.88 (s, 1H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.16 (s, 1H), 8.17 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.40 (s, 1H), 10.64 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) ) pyridine-3-carboxamide (compound No. 4-17) XH NMR (400 MHz, DMSO-dg) d 1.27 (s, 9H), 2.06 (s, 3H), 4.39 (s, 2H), 7.10 (d, J = 5.1 Hz, 1H), 7.28 (dd, J = 7.7, 4.9 Hz, 1H), 7.36 (d, J = 8.7 Hz, 2H), 7.60 (d, J = 8.7 Hz, 2H), 7.94 (dd, J = 7.7, 1.8 Hz, 1H), 8.15-8.17 (m, 2H), 8.57 (dd, J = 4.9, 1.8 Hz, 1H), 10.39 (s, 1H), 10.41 (s, 1H) 2- (2 -acetylaminopyridin-4-ylmethylthio) -N- (4-fluoro-3-methylphenyl) pyridine-3-carlboxamide (compound No. 4-18) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 2.23 (d, J = 1.5 Hz, 3H), 4.39 (s, 2H), 7.09, 7.14 (m, 2H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.48 (m, 1H), 7.63 (d, J- = 5.6 Hz, 1H), 7.95 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.17 (m, 2H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.44 (s, IH) 2- (2-Acetylaminopyridin-4-ylmethylthio) -N- (3-fluoro-4-methylphenyl) pyridin-3-carboxamide (Compound No. 4-19) XH NMR (400 MHz, DMSO-dg) ) d 2.06 (s, 3H), 2.20 (d, J = 1.2 Hz, 3H), 4.40 (s, 2H), 7.09 (dd, J- = 5.1, 1.5 Hz, 1H), 7.24 (t, J = 8.4 Hz, 1H), 7.29 (dd, J = 7.6, 4.7 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 13.7 Hz, 1H), 7.96 (dd, J = 7.6 , 1.7 Hz, 1H), 8.15-8.17 (m, 2H), 8.59 (dd, J = 4.7, 1.7 Hz, 1H), 10.41 (s, 1H), 10.56 (s, 1H) 2- (2-acetylaminopyridin- 4-ylmethylthio) -N- (3 * -methylphenyl) pyridine-3-carboxamide (compound No-4-20) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 2.30 (s, 3H) , 4.40 (s, 2H), 6.93 (d, J = 8.1 Hz, 1H), OlO (dd, J = 5.1, 1.5 Hz, 1H), 7.22 (t, J = 8.1 Hz, 1H), 7.29 (dd) , J = 7.6, 4.9 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.56 (s, 1H), 7.96 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.17 (m, 2H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.39 (s, 1H), 10.41 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (lH-indazol-5-yl) pyridin-3-carboxamide (Compound No. 4-21) XH NMR (400 MHz, DMSO-d6) d 2.06 (s, 3H), 4.40 (s, 2H), 7.10 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.50-7.55 (m, 2H), 7.98 (dd, J = 7.6, 1.7 Hz , 1H), 8.05 (s, 1H), 8.15-8.18 (m, 2H), 8.22 (s, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.47 ( s, 1H), 13.03 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (lH-indazol-6-yl) pyridin-3 -carboxamide (Compound No. 4-22) XH NMR ( 400 MHz, DMSO-dg) d 2.06 (s, 3H), 4.41 (s, 2H), 7.10 (dd, J = 5.2, 1.6 Hz, 1H), 7.24 (dd, J = 8.8, 1.7 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.97-8.00 (m, 2H), 8.16-8.18 (m, 2H), 8.21 (s, 1H) , 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.60 (s, 1H), 12.97 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- ( 3,4-dimethylphenyl) pyridin-3-carboxamide (Compound No. 4-23) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 2.18 (s, 3H), 2.20 (s, 3H) , 4.40 (s, 2H), 7.08-7.10 (m, 2H), 7.27 (dd, J = 7.6, 4.9 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.48 (s, 1H), 7.93 (dd J = 7.6, 1.6 Hz, 1H), 8.16-8.17 (m, 2H), 8.57 (dd, J = 4.9, 1.6 Hz, 1H), 10.29 (s, 1H), 10.40 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dichlorophenyl) pyridine-3-carboxamide (Compound No. 4-24) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 4.41 (s, 2H), 7.10 (dd, J = 5.1, 1.7 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (t, J = 2.0 Hz, 1H), 7.77 (s, 2H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.17 (s, 1H), 8.17 (d, J = 5.1 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H),. 10.77 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No. 4-25) XH-NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 4.41 (s, 2H), 7.10 (dd, J = 5.1, 1.6 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.5 Hz, 2H), 7.92 (d, J = 8.5 Hz, 2H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.16 (s, 1H), 8.17 (d, J = 5.1 Hz, 1H), 8.61 ( dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.81 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-n-propylphenyl) pyridin-3 - carboxamide (Compound No. 4-26) XH NMR (400 MHz, DMSO-ds) d 0.88 (t, J = 7.3 Hz, 3H), 1.52-1.60 (m, 2H), 2.06 (s, 3H), 2.50- 2.53 (m, 2H), 4.39 (s, 2H), 7.09 (dd, J = 5.1, 1.5 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 7.28 (dd, J = 7.6, 4.9 Hz , 1H), 7.59 (d, J = 8.4 Hz, 2H), 7.94 (dd, J = 7.6, 1.7 Hz, 1H), 8.16 (s, 1H), 8.16 (d, J = 5.1 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.38 (s, 1H), 10.40 (s, 1H) 2- [2- (N-acetyl-N-methylamino) pyridin-4-ylmethylthio] -N- ( 4-chlorophenyl) pyridin-3-carboxamide (compound No. 4-27) XH NMR (500 MHz, DMSO-dg) d 1.95 (s, 3H), 3.22 (s, 3H), 4.43 (s, 2H), 7.29-7.31 (m, 2H), 7.42 (dd, J = 6.7, 2.1 Hz, 2H), 7.52 (s, 1H), 7.72 (d, J = 8.9 Hz, 2H ), 7.99 (dd, J = 7.6, 1.5 Hz, 1H), 8.34 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.60 (s, 1H) 2- [2- (N-Acetyl-N-methylamino) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 4-28) XH NMR (400 MHz, DMSO-d6) d 1.95 (s, 3H), 3.22 (s, 3H), 4.44 (s, 2H), 7.30-7.32 (m, 2H), 7.38 (d, J = 8.3 Hz, 2H), 7.52 (s, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.99 (dd, J = 7. 6, 1.7 Hz, 1H), 8.34 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4. 9, 1.7 Hz, 1H), 10.66 (s, 1H) 2- [2- (N-acetyl-N-methylamino) pyridin-4-methylmethyl] -? - (4-tert-butylphenyl) pyridine-3-carboxamide (compound? or. 4-29) RM? XH (400 MHz, DMSO-dg) d 1.27"(s, 9H), 1.95 (s, 3H), 3.22 (s, 3H), 4.43 (s, 2H), 7.28-7.30 (m, 2H), 7.36 (d, J = 8.5 Hz, 2H), 7.51 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 6.1 Hz, 1H), 8.34 (d, J = 5.1 Hz, 1H), 8. 58 (dd, J = 4.9, 1.7 Hz, 1H), 10.39 (s, 1H). 2- [2- (N-Acetyl-N-methylamino) pyridin-4-ylmethylthio] -? - (isoquinolin-3-yl) pyridin-3-carboxamide (compound? O. 4-30) RM? XH (400 MHz, DMSO-dg) d 1.95 (s, 3H), 3.22 (s, 3H), 4.45 (s, 2H), 7.28-7.31 (m, 2H), 7.52 (s, 1H), 7.58 (m, 1H), 7.75 (m, 1H), 7.98 (d, J = 8.1 Hz, 1H ), 8.06-8.09 (m, 2H), 8.35 (d, J = 5.1 Hz, 1H), 8.58-8.60 (m, 2H), 9.20 (s, 1H), 11.17 (s), 1H) 2- [2- (? -methyl-? - propionylamino) pyridin-4-ylmethylthio] -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound? O. 4-31) XH NMR (500 MHz , DMSO-dg) d 0.93 (t, J = 7, 3 Hz, 3H), 2.22 (c, J = 7.3 Hz, 2H), 3.21 (s, 3H), 4.44 (s, 2H), 7.30-7.32 ( m, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.50 (s, 1H), 7.81 (d, J = 8.9 Hz, 2H), 8.00 (dd, J = 7.6, 1.8 Hz, 1H), 8.35 (d, J = 4.9 Hz, 1H), 8.60 (dd, J = 4.7, 1.8 Hz, 1H), 10.66 (s, 1H) N ^ - (3-chlorophenyl) -2- [2- (N-methyl -N-propionylamino) pyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 4-32) XH NMR (500 MHz, DMSO-dg) d 0.93 (t, J = 7.4 Hz, 3H), 2.22 (c , J = 7.4 Hz, 2H), 3.21 (s, 3H), 4.44 (s, 2H), 7.19 (ddd, J = 7-9, 2.1, 0.9 Hz, 1H), 7.31-7.32 (m, 2H), 7.39 (t, J = 8.2 Hz, 1H), 7.51 (s, 1H), 7.58 (dd, J = 8.2, 1.2 Hz, 1H), 7.89 (t, J = 1.8 Hz, 1H), 8.00 (dd, J = 7.6, 1.8 Hz, 1H), 8.35 (d, J = 5.5 Hz, 1H), 8.60- (dd, J = 4.9, 1.8 Hz, 1H), 10.64 (s, 1H) 2- (2-acetylaminopyridin-4) -ylmethylthio) -N- (2,2-dime tylpropyl) pyridin-3-carboxamide (compound No. 4-33) RM? XH (500 MHz, DMSO-ds) d 0.90 (s, 9H), 2.06 (s, 3H), 3.04 (d, J = 6, 4 Hz, 2H), 4.36 (s, 2H), 7.08 (dd, J = 5.2, 1.5 Hz, 1H), 7.21 (dd, J = 7.6, 4.9 Hz, 1H), 7.77 (dd, J = 7.6, 1.8 Hz, 1H), 8.14 (broad s, 1H), 8.16 (d, J = 5.2 Hz, 1H), 8.43 (t, J = 6.4 Hz, 1H), 8.51 (dd, J = 4.9, 1.8 Hz, 1H), 10.40 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -? - [2- (4-methoxyphenyl) ethyl] iridin-3-carboxamide (Compound? 4-34) XH NMR (500 MHz, DMSO-d6) d 2.06 (s, 3H), 2.75 (t, J = 7.3 Hz, 2H), 3.35-3.41 (m, 2H), 3.71 (s, 3H), 4.34 (s, 2H), 6.83 (d, J = 8.6 Hz, 2H), 7.08 (dd, J = 5.2, 1.5 Hz, 1H), 7.15 (d, J = 8.6 Hz, 2H), 7.21 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (dd, J = 7.6, 1.8 Hz, 1H), 8.15 (s broad , 1H), 8.17 (d, J = 5.2 Hz, 1H), 8.52 (dd, J = 4.9, 1.8 Hz, 1H), 8. 57 (t, J = 5.5 Hz, 1H), 10.41 (s, 1H) ) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (2-chlorophenyl) pyridin-3-carboxamide (Compound No. 4-35) XH NMR (400 MHz, DMSO-dg) d 2.06 * (s, 3H) ), 4.40 (s, 2H), 7.11 (dd, J = 4.9, 1.5 Hz, 1H), 7.24-7.33 (m, 2H), 7.39 (m, 1H), 7.55 (dd, J = 8.0, 1.5 Hz, 1H), 7.60 (d , J = 7.3 Hz, 1H), 8.04 (d, J = 6.3 Hz, 1H), 8.16-8 ': i9 (m, 2H), 8.60 (dd, J = 4.6, 1.7 Hz, 1H), 10.23 (s) , 1 H), 10.42 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (5-chloro-2,4-dimethoxyphenyl) pyridine-3-carboxamide (Compound No. 4-36) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 3.85 (s, 3H), 3.90 (s, 3H), 4.38 (s, 2H), 6.87 (s, 1H), 7.10 (dd, J = 5.1, 1.5 Hz, 1H), 7.26 (m, 1H), 7.76 (s, 1H), 7.96 (d, J = 6.6 Hz, 1H), 8.15-8.18 (m, 2H), 8.57 (d, J = 3.7 Hz, 1H), 9.71 (s, 1H), 10.41 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3, 5-dimethyl-4-hydroxyphenyl) pyridin-3-carboxamide (compound No. 4-37) XH NMR (400 MHz, DMSO-d6) d 2.06 (s, 3H), 2.15 (s, 6H), 4.38 (s, 2H), 7.10 (dd, J = 5.1, 1.5 Hz, 1H ), 7.23-7.28 (m, 3H), 7.90 (dd, J = 7.6, 1.7 Hz, 1H), 8.09 (s, 1H), 8.15-8.18 (m, 2H), 8.56 (dd, J = 4.8, 1.7 Hz, 1H), 10.08 (s, 1H), 10.41 (s, 1 H) N- (3,5-dimethylphenyl) -2- [2- (2, 5-dioxopyrrolidin-1-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 4-38) NMR XH (500 MHz, DMSO-dg) d 2.26 (s, 6H), 2.80 (s, 4H), 4.48 (s, 2H), 6.76 (s, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.40 (s, 1H), 7.52 (d, < - J = 4.9 Hz, 1H), 7.94 (dd, J = 7.6, 1.5 Hz, 1H), 8.47 (d, J = 4.9 Hz, 1H), 8.57 (dd, J = 4.9, 1.5 Hz, 1H) , 10.31 (s, 1H) N- (3, 5-dimethylphenyl) -2- (2-metoxicarbonilaminopiridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 4-39) XH NMR (400 MHz, DMSO-dg ) d 2.25 (s, 6H), 3.65 (s, 3H), 4.39 (s, 2H), 6.76 (s, 1H), 7.06 (m, 1H), 7.27-7.33 (m, 3H), 7.91-7.94 (m, 2H), 8.13 (d, J = 5.4 Hz , 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.10 (s, 1H), 10.30 (s, 1H) 2- [2- (4-chlorophenyl) sulfonylaminopyridin-4-ylmethylthio] -N- (3, 5-dimethylphenyl) pyridin-3-carboxamide (Compound No. 4-40) XH NMR (400 MHz, DMSO-dg) d 2.26 (s, 6H), 4.34 (s, 2H), 6.77 (S, 1H ), 6.85 (m, 1H), 7.27-7.31 (m, 2H), 7.34 (s, 2H), 7.51 (d, J = 7.6 Hz, 2H), 7.77-7.80 (m, 3H), 7.97 (d , J = 6.3 Hz, 1H), 8.50 (m, 1H), 10.31 (s, 1H) N- (3,5-dimethylphenyl) -2- [2- (1-oxo-3-buten-1-ylamino) pyridin-4-ylmethylthio] pyridin-3-carboxamide (Compound No. 4-41) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 3.16- 3.20 (m, 2H), 4.40 (s, 2H), 5.10-5.19 (m, 2H), 5.98 (m, 1H), 6.76 (s, 1H), 7.11 (dd, J = 5.1, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, '4.9 Hz, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1. 7 Hz, 1H), 8.15 (s, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.57 (m, 1H), 10.29 (s, 1H), 10.44 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) benzamide (compound? or 4-42) »RM ? XH (500 MHz, DMSO-dg) d 2.06 (s, 3H), 4.24 (s, 2H), 7.05 (d, J = 5.2 Hz, 1H), 7.30 (t, J = 7.3 Hz, 1H), 7. 39 (d, J = 8.9 Hz, 2H), 7.44 (t, J = 7.3 Hz, 1H), 7.48 (d, J = 7.3 Hz, 1H), 7.52 (d, J = 7.3 Hz, 1H), 7.75 (d, J = 8.9 Hz, 2H), 8.11 (s, 1H), 8.17 (d, J = 5.2 Hz , 1H), 10.43 (s, 1H), 10.48 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (3,5-dimethylphenyl) benzamide (compound? o. 4-43) RM? XH (500 MHz, DMSO-ds) d 2.07 (s, 3H), 2.25 (s, 6H), 4.23 (s, 2H), 6.74 (s, 1H), 7.06 (dd, J = 4.9, 1.5 Hz, 1H), 7.28 (m, 1H), 7.35 (s, 2H), 7.40 (m, 1H), 7.45 (d, J = 9. 2 Hz, 1H), 7.48 (m, 1H), 8.11 (s, 1H), 8.18 (dd, J = 5.2, 0. 6Hz, 1H), 10.18 (s, 1H), 10.44 (s, 1H) 2- (2-Acetylaminopyridin-4-ylmethylthio) -? -. (4-tertbutyl) benzamide (compound or 4-44) XH NMR (500 MHz, DMSO-dg) d 1.27 (s, 9H), 2.07 (s, 3H), 4.23 (s, 2H), 7.06 (d, J = 4.9 Hz, 1H), 7.28 (t, J = 7.3 Hz , 1H), 7.35 (d, J = 8.6 Hz, 2H), 7.41 (t, J = 7.3 Hz, 1H), 7.47 (d, J = 7.3 Hz, 1H), 7.50 (d, J = 7.3 Hz, 1H ), 7.63 (d, J = 8.6 Hz, 2H), 8.11 (s, 1H), 8.18 (d, J = 4.9 Hz, 1H), 10.26 (s, 1H), 10.43 (s, 1H) 2- (2 -acetilaminopiridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) benzamide (compound No. 4-45) XH NMR (500 MHz, DMSO-dg) d 2.06 (s, 3H), 4.24 (s, 2H), 7.06 (d, J = 5.2 Hz, 1H), 7.30 (t, -J = 7.6 Hz, 1H), 7.35 (d, J = 8.6 Hz, 2H), 7.43 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 8.6 Hz, 2H), 8.11 (s, 1H), 8.17 (d, J = 5.2 Hz'-, 1H), 10.43 ( s, 1H), 10.54 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) benzamide (Compound No. 4-46) XH NMR (500 MHz, DMSO-dg ) d 2.06 (s, 3H), 4.24 (s, 2H), 7.07 (d, J = 4.9 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H) ), 7.48 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 8.08 (d, J = 7.6 Hz, 1H), 8.11 (s, 1H), 8.17 (d, J = 4.9 Hz, 1H), 8.60 (s, 1H), 9.18 (s, 1H), 10.43 (s, 1H), 10.95 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) benzamide (Compound No. 4-47) XH NMR (500 MHz, DMSO-dg) d 1.20 (d, J = 7.0 Hz, 6H), 2.07 (s, 3H), 2.86 (m, 1H), 4.24 (s, 2H), 6.98 (d, J = 7.6 Hz , 1H), 7.07 (d, J = 5.2 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.62 (s, 1H), 8.11 (s, 1H), 8.18 (d, J = -5.2 Hz, 1H), 10.27 (s, 1H) , 10.44 (s, 1H) 2- (2-acetylaminopyridin-i-4-ylmethylthio) -N- (4-chloro-3-methylphenyl) benzamide (Compound No. 4-48) XH NMR (500 MHz, DMSO-dg ) d 2.06- (s, 3H), 2.32 (s, 3H), 4.23 (s, 2H), 7.06 (d, J = 5.2 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.36 (d, J = 8.6 Hz, 1H), 7.42 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.53 (m, 1H), 7.74 (s, 1H), 8.11 (s, 1H), 8.18 (d, J = 5.2 Hz, 1H), 10.40 (s, 1H), 10.43 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (lH-indazol-6-yl) ) benzamide (Compound No. 4-49) XH NMR (500 MHz, DMSO-dg) d 2.06 (s, 3H), 4.25 (s, • 2H), 7.07 (d, J = 5.2 Hz, 1H), 7.26 ( d, J = 8.6 Hz, 1H), 7.31 (t, J = 7.3 Hz, 1H), 7.42 (t, J = 7.3 Hz, 1H), 7.49 (d, J = 7.3 Hz, 1H), 7.55 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 8. 6 Hz, 1H), 7.99 (s, 1H), 8.11 (s, 1H), 8.17 (d, J = 5.2 Hz, 1H), 8. 25 (S, 1H), 10. 43 (s, 1H), 10. 49 (s, 1H), 12. 93 (s, 1H) 2 - (2-acetylaminopyridin-4-methylmethyl) -N- (2,2 -dimethylpropyl) benzamide (Compound No. 4-50) XH NMR (500 MHz, DMSO-dg) d 0.91 (s, 9H), 2.07 (s, 3H), 3.04 (d, J = 6.4 Hz, 2H), 4.20 (s, 2H), 7.05 (dd, J = 4.9, 1.8 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.31-7.37 (m, 2H), 7.40 (d, J = 7.6 Hz, 1H), 8.09 (broad s, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.25 '(t , J = 6.4 Hz, 1H), 10.43 (s, 1H) 3- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) thiophene-2-carboxamide (Compound No. 4-51) XH NMR ( 500 MHz, DMSO-dg) d 1.27- (s, 9H), 2.06 (s, 3H), 4.27 (s, 2H), 6.99 (d, J = 4.9 Hz, 1H), 7.24 (d, J = 5.2 Hz, 1H), 7.34 (d, J = 8.9 Hz, 2H), 7.52 (d, J = 8.9 Hz, 2H), 7.83 (d, J = 5.2 Hz, 1H), 8.11 (s, 1H), '8.16 (d, J = 4. 9 Hz, 1H), 9.90 (s, 1H), 10.43 (s, 1H) 3- (2-acetylaminopyridin-4-ylmethylthio) -N- (lH-indazol-6-yl) thiophene-2-carboxamide (compound No. 4-52) XH NMR (500 MHz, DMSO-dg) d 2.04 (s, 3H), 4.28 (s, 2H), 7.01 (d, J = 4.9 Hz, 1H), 7.20 (d, J = 8.6 Hz , 1H), 7.27 (d, J = 5.2 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 5.2 Hz, 1H), 7.99 (broad s, 1H), 8.09 ( s, 1H), 8 10 (s, 1H), 8. 16 (d, J = 4.9 Hz, 1H), 10. 12 (s, 1H), 10. 41 (s, 1H), 12. 94 (s, 1H) 3- (2-acetylaminopyrin-4-ylmethylthio) -N- (isoquinolin-3-yl) thiophene-2-carboxamide (Compound No. 4-53) XH-NMR (500 MHz, DMSO-dg) d 1.96 (s, 3H), 4.31 (s, 2H), 6.92 (d, J = 5.2 Hz, 1H), 7.32 (d, J = 5.2 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H) , 7.75 (t, J = 7.6 Hz, 1H), 7.91 (d, J = 5.2 Hz, 1H), 7.93 (d, J = 7.6 Hz, 1H), 8.03 (s, 1H), 8.08 (d, J = 5.2 Hz, 1H), 8.10 (d, J = 7.6 Hz, 1H), 8.45 (s, 1H), 9.17 (s, 1H), 10.32 (s, 1H), 10.55 (s, 1H) 3- (2- acetylaminopyridin-4-ylmethylthio) -N- (2,2-dimethylpropyl) thiophene-2-carboxamide (Compound No. 4-54) XH NMR (500 MHz, DMSo-dg) d 0.85 (s, 9H), 2.07 (s) , 3H), 3.01 (d, J = 6.1 Hz, 2H), 4.24 (s, 2H), 6.88 (d, J = 5.1, 1.7 Hz, 1H), 7.23 (d, J = 5.1 Hz, -1H), 7.75 (d, J = 5.1 Hz, 1H), 7.94 (d, J = 6.1 Hz, 1H), 8.04 (broad s, 1H), 8.16 (d, J = 5.1 Hz, 1H), 10.45 (s, 1H) 3- (2-Acetylaminopyridin-4-ylmethylthio) -N- [2- (4-methoxyphenyl) ethylthiophene-2-carboxamide (Compound No. 4-55) XH-NMR (500 MHz, DMSO-dg) d 2.06 (s, 3H ), 2.71 (t, J = 7.3 Hz, 2H), 3.33-3.38 (m, 2H), 3.71 (s, 3H), 4.19 (s, 2H), 6.85 (d, J = 8.6 Hz, 2H), 6.95 (dd, J = 4.9 , 1.5 Hz, 1H), 7.14 (d, J = 8.6 Hz, 2H), 7.15 (d, J = 5.2 Hz, 1H), 7.71 (d, J = 5.2 Hz, 1H), 8.06 (t, J = 5.5 Hz, 1H), 8.08 (broad s, 1H), 8.18 (d, J = 4.9 Hz, 1H), 10.46 (s, 1H) 3- (2-acetylaminopyridin-4-ylmethylthio) -N- (3, 5 dimethylphenyl) thiophene-2-carboxamide (compound No. 4-56) XH NMR (400 MHz, DMSO-dg) d 2.05 (s, 3H), '2.25 (s, 6H), 4.27 (s, 2H), 6.74 ( s, 1H), 6.97 (dd, J = 5.1, 1.5 Hz, 1H), 7.22, 7.27 (m, 3H), 7.83 (d, J = 5.1 Hz, 1H), 8.11 (s, 1H), 8.16 (d , J = 5.1 Hz, 1H), 9.82 (s, 1H), 10.43 (s, 1H) 3- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) thiophene-2-carboxamide (compound No. 4-57) X H NMR (500 MHz, CDCl 3) d 2.11 (s, 3 H), 3.96 (s, 2 H), 6.44 (d, J = 6.7, 1.9 Hz, 1 H), 7.16 (d, J = 5.2 Hz, 1H), 7.26 (d, J = 8.9 Hz, 2H), 7.46 (d, J = 8.9 Hz, 2H), 7.57 (d, J = 5.2 Hz, 1H), 8.00 (d, J = 6.7 Hz, 1H) , 8.03 (s, 1H), 8.07 (s, 1H)9.79 (s, 1H) 3- (2-acetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) thiophene-2-carboxamide - (Compound No. 4-58) XH NMR (400 MHz, CDCl3) d 2.10 (s, 3H), 3.98 (s, 2H), 6.48 (dd, J = 5.1, 1.7 Hz, 1H), 7.15 (d, * J = 0.7 Hz, 1H), 7.17 (d, J = 5.1 Hz, 2H ), 7.54 (dd, J = 7.8, 2.2 Hz, 1H), 7.58 (d, J = 5.1 Hz, 2H), 8.00, 8.02 (m, 2H), 8.09 (s, 1H), 9.84 (s, 1H) N- (3, 5-dimethyl-phenyl) -2- (2-methoxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (Compound No. 4-59) XH-NMR (500 MHz, DMSO-dg) d 2.25 (s, 6H), 3.35 (s, 3H), 4.04 (s, 2H), 4.42 (s, 2H), 6.76 (s, 1H), 7.15 (dd, J = 5.2, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.93 (dd, J = 7.6, 1.8 Hz, 1H), 8.17 (s, 1H), 8.19 (d, J = 4.9 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 9.89 (s, 1H), 10.30 (s, 1H) 2- (2-methoxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 4-60) XH NMR (500 MHz, DMSO, d6) d 3.35 (s, 3H), 4.03 (s, 2H), 4.4 3 (s, 2H), 7.15 (dd J = 5.2, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.99 (dd, J = 7.6, 1.5 Hz, 1H), 8.17 (s, 1H), 8.19 (dd, J = 5.2, 0.6 Hz, 1H), 8.60 (dd, J = 4.9 , 1.8 Hz, 1H), 9.89 (s, 1H), 10.66 (s, 1H) N- (3, 5-dimethylphenyl) -2- (2-phenoxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (Compound No. 4-61) NMR XH (500 MHz, DMSO-d6) d 2.25 (s, 6H), 4.41 (s, 2H), 4.76 (s, 2H), 6.76 (s, 1H), 7.03-7.09 (m, 3H) ), 7.16 (d, J = 4.9 Hz, 1H), 7.27 (dd, J = 7.6, 4.9 Hz, 1H), 7.28, 7.30 (m, 3H), 7.31 (s, 1H), 7.92 (dd, J = 7.6, 1.8 Hz, 1H), 8.15 (s, 1H), 8.22 (d, J = 4.9 Hz, 1H), 8.56 (dd, J = 4.9, 1.8 Hz, 1H), 10.30 (s, 1H), 10.43 ( s, 1 H) 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridin-3-carboxamide (Compound No. 4-62) XH NMR (500 MHz, DMSO-dg) d 2.10 (s , 3H), 4.41 (s, 2H), 4.68 (s, 2H), 7.14 (d, J = 5.2 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 Hz, 2H), 7.98 (dd, J = 7.6, 1.5 Hz, 1H), 8.10 (broad s, 1H), 8.20 (d, J = 5.2 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.59 (s, 1H), 10.60 (s, 1H) N- (3, 5-dimethylphenyl) -2- (3-methanesulfonylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide ( Compound No. 4-63) NMR XH (500 MHz, CDl 3) d 2.32 (s, 6H), 3.07 (s, 3H), 4.36 (s, 2H), 6.83 (a, 1H), 7.21-7.25 (m, 4H), 7.90 (d, J = 6.4 Hz, 1H), 7.94 (s, 1H), 8.33 (d, J = 4.9 Hz, 1H), 8.72 (d, J = 4.5, 1.5 Hz, 1H), 8.78 (s, 1H) , 10.64 (s, 1H) 2- (3-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (Compound No. 4-64) XH NMR (400 MHz, CDCl3) d 2.19 ( s, 3H), 2.30 (s, 6H), 4.31 (s, 2H), 6.81 (s, 1H), 7.16-7-.22 (m, 2H), 7.25 (s, 2H), 7.87 (d, J = 7.6 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.48-8.52 (m, 2H), 8.94 (s, 1H), 9.38 (s, 1H) N- (4-acetoxy-3, 5-dimethylphenyl) -2- (2-acetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 4-65) XH NMR (500 MHz, DMSO-dg) d 2.06 (s, 3H), 2.07 (s) , 6H), 2.33 (s, 3H), 4.39 (s, 2H), 7.10 (dd, J = 5.2, 1.5 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.42 (s, 2H) ), 7.94 (dd, J = 7.6, 1.8 Hz, 1H), 8.16-8.18 (m, 2H), 8.58 (dd, J = 4.9, 1.8 Hz, 1H), 10.38 (s, 1H), 10.41 (s, 1H) 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3-trifluoromethylphenyl) pyridin-3-carboxamide (Compound No. 4-66) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H ), '4.41 (s, 2H), 7.10 (dd, J = 5.1, 1.6 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.61 (dd, J = 8.3 , 7.6 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 8.03 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.18 (m, 3H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.79 (s, 1H) 2- [2, (4-hydroxycarbonylbutyryl) aminopyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 4-67) XH NMR (400 MHz, DMSO-dg) d 1.73-1.82 (m, 2H), 2.24 (t, J = 7.6 Hz, 2H), 2.25 (s, 6H), 2.39 (t , J = 7.3 Hz, 2H), 4.39 (s, 2H), 6.76 (s, 1H), 7.10 (d, J = 6.6 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7 ': 32 (s, 2H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 8.17 (d, J = 6.6 Hz, 1H), 8.17 (s, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.31 (s, 1H), 10.40 (s, 1H), 12.04 (broad s, 1H) 2- [2- (3,5-dioxomorpholin-4-yl) pyridin-4-ylmethylthio ] -N- (3, 5-dimethylphenyl) pyridine-3-carboxamide (Compound No. 4-68) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 4.48 (s, 2H), 4.54 (s, 4H), 6.76 (s, 1H) , 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.33 (s, 2H), 7.45 (s, 1H), 7.53 (d, J = 4.9 Hz, 1H), 7.94 (dd, J = 7.6, 1.7 Hz, 1H), 8.46 (d, J = 4.9 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.33 (s, 1H) Example 5 N- (3,5-dimethylphenyl) -2- [2- (N '-n-propylureido) pyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 5-1) n-isocyanate is added propyl (20 mg, 0.23 mmole) to a solution of 2- (2-aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (the free base of compound No. 3-1, 28 mg, 0.077 mmol) in 0.60 ml of N, N-dimethylformamide at room temperature and the mixture is stirred for 4 hours at 80 ° C. 10 ml of ethyl acetate are added to the reaction mixture, the whole is washed with 15 ml of water and 15 ml of brine and then the organic layer is dried over anhydrous magnesium sulfate. The organic layer is evaporated under reduced pressure and the resulting residue is purified by chromatography on a silica gel column to provide 12 mg of the objective compound as a colorless solid (33% yield).

RM? XH (500 MHz, DMSO-dg) d 0.87 (t, J = 7.6 Hz, 3H), 1.46 (m, 2H), 2.25 (s, 6H), 3.11 (m, 2H), 4.33 (s, 2H), 6.76 (s, 1H), 6.93 (d, J = 5.2 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.37 (s, 1H), 7.93 (dd, J = 7.6, 1.5 Hz, 1H), 8.05 (d, J = 5.2 Hz, 1H), 8.23 (s broad, 1H), 8.57 (dd, J = 4.9, 1.5 Hz, 1H), 9.13 (s, 1H), 10.29 (s, 1H) As described in the following, the compounds numbers 5-2-6 using the corresponding compounds which are selected from the reference compounds (number 3-1-37), commercially available compounds or known compounds, according to the method of synthesis of the compound (number 5-1) . 2- [2- (N '-terbutylureido) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (Compound No. 5-2) XH NMR (500 MHz, DMSO-d6) d 1.30 (s, 9H), 2.25 (s), 6H), 4.33 (s, 2H), 6.76 (s, 1H), 6.91 (d, - J = 5.2 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H ), 7.42 (s, 1H), 7.93 (dd, J = 7.6, 1.5 Hz, 1H), 8.03 (d, J = 5.2 Hz, 1H), 8.06 (broad s, 1H), 8.57 (dd, J = 4.9) , 1.5 H'z, 1H), 8.91 (s, 1H), 10.30 (s, 1H) 2- [2- (N'-4-chlorophenyluride) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) ) pyridine-3-carboxamide (compound No. 5-3) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 4.38 (s, 2H), 6.76 (s, 1H), 7.05 (d, J = 5.2 Hz, 1H), 7.27-7.50 (m, 4H), 7.53-7.56 (m, 4H), 7.94 (dd, J = 7.6, 1.7 Hz, 1H), 8.16 (d, J = 5.2 Hz, 1H ), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 9.48 (s, 1H), 10.30 (s, 1H), 10.69 (s, 1H) N- (3,5-dimethylphenyl) -2- [2 - (N '-methyloureido) pyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 5-4) XH NMR (500 MHz, DMSO-dg) d 2.26 (s, 6H), 3.05 (d, J = 4.6 Hz, 3H), 4.35 (s, 2H), 6.76 (s, 1H), 7.05 (dd, J = 5.5, 1.5 Hz, 1H), 7.21 (s, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.94 (dd, J = 7.6, 1.5 Hz, 1H), 8.10 (d, J = 5.5 Hz, 1H), 8.58 (dd, J = 4.9, 1.5 Hz, 1H), 10.29 (s, 1H), - 10.54 (s, 1H), 11.49 (d, J = 4.6 Hz, 1H) N- (4-chloro-phenyl) -2- [2- (N '-n-propylureido) pyridin-4-ylmethylthio] pyridin-3-carboxamide (Compound No. 5-5 ) NMR XH (400 MHz, DMSO-dg) d 0.87 (t, J = 6.3 Hz, 3H), 1.40-1.50 (m, 2H), 3.10 (c, J = 6.8 Hz, 2H), 4.34 (s, 2H) ), 6.93 (d, J = 5.4 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (s, 1H), 7.42 (d, J = 9.0 Hz, -2H), 7.73 ( d, J = 9.0 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.05 (d, J = 5.4 Hz, 1H), 8.24 (broad s, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 9.14 (s, 1H), 10.59 (s, 1H) 2- [2- (N '-n-propylureido) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine- 3-carboxamide (compound No. 5-6) XH-NMR (500 MHz, DMSO-d6) d 0.87 (t, J = 6.3 Hz, 3H), 1.43-1.48 (m, 2H), 3.11 (c, J = 7.0 Hz, 2H), 4.35 (s, 2H), 6.93 (d, J = 4.9 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.36-7.38 (m, 3H), 7.81 (d , J = 8.6 Hz, 2H), 7.99 ( dd, J = 7.6, 1.5 Hz, 1H), 8.05 (d, J = 4.9 Hz, 1H), 8.23 (broad s, 1H), 8.60 (dd, J = 4.9, 1.5 Hz, 1H), 9.13 (s, 1H), 10.65 (s, 1H) Example 6 N- (3,5-dimethylphenyl) -2- (2-formylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 6-1) 2- (2-aminopyridin-4-ylmethylthio) - N- (3, 5-dimethylphenyl) pyridine-3-carboxamide (the free base of compound No. 3-1, 50 mg, 0.14 mmol) in 0.2 ml of anhydrous tetrahydrofuran, is added thereto a solution of N-formylbenzotriazole (19 mg, 0.13 mmol) in 0.2 ml of anhydrous tetrahydrofuran, and then the mixture is refluxed for 16 hours. The mixture is diluted in 15 ml of dichloromethane and then the whole is washed with 4.0 ml of an aqueous solution of 2N sodium hydroxide twice and dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure to provide 60 ml of the objective compound, quantitatively, as a colorless solid.

NMR XH (400 MHz, DMSO-dg) d 2.25 (s, 6H), 3.30 (s, 1H), 4.37 (s, 2H), 6.76 (s, 1H), 6.97 (s, 1H), 7.13 (m, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H) ), 7.93 (d, J '= 7.6 Hz, 1H), 8.16 (m, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.30 (s, 1H), 10.54 (s, 1H) Example 2- (2-aminopyridin-4-ylmethylthio) -N- (tert-butoxycarbonylmethyl) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 7-1) A solution of 2- (2-aminopyridine) -4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (the free base of compound No. 3-1, 50 mg, 0.14 mmole) in 2 ml of anhydrous N, N-dimethylformamide is added drop to a suspension of 60% sodium hydride (13 mg, 0.30 mmol) in 1.0 ml of anhydrous N, N-dimethylformamide, under cooling with ice and the mixture will be stirred for 5 minutes. The bromoacetic acid terbutyl ester (22uL, 0.15 mmole) is added to the reaction mixture and the mixture is stirred for 30 minutes _ at room temperature. The mixture is poured into 15 ml of ice water and the whole is extracted with 15 ml of ethyl acetate. The organic layer is washed with 30 ml of a saturated aqueous solution of sodium hydrogen carbonate and 30 ml of brine and dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and the resulting residue is purified by gel column chromatography. of silica to provide 45 mg of the objective compound as a colorless amorphous substance. (69% yield) NMR XH (500 MHz, DMSO-dg) d 1.42 (s, 9H), 2.05 (s, 6H), 4.27 (s, 2H), 4.38 (s, 2H), 5.85 ("S, 2H), 6.45-6.46 (m, 2H), 6.77-6.79 (m, 3H), 6.95 (s, 1H), 7.28 (s, 1H), 7.78 (dd, J = 4.9, 0.9 Hz, 1H), 8.33 (s, 1H) EXAMPLE 8 N- (3,5-Dimethylphenyl) -2- (2-phenylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 8-1) While nitrogen is bubbled, 2- (2-aminopyridine) is added. 4-ylmethylthio) -N- (3, 5-dimethylphenyl) pyridine-3-carboxamide (the free base of compound No. 3-1, 63 mg, 0.18 mmol), cesium carbonate (130 mg, 0.38 mmol), iodobenzene (37DL, 0.33 mmol), 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene '(8.1 mg, 0.014 mmol) and tris (dibenzylidene ketone) dipalladium (O) (4.3 mg, -0.0047 mmol) at 2.0 ml of 1,4-dioxane. The mixture is stirred for 20 hours at 9 [deg.] C. in a sealed tube, the mixture is diluted with 30 ml of ethyl acetate and the whole is washed with 30 ml of a saturated aqueous solution of sodium hydrogen carbonate. The organic layer is dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The resulting residue is purified by silica gel column chromatography. The resulting solid is filtered off with diethyl ether and dried under reduced pressure to provide 31 mg of the objective compound as a colorless solid. (Yield 31%) NMR XH (500 MHz, DMSO-dg) d 2.25 (s, 6H), 4.34 (s, 2H), 6.75-6.76 (m, 2H), 6.85-6.87 (m, 2H), 7.22 (t, J = 7.8 Hz, 2H), 7.29 (dd, J = 7.3, 4.9 Hz, 1H), 7.33 (s, 2H), 7.61 (d, J = 7.6 Hz, 2H), 7.93 (d, J = 7.6 Hz, 1H), 8.03 (d, J = 5.5 Hz, 1H), 8.58 (d, J = 4.9 Hz, 1H), 8.97 (s, 1H), 10.31 (S, 1H) EXAMPLE 9 N- (3,5-dimethylphenyl) -2- [2- (N '-methylureido) pyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 9-1) While nitrogen is bubbling, 2- (2-bromopyridin-4-methylmeththio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (reference compound 3-4, 100 mg, 0.23 mmol), cesium carbonate (91 mg) are added. , 0.28 mmol),? -methylurea (52 mg, 0.70 mmol), 4,5-bis (diphenylphosphino) -9, 9-dimethylxantene (81 mg, 0.014 mmol) and tris (dibenzylideneacetone) dipalladium (0) (4.3 mg, 0.0047 mmole) to 2.0 ml of 1,4-dioxane. The mixture is stirred for 5 hours at 50 ° C in a sealed tube, the mixture is diluted with 30 ml of ethyl acetate and then the whole is washed 2 times with 30 ml of a saturated aqueous solution of sodium hydrogen carbonate. The organic layer is dried over anhydrous magnesium sulfate and the solvent is evaporated under reduced pressure. The residue is purified by column chromatography on silica gel. The resulting solid is filtered off with ethyl acetate and dried under reduced pressure to provide 21 mg of the objective compound as a colorless solid. (Performance 22%) NMR XH (500 MHz, DMSO-dg) d 2.25 (s, 6H), 2.71 (d, J = 4.6 Hz, 3H), 4.33 (s, 2H), 6.76 (s, 1H), 6.93 (dd, J = 5.3, 1.4 Hz, 1H), 7.28 (dd, J = 7.5, 4.7 Hz, 1H), 7.33 (m, 3H), 7.92 (dd, J = 7.5, 1.5 Hz, 1H), 8.05 (d, J = 5.3 Hz, 1H), 8.15 (s, 1H), 8.57 (dd, J = 4.7, 1.5 Hz, 1H), 9.20 (s, 1H), 10.29 (s, 1H) As described in the following, compounds are obtained (No. 9-2-4) using the corresponding compounds that are selected from the compounds (No. 3-4-7), commercially available compounds or known compounds according to the method of synthesis of the compound (No. 9-1 ). 2- [2- (N '-methylureido) pyridin-4-methylmethyl] -N- (4-trifluoromethoxy-phenyl) -pyridine-3-carboxamide (compound No. 9-2) XH-NMR (500 MHz, DMSO-dg) d 2.70 (d, J = 4.6 Hz, 3H), 4.34 (s, 2H), 6.93 (dd, J = 5.5, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.33 (s, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.80 (d, J = 8.9 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.05 (d, J =, 5.5 Hz, 1H), 8.15 (s, 1H) , 8.60 (dd, J = 4.8, 1.7 Hz, 1H), 9.21 (s, 1H), 10.66 (s, 1H) N- (4-chlorophenyl) -2- [2- (N '-methylureido) pyridin-4 -ylmethylthio] pyridine-3-carboxamide (compound No. 9-3) - XH NMR (400 MHz, DMSO-dg) d 2.71 (d, J = 4.6 Hz, 3H), 4.34 (s, 2H), 6.93 (dd) , J = 5.1, 1.4 Hz, 1H), 7.28-7.33 (m, 2H), 7.41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.04 (d, J = 5.1 Hz, 1H), 8.16 (s, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 9.21 (s, 1H), 10.60 ( s, 1H) N- (4-difluoromethoxyphenyl) -2- [2- (N-methylureido) pyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 9-4) XH NMR (400 MHz, DMSO-dg ) d 2.70 (d, J = 4.6 Hz, 3H), 4.34 (s, 2H), 6.93 (dd J = 5.1, 1.3 Hz, 1H), 7.17 (t, J = 74.1 Hz, 1H), 7, 18 ( d, J = 8.9 Hz, 2H), 7.28-7.33 (, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.97 (dd> J = 7.8, 1.7 Hz, 1H), 8.04 (d, J = 5.1 Hz, 1H), 8.17 (s, 1H), 8. 59 (dd, J = 4.8, 1.7 Hz, 1H), 9.22 (s, 1H), 10.55 (s, 1H) Example 10 2- (2-Acetoxyacetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (Compound No. 10-1) While nitrogen is bubbled, 2- (2-bromopyridine- 4-methylmeththyl) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (reference compound 3-4, 1.9 g, 4.7 mmol) cesium carbonate (1.8 mg, 5.6 mmol), acetoxyacetamide (1.6 g , 5.6 mmol), 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (810 mg, 1.4 mmol) and tris (dibenzylideneacetone) dipalladium (0) (430 mg, 0.47 mmol) to 20 ml of 1,4- dioxane The mixture is stirred for 3 hours at 100 D in a sealed tube and diluted with 300 ml of ethyl acetate and then the whole is washed with 300 ml of a saturated aqueous solution of sodium hydrogen carbonate. The organic layer is dried over anhydrous magnesium sulfate and the solvent is evaporated under reduced pressure. The resulting residue is purified by silica gel column chromatography to provide 1.0 g of the objective compound as a light yellow solid. (Performance 47%) Or the compound is also synthesized as described below. Acetoxyacetic acid is dissolved (1.2 g, mmoles) in 12 ml of pyridine at room temperature, acetoxyacetyl chloride (1.1 ml, mmol) and the mixture is stirred for 4 hours at room temperature. It is also added to it 2- (2-aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (the free base of compound No. 3-1, 1.0 g, 2.5 mmol) and the mixture is stirred for 15 hours. 100 ml of ethyl acetate are added to the reaction mixture and the whole is washed three times with 150 ml of 1 N hydrochloric acid, twice with 150 ml of a saturated aqueous solution of sodium acid carbonate and 150 ml of brine. The organic layer is dried over anhydrous sodium sulfate. The solvent is evaporated under reduced pressure and the resulting residue is purified by column chromatography on silica gel. The resulting solid is filtered off with ethyl acetate and then dried under reduced pressure to provide 0.97 g of the objective compound as a brown solid. (Yield 77%) XH NMR (400 MHz, DMSO-dg) d 2.10 (s, 3?), 2.25 (s, 6H), 4.40 (s, 2H), 4.68 (s, 2H), 6.76 (s, 1H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.8 Hz, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1.8 Hz, 1H), 8.10 (s, 1H), 8.20 ( d, J = 5.1 Hz, 1H), 8.57 (dd, J = 4.8, 1.8 Hz, 1H), 10.30 (S, 1H), 10.60 (s, 1H) As described above, the compounds are obtained (No 10-2-21) using the corresponding compounds of the reference compounds (No. 3-4, 5), the compounds (No. 3-1-37), commercially available compounds or known compounds according to the method of synthesis of the compound (No. 10-1). 2- (2-Acetoxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 10-2) XH NMR (400 MHz, DMSO-dg) d 2.09 (s, 3H), 4.41 (s, 2H), 4.68 (s, 2H), 7.14 (dd, J = 5.2, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.36 (d, J = 8.3 Hz , 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.98 (dd, J = 7.6, 1.8 Hz, 1H), 8.10 (s, 1H), 8.20 (d, J = 5.2 Hz, ÍH), 8.59 (dd, J = 4.8, 1.8 Hz, 1H), 10.59 (s, 1H), 10.65 (s, 1H) 2- (2-tert-butoxycarbonylaminoacetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3 ^ carboxamide (compound No. 10-3) XH NMR (500 MHz, DMSO-dg) d 1.39 (s, 9H), 2.25 (s, 6H), 3.75 (d, J = 6.3 Hz, 2H), 4.40 (s) , 2H), 6.76 (s, 1H), 7.03 (m, 1H), 7.12 (dd, J = 5.1, 1.7 Hz, 1H), 7.28 (m, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 8.14 (d, J = 0.7 Hz, 1H), 8.18 (dd, J = 5.1, 0.7 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.30 (s, 1H), 10.31 (s, 1H) 2- [2- (2-acetoxypropionylamino) pyridin-4-ylmethylthio] -N- (3, 5-dime tylphenyl) pyridin-3-carboxamide (compound No. 10-4) XH NMR (400 MHz, CDC13) d 1.55 (d, J = 6.7 Hz, 3H), 2.19 (s, 3H), 2.32 (s, 6H), 4.50 (s, 2H), 5.31 (c, J = 6.7 Hz, 1H), 6.81 (s, 1H), 7.11-7.14 (m, 2H) ), 7.27 (s, 2H), 7.85 (dd, J = 7.6, 1.8 Hz, 1H), 8.03 (s, 1H), 8.17 (d, J = 5.2 Hz, 1H), 8.29 (s, 1H), 8.43 (s, 1H), 8.52 (dd, J = 4.9, 1.8 Hz, 1H) N- (3,5-dimethylphenyl) -2- [2- (3-methoxypropionyl) aminopyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 10-5) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 2.60 (t, J = 6.2 Hz, 2H), 3.21 (s, 3H), 3.59 (t, J = 6.2 Hz, 2H), 4.40 (s, 2H), 6.76 (s, 1H), 7.11 (dd, J = 5.2, 1.4 Hz, 1H), 7. 28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 8.17 (s, 1H), 8.18 (s, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.31 (s, 1H), 10.42 (s, 1H) 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N- (indan-5-yl) pyridin-3 -carboxamide (compound No. 10-6) XH NMR (400 MHz, DMSO-dg) d 2.02-2.06 (m, 2H), 2.10 (s, 3H), 2.79-2.87 (m, 4H), 4.40 (s, 2H), 4.68 (s, 2H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.17 (d, O = 8.1 Hz, 1H), 7.28 (dd, J = 7.6, 4.8 Hz, 1H), 7.37 (d, J = 7.3 Hz, 1H), 7.62 (s, 1H), 7.93 (m, 1H), 8.10 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.57 (dd, J = 4.8, 1.7 Hz, 1H), 10.34 (s, 1H), 10.60 (s, 1H) 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N- (3-methylphenyl) pyridine-3-carboxamide (compound No. 10-7) XH NMR (400 MHz, DMSO-dg) d 2.10 (s, 3H), 2.30 (s, 3H), 4.41 (s, 2H), 4.69 (s, 2H), 6.93 (d, J = 7.8 Hz, 1H), 7.15 (dd, J = 5.1, 1.5 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7. 29 (dd, J = 7.6, 4.9 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.57 (m, 1H), 7.94 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (s) , 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.39 (s, 1H), 10.60 (s, 1H) 2- (2-acetoxyacetylaminopyridin- 4-ylmethylthio) -N- (4-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No. 10-8) XH NMR (400 MHz, DMSO-dg) d 2.10 (s, 3H), 4.42 (s, 2H), 4.72 (s, 2H), 7.15 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.91 (d, J = 8.8 Hz, 2H), 8.02 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.60 (s, 1H), 10.82 (s, 1H) N- (4-chlorophenyl) -2- (2-methoxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 10-9) XH NMR (400 MHz, DMSO-dg) d 3.35 (s, 3H), 4.04 (s, 2H), 4.42 (s, 2H), 7.15 (dd, J = 5.1, 1.5-Hz, 1H) , 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.17 (s, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.90 (s, 1H), 10.60 (s, 1H) 2 - (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N- (4-tert-butylphenyl) pyridine-3-carboxamide (Compound No. 10-10) XH-NMR (400 MHz, DMSO-dg) d 1.27 (s, 9H), 2.10 (s, 3H), 4.40 (s, 2H), 4.68 (s, 2H), 7.14 (d, J = 5.1 'Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (d) , J = 8.5 Hz, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.94 (d, J = 7.6 Hz, 1H), 8.10 (broad s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.57 (dd) , J = 4.9, 1.7 Hz, 1H), 10.39 (s, 1H), 10.60 (s, 1H) 2- [2- (3-methoxypropionyl) aminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine- 3-carboxamide (compound No. 10-11) XH NMR (400 MHz, DMSO-dg) d 2.60 (t, J = 6.1 Hz, 2H), 3.22 (s, 3H), 3.59 (t, J = 6.1 Hz, 2H), 4.41 (s, 2H), 7.11 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 8.7 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.18 (s, 1H), 8.60 (d, J = 4.9, 1.7 Hz, 1H), 10.42 (s, 1H), 10.66 (s, 1H) 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N - '(3-chloro-4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 10-12) XH NMR (400 MHz, DMSO-dg) d 2.10 (s, 3H), 4.42 (s, 2H), 4.68 (s, 2H), 7.15 (d, J = 5.1 Hz, 1H ), 7.32 (d, J = 7.6, 4.9 Hz, 1H), 7.59 (d, J = 9.0 Hz, 1H), 7.71 (dd, J = 9.0, 2.4 Hz, 1H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.08 (d, J = 2.4 Hz, 1H), 8.10 (broad s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.61 (s, 1H), 10.81 (s, 1H) 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -? - (3'-trifluoromethylphenyl) pyridin-3-carboxamide (compound? O. 10-13) XH NMR (400 MHz, DMSO-dg) d 2.10 (s, 3H), 4.42 (s, 2H), 4.68 (s, 2H), 7.15 (d, J = 5.1 Hz, 1H), 7.32 ( d, J = 7.6, 4. 9 Hz, 1H), 7.48 (d, J = 1.8 Hz, 1H), 7.60 (t, J = 8.1 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 8.03 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (broad s, 1H), 8.18 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.61 (s) , 1H), 10.79 (s, 1H) 2- (2-acetoxyacetylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridine-3-carboxamide (Compound No. 10-14) XH NMR (400 MHz, DMSO- dg) d 1.20 (d, J = 6.8 Hz, 6H), 2.13 (s, 3H), 2.85 (m, 1H), 4.40 (s, 2H), 4.68 (s, 2H), 7.15 (d, J = 5.1 Hz, 1H), 7.23-7.30 (m, 2H) ), 7.50 (m, 1H), 7.58-7.60 (m, 2H), 7.96 (dd, J = 7.6, 1.7 Hz, 1H), 8. 10 (s broad, 1H), 8.20 (d, J = 5.1 Hz, 1H-), 8.57 (dd, J = 4.6, 1.7 Hz, 1H), 10.40 (s, 1H), 10.60 (s, 1H) 2- (2-Ethoxycarbonylacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 10-15) XH NMR (400 MHz, DMSO-dg) d 1.19 (t, J = 7.1 Hz, 3H), 3.53 (s, 2H), 4.10 (c, J = 7.1 Hz, 2H), 4.42 (s, 2H), 7.15 (dd, J = 5.1, 1.1 Hz, 1H), 7.31 (dd, J = 7.6 , 4.9 Hz, 1H), 7.37 (d, J = '8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.16 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.63 (s, 1H), 10.66 (s, 1H) 2- [2- (3- terbutoxycarbonylaminopropionylamino) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 10-16) X H NMR (500 MHz, CDCl 3) d 1.42 (s, 9H), 2.59 (t, J = 5.7 Hz, 2H), 3.42-3.50 (m, 2H), 4.53 (s, 2H), 5.05 (s, 1H), 7.09 (dd, J = 5.2, 1.5 Hz, 1H), 7.16 (dd, J = 7.6, 4.8 Hz, 1H), 7.22 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.90 (dd, J = 7.6, 1.8 Hz, 1H), 7.98 (s, 1H), 8.15 (d, J = 5.2 Hz, 1H), 8.24 (s, 1H), 8.28 (s, 1H), 8.54 (dd, J = 4.8 , 1.8 Hz, 1H) 2- [2- ((4S) -tertbutoxycarbonylamino-5-hydroxypentanoyl) aminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. -17) XH NMR (400 MHz, DMSO-dg) d 1.36 (s, 9H), 1.42 (m, 1H), 1.82 (m, 1H), 2.32-2.39 (m, 4H), 3.22 (m, 1H), 4.40 (s, 2H), 4.61 (m, 1H), 6.47 (m, 1H), 7.09 (m , 1H), 7.29 (dd, J = 7.6, 4.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.8 Hz, 1H), 8.16 (s, 1H), 8.17 (s, 1H), 8.60 (dd, J = 4.8, 1.8 Hz, 1H), 10.34 (s, 1H), 10.66 (s, 1H) 2- [ 2- (2-Oxopyrrolidin-1-yl) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 10-18) XH-NMR (400 MHz, DMSO-dg) d 1.97 -2.05 (m, 2H), 2.51-2.57 (m, 2H), 3.94 (t, J = 7.1 Hz, 2H), 4.42 (s, 2H), 7.15 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.80 (d, J = 8.7 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H ), 8.25 (d, J = 5.1 Hz, 1H), 8.40 (s, 1H), 8.60 (dd, J = 4.8, 1.7 Hz, 1H), 10.65 (s, 1H) 2- (2-cyanoacetylaminopyridin-4) ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 10-19) XH NMR (500 MHz, CDC13) d 3.66 (s, 2H), 4.55 (s, 2H), 7.16 (dd, J = 7.6 , 4.9 Hz, 1H), 7.23 (d, J = 8.6 Hz, 2H), 7.24-7.29 (m, 2H), 7.75 (d, J = 8.6 Hz, 2H), 7.89 (dd, J = 7.6, 1.8 Hz , 1H), 8.16 (d, J = 5.5 Hz, 1H), 8.20 (s, 1H), 8.41 (s, 1H), 8.52 (dd, J = 4.9, 1.8 Hz, 1H) 2- (2-acetoxyacetylaminopyridin- 4 -ylmethylthio) -N- (4-difluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 10-20) XH NMR (400 MHz, DMSO-dg) d 2.06 (s, 3H), 3.30 (s, 2H), 4.40 (s, 2H), 7.10 (dd, J = 5.1, 1.5 Hz, 1H), 7.16 (t, J = 74.2 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.97 '(dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.17 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (S, 1H), 10.55 (s, 1H) 2- (2-tert-butoxycarbonylaminoacetylaminopyridin-4-ylmethylthio) -? - (4-difluoromethoxyphenyl) pyridine-3-carboxamide (compound? . 10-21) XH NMR (400 MHz, DMSO-dg) d 1.39 (s, 9H), 3.75 (d, J = 6.1 Hz, 2H), 4.41 (s, 2H), 7.04 (t, J = 6.1 Hz, 1H), 7. 12 (d, J = 5.2 Hz, 1H), 7.17 (t, J = 74.2 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.96 (d, J = 7.6, 1.6 Hz, 1H) , 8.14 (s, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.59 (dd, J = 4.9, 1.6 Hz, 1H), 10.31 (s, 1H), 10.54 (s, 1H) Example 11 2- (2-Aminopyridin-4-ylmethylthio) -N-carboxymethyl-N- (3,5-dimethylphenyl) pyridin-3-carboxamide monohydrochloride (compound No. 1-1) 2- (2-aminopyridin-4-ylmethylthio) -N- (tert-butoxycarbonylmethyl) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (Compound No. 7-1, 40 mg, 0.084 mmol) in 1.0 ml of ethyl acetate and 1.0 ml of 4 N hydrochloric acid in ethyl acetate is added thereto, and then the mixture is stirred for 18 hours at room temperature. The precipitated solid is filtered off with diethyl ether and dried under reduced pressure to give 30 mg of the objective compound as a colorless solid. (Performance 86%) NMR XH (500 MHz, DMSO-dg) d 2.04- (s, 6H), 4.44 (broad s, 4H), 5.35 (s broad, 1H), 6.77 (s, 3H), 6.87 (d, J = 6.9 Hz , 1H), 6.98 (s, 1H), 7.03 (s, 1H), 7.31 (s, 1H), 7.87 (d, J = 6.9 Hz, 1H), 8.02 (s, 2H), 8.32 (d, 1H) , 13.52 (s, 1H) As described in the following, compounds (Nos. 11-2-3) are obtained by using the corresponding compounds selected from the compounds (Nos. 10-3, 17), commercially available compounds. or known compounds, according to the method of synthesis of the compound (No. 11-1). 2- (2-Aminoacetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide monohydrochloride (compound No, 11-2) XH NMR (500 MHz, DMSO-dg) d 2.25 (s) , 6H), 3.81 (s, 2H), 4.46 (s, 2H), 6.76 (s, 1H), 7.10 (s broad, 1H), 7.23 (dd, J = 5.2, 1.3 Hz, 1H), 7.29 (dd) , J = 7.6, 4.9 Hz, 1H), 7.34 (s, 2H), 7.97 (dd, J = 7.6, 1.8 Hz, 1H), 8.13 (s, 1H), 8.24 (d, J = 5.2 Hz, 1H) , 8.28 (s, 2H), 8.57 (dd, J = 4.9, 1.5 Hz, 1H), 10.36 (s, 1H), 11.09 (s, 1H) 2- [2- ((4S) -amino-5) monochlorohydrate -hydroxypentanoyl) aminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 11-3) XH NMR (500 MHz, DMSO-dg) d 1.78-1.86 (m, 2H), 2.26-2.29 (m, 2H), 3.12 (s, 1H), 3.36-3-39 (m, 2H), 3.44 (m, 1H), 3.60 (m, 1H), 3.96 (s, 1H), 4.42 (s, 2H), 7.17 (d, J = 5.2 Hz, 1H), 7.31 (dd, J = 7.6, 4.8 Hz, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.83 [s, 1H), 8.01 (dd, J = 7.6, 1.8 Hz, 1H), 8.13 (s, 1H), 8.20 (d, J = 5.2 Hz, 1H), 8.60 (dd, J = 4.8, 1.8 Hz, 1H), 10.64 (s, 1H), 10.68 (s, 1H) Example 12 2- (2-Hydroxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 12-1) 2- (2-Acetoxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide is dissolved (Compound No. 10-2, 25 mg, 0.048 mmol) in the mixture of 2.0 ml of methanol and 1.0 ml of tetrahydrofuran and thereto, under cooling with ice, 6 [mu] L) of a 4 N aqueous solution of hydroxide is added thereto. of sodium. The mixture is stirred for 15 minutes at room temperature and diluted with 30 ml of ethyl acetate and then the whole is washed with 30 ml of a saturated aqueous solution of sodium acid carbonate and 30 ml of brine. The organic layer is dried over anhydrous magnesium sulfate and the solvent is evaporated under reduced pressure to provide 23 mg of the objective compound quantitatively as a light yellow solid.

NMR XH (500 MHz, DMSO-dg) d 4.01 (d, J = 5.8 Hz, 2H), 4.43 (s, 2H), 5.72 (t, J = 5.8 Hz, 1H), 7.15 (d, J = 6. 7 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.98 (dd, J = 7.6, 1. 8 Hz, 1H), 8.19 (s, 1H), 8.20 (s, 1H), 8.60 (dd, 'J = 4.9, 1.8 Hz, 1H), 9.58 (s, 1H), 10.65 (s, 1H). described in the following, the compounds are obtained (No. 12-2-16) using the corresponding compounds from the compounds (No. 10-1-21), commercially available compounds or known compounds, according to the method of synthesis of the compound (No. 12-1). N- (3,5-dimethylphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 12-2) XH NMR (500 MHz, DMSO-dg) d 2.25 (s, 6H), 4.01 (d, J = 6.1 Hz, 2H), 4.42 (s, 2H), 5.73 (t, J = 6.0 Hz, 1H), 6.76 (s, 1H) , 7.15 (d, J = 6.7 Hz, 1H), 7.28 (dd, J = 7.3, 4.9 Hz, 1H), 7.32 (s, 2H), 7.93 (d, J = 5.8 Hz, 1H), 8.19-8.20 ( m, 2H), 8.57 (dd, J = 4.9, 1.8 Hz, 1H), 9.58 (s, 1H), 10.30 (s, 1H) N- (4-chlorophenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) ) pyridine-3-carboxamide (compound No. 12-3) XH NMR (400 MHz, DMSO-dg) d 4.01 (d, J = 6.1 Hz, 2H), 4.43 (s, 2H), 5.74 (t, J = 6.1 Hz, 1H), 7.15 (d, J = 5.4 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.60 (s, 1H) N- (3, 5-dimethylphenyl) -2- [2- (2-hydroxypropionylamino) pyridin-4-ylmethylthio] pyridine-3-carboxamide (compound 12-4) XH NMR (400 MHz, CDC13) d 1.52 (d, J = 6.9 Hz, 3H), 1.64 (s, 1H), 2.31 (s, 6H), 4.37 (c, J = 6.9 Hz, 1H), 4.49 (s, 2H), 6.80 ( d, J = 0.7 Hz, 1H ), 7.09-7.13 (m, 2H), 7.27 (s, 2H), 7.84 (dd, J = 7.6, 1.7 Hz, 1H), 8.06 (s, 1H), 8.13 (dd, J = 5.1, 0.5 Hz, 1H), 8.34 (s, 1H), 8.51 (dd, J = 4.8, 1.7 Hz, 1H), 9.27 (s, 1H) N- (3,5-dimethyl-4-hydroxyphenyl) -2- (2-hydroxyacetylaminopyridine) -4-ylmethylthio) pyridine-3-carboxamide (compound No. 12-5) XH NMR (500 MHz, DMSO-dg) d 2.15 (s, 6H), 4.01-4.05 (m, 2H), 4.41 (s, 2H ), 5.75 (s broad, 1H), 7.15 (dd, J = 5.3, 1.4 Hz, 1H), 7.24 (s, 2H), 7.26 - (dd, J = 7.6, 4.9 Hz, 1H), 7.90 (dd, J = 7.6, 1.5 Hz, 1H), 8.10 (s, 1H), 8.18, 8.20 (m, 2H), 8.56 (dd, J = 4.9, 1.5 Hz, 1H), 9.59 (s, 1H), 10.09 (s) , 1H) 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (3-methylphenyl) pyridine-3-carboxamide (compound No. 12-6) XH-NMR (500 MHz, DMSO-dg) d 2.30 (s, 3H), 4.01 (d, J = 6.1 Hz, 2H), 4.42 (s, 2H), 5.74 (t, J = 6.1 Hz, 1H), 6.93 (d, J = 7.8 Hz, 1H), 7.16 (dd, J = 5.2, 1.5 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.56 ( s, 1H), 7.95 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.20 (m, 2H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.38 (s, 1H) 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethylphenyl) pyridin-3-carboxamide (compound No. 12-7) XH-NMR (500 MHz, DMSO-dg) d 4.01 (d, J = 6.1 Hz, 2H), 4.44 (s, 2H), 5.74 (t, J = 6.1 Hz, 1H), 7.16 (dd, J = 5.2, 1.2 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H ), 7.73 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.6 Hz, 2H), 8.02 (dd, J = 7.6, 1.8 Hz, 1H), 8.18-8.20 (m, 2H), 8.61 (dd, J = 4.9, 1.8 Hz, 1H), 9.59 (s, 1H), 10.82 (s, 1H) N- (4-tert-butylphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (compound No. 12-8) NMR XH (400 MHz, DMSO-dg) d 1.27- (s, 9H), 4.01 '(d, J = 5.5 Hz, 2H), 4.42 (s, 2H), 5.74 (t, J = 5.5 Hz, 1H), 7.16 (d, J = 6.6 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (d, J = 8.5 Hz, 2H), 7.60 (d, J = 8.5 H'z, 2H), 7.94 (d, J = 7.6 Hz, 1H), 8.18-8.20 (, 2H), 8.58 - (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (broad s, 1H), 10.40 (s, 1H) 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (isoquinolin-3-yl) pyridine -3-carboxamide (compound No. 12-9) XH-NMR (500 MHz, DMSO-dg) d 4.03 (d, J = 5.9 Hz, 2H), 4.44 (s, 2H), 5.74 (t, J = 5.9 Hz) , 1H), 7.17 (dd, J = 5.2, 1.6 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.58 (m, 1H), 7.75 (m, 1H), '7.98 (d , J = 7.6 Hz, 1H), 8.05-8.10 (m, 2H), 8.17-8.21 (m, 2H), 8.58 (dd, J = 4.9, 1.6 Hz, 1H), 8.60 (s, 1H), 9.19 ( s, 1H), 9.60 (s, 1H), 11.16 (s, 1H) N- (3-chlorophenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (compound No. 12-10) NMR XH (400 MHz, DMSO-dg) d 4.01 (d, J = 5.9 Hz, 2H), 4.43 (s, 2H), 5.74 (t, J = 5.9 Hz, 1H), 7.15-7.20 (m, 2H) , 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 7.58 (m, 1H), 7.88 (d, J = 1.7 Hz, 1H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.19 (m, 2H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.65 (s, 1H) 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (indan-5-yl) pyridine-3-carboxamide (compound No. 12-11) XH NMR (400 MHz, DMSO-dg) d 1- 99-2.06 (m, 2H), 2. 80-2.87 (m, 4H), 4.01 (d, J = 4.9 Hz, 2H), 4.42 (s, 2H), 5.74 (s, 1H), 7.14-7.18 (m, 2H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 6.9 Hz, 1H), 7.61 (s, 1H), .93 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.21 (m, 2H) , 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 9.58 (s, 1H), 10.34 (s, 1H) N- (3-chloro-4-trifluoromethoxyphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) ) pyridine-3-carboxamide (compound No. 12-12) XH NMR (400 MHz, DMSO-dg) d 4.01 (s, 2H), 4.44 (s, s, 2H), 5.74 (t, J = 5.6 Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 7.32 (d, J = 7.6, 4.9 Hz, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.71 (dd, J = 8.8, 2.4 Hz, 1H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.08 (d, J = 2.4 Hz, 1H), 8.19 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.81 (s, 1H) 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridin-3- carboxamide (compound No. 12-13) NMR XH (400 MHz, DMSO-dg) d 1.20 (d, J = 6.8 Hz, 6H), 2.88 (m, 1H), 4.01 (d, J = 5.9 Hz, 2H), 4.42 (s, 2H), 5.74 (t, J = 5.9 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 7.16 (d, J = 6.6 Hz, 1H), 7.26 (t, J = 8.2 Hz, 1H), 7.29 (dd) , J = 7.6, 4.9 Hz, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.59 (broad s, 1H), 7.96 (d, J = 6.6 Hz, 1H), 8.19 (d, J = 8.2 Hz, 1H), 8.20 (s, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.40 (s, 1H) 2- (2-hydroxycarbonyl-acetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 12-14) XH NMR (400 MHz, DMSO-dg) d 3.42 (s, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.1, 1.3 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.98 ( dd, J = 7.6, 1.7 Hz, 1H), 8.17 (s, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.58 (s, 1H) ), 10.67 (s, 1H) N- (4-difluoromethoxyphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 12-15) X-NMR H (400 MHz, DMSO-dg) d 4.01 (d, J = 5.9 Hz, 2H), 4.43 (s, 2H), 5.74 (t, J = 5.9 Hz, 1H), 7.14-7.19 (m, 3H), 7.19 (t, J = 74.6 Hz, 1H), 7.30 (dd, J 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz,, 1H ), 8.19-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.55 (s, 1H) 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) - N- (3-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No. 12-16) XH NMR (400 MHz, DMSO-dg) d 4.01 (d, J = 5.9 Hz, 2H), 4.44 (s, 2H), 5.74 (t, J = 5.9 Hz, 1H), 7.16 (dd, J = 5.4, 1.2 Hz, 1H), 7.32 (dd, J = 7.7, 4.9 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H ), 7.61 (t, J = 8.1 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 8.03 (dd, J = 7.7, 1.7 Hz, 1H), 8.17-8.20 (m, 3H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 9.59 (s, 1H), 10.79 (s, 1H) Example 13 2- [2-bis (acetoxyacetyl) aminopyridin-4-ylmethyl] -N- (4 -trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 13-1) 2- (2-aminopyridin-4-ylmethylthio) -N- (4-trifluoromethox) is dissolved ifenyl) pyridine-3-carboxamide (compound No. 3-11, 800 mg, 1.9 mmol) in 10 ml of pyridine and acetoxyacetyl chloride (0.66 ml, 6.1 mmol) is added thereto while cooling with ice and the mixture is stirred for 18 hours at room temperature. The mixture is diluted with 100 ml of ethyl acetate and the whole is washed twice in succession, with 100 ml of a saturated aqueous solution of sodium acid carbonate and 50 ml of 1 N hydrochloric acid. The organic layer is washed again with 100 ml. ml of a saturated aqueous solution of sodium hydrogen carbonate and dried over anhydrous magnesium sulfate and then the solvent is evaporated under reduced pressure. The resulting solid is recrystallized from ethyl acetate-hexane to provide 300 mg of the objective compound as a colorless solid. (Yield 30%) NMR XH (400 MHz, DMSO-dg) d 2.06 (s, 6H), 4.48 (s, 2H), 4.72 (s, 4H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 8.3 Hz, 2H), 7.57-7.59 (m, 2H), 7.81 (d, J = 9.0 Hz, 2H), 8.01 (dd, J = 7.6, 1.7 Hz, 1H), 8.49 (d, J = 5.8 Hz, 1H), 8.56 (dd, J = 4.9, 1.7 Hz, 1H), 10.67 (s, 1H) As described in the following, compounds (No. 13-2-14) are obtained using the compounds corresponding which are selected from the compounds (No. 3-1-37), commercially available compounds or known compounds, according to the method of synthesis of the compound (No. 13-1). 2- [2-bis (acetoxyacetyl) aminopyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (Compound No. 13-2) XH-NMR (400 MHz, DMSO-dg) d 2.07 (s, 6H), 2.26 (s, 6H), 4.47 (s, 2H), 4.72 (s, 4H), 6.76 (s, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.33 ( s, 2H), 7.58 (s, 1H), 7.59 (d, J = 5.6 Hz, 1H), 7.95 (dd, J = 7.6, 1.7 Hz, 1H), 8.49 (d, J = 5.6 Hz, 1H), 8.54 (dd, J = 4.9, 1.7 Hz, 1H), 10.31 (s, 1H) N- (3,5-dimethylphenyl) -2- (2-ethoxycarbonyloxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 13-3) XH NMR (500 MHz, DMSO-dg) d 1.23 (t, J = 7.0 Hz, 3H), 2.25 (s, 6H), 4.15 (c, J = 7.0 Hz, 2H), 4.41 (s, 2H), 4.73 (s, 2H), 6.76 (s, 1H), 7.15 (dd, J = 5.2, 1.6 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H) ), 7.92 (dd, J = 7.6, 1.6 Hz, 1H), 8.11 (s, 1H), 8.20 (d, J = 5.2 Hz, 1H), 8.57 (dd, J = 4.9, 1.6 Hz, 1H), 10.30 (s, 1H), 10.65 (s, 1H) 2- [2- (3-hydroxycarbonylpropionyloxy) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphene) nil) pyridine-3-carboxamide (compound No. 13-4) XH NMR (400 MHz, DMSO-dg) d 2.49, 2.52 (m, 2H), 2.60-2.64 (m, 2H), 4.41 (s, 2H) , 4.71 (s, 2H), 7.15 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (broad s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.59 (s, 1H), 10.67 (s, 1H), 12.28 (broad s, 1H) N- (3,5-dimethylphenyl) - 2- (2-methanesulfonylaminoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 13-5) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 2.96 (s, 3H), 3.89 (s, 2H), 4.41 (s, 2H), 6.76 (s, 1H), 7.14 (m, 1H), 7. 28 (dd, J = 7.6, 4.8 Hz, 1H), 7.32 (s, 2H), 7.47 (s, 1H), 7. 92 (d, J = 7.6 Hz, 1H), 8.16 (s, 1H), 8.10 (d, J = 4.5 Hz, 1H), 8.57 (dd, J = 4.8, 1.5 Hz, 1H), 10.30 (s, 1H), . 38 (s, 1H) 2- (2-diethylaminocarbonyloxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 13-6) XH-NMR (400 MHz, DMSO-dg) d 1.02 -O? 4 (m, 6H), 3. 20-3.34 (m, 4H), 4.41 (s, 2H), 4.66 (s, 2H), 7.13 (dd, J = 5.1, 1.5 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H) , 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.13 (s, 1H), 8.19 (d, J = 5..1 Hz, 1H), 8. 59 (dd, J = 4.9, 1.7 Hz, 1H), 10.52 (s, 1H), 10.66 (s, 1H) 2- (2-dimethylaminocarbonyloxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 13-7) XH NMR (400 MHz, DMSO-d6) d 2.83 (s, 3H), 2.92 (s, 3H), 4.42 (s, 2H), 4.64 (s, 2H), 7.14 (dd), J = 5.1, 1.3 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.12 (s, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.52 (s, 1H), 10.67 (s, 1H) 2- (2-morpholinocarbonioxylacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 13-8) XH NMR (400 MHz, DMSO-dg ) d 3.30-3.35 (m, 4H), 3.58 (t, J = 4.9 Hz, 4H), 4.42 (s, 2H), 4.68 (s, 2H), 7, 14 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.12 (s, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.56 (s, 1H), 10.66 (s, 1H) ) 2- (2-isobutyryloxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 13-9) XH-NMR (500 MHz, DMSO-dg) d 1.13 (d, J = 7.0 Hz, 6H), 2.64 (m, 1H), 4.41 (s, 2H), 4.70 (s, 2H), 7.14 (dd, J = 5.0, 1.2 Hz, 1H) , 7.30 (dd, J = 7.5, 4.7 Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.80 (d, J = 8.9 Hz, 2H), 7.98 (dd, J = 7.5, 1.7 Hz, 1H), 8.11 (s, 1H), 8.20 (dd, J = 5.0, 0.6 Hz, 1H), 8.59 (dd, J = 4.7, 1.7 Hz, 1H), 10.60 (s, 1H), 10.66 (s, 1H) ) 2- [2- (4-hydroxycarbonylbutyryl) oxyacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 13-10) XH NMR (400 MHz, DMSO-dg) d 1.75-1.79 (, 2H), 2.31 (t, J = 7.3 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 4.41 (s, 2H), 4.70 (s, 2H), 7.14 (d, J = 5.1 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 8.3 Hz, 2H), 7.98 (dd, J- = 7.6, 1.7 Hz, 1H), 8.11 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.61 (s, 1H) , 10.67 (s, 1H), 12.17 (s broad, 1H) 2- (2-acetoxyacetoxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 13-11) XH NMR ( 400 MHz, DMSO-dg) d 2.11 (s, 3H), 4.42 (s, 2H), 4.77 (s, 2H), 4.79 (s, 2H), 7.15 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H ), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (s, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.64 (s, 1H), 10.66 (s, 1H) 2- (2-methoxyethoxyethoxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 13-12) XH NMR (400 MHz, DMSO-dg) d 3.22 (s, 3H), 3.44- 3.47 (m, 2H), 3.53-3.58 (m, 4H), 3.64-3.67 (m, 2H), 4.11 (s, 2H), 4.43 (s, 2H), 7.16 (d, J = 5.1 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.18- 8.20 (m, 2H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.78 (s, 1H), 10.66 (s, 1H) 2- (2-dimethylaminoacetylaminoacetylaminopyridin-4-ylmethylthio) -N- (4 trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 13-13) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 2.92 (s, 2H), 3.95 (d, J = 5.9 Hz, 2H), 4.41 (s, 2H), 7.12 (dd, J = 5.1, 1.5 Hz, 1H), 7.29 (dd, J = 7.7, 4.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.7, 1.6 Hz, 1H), 8.01 (s, 1H), 8.13 (s, 1H), 8.19 (dd, J = 5.1, 0.5 Hz) , 1H), 8.59 (dd, J = 4.8, 1.6 Hz, 1H), 10.45 (s, 1H), 10.66 (s, 1H) N- (4-difluoromethoxyphenyl) -2- (2-dimethylaminocarbonyl-acetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 13-14) X H NMR (400 MHz, DMSO-d 6) d 2.83 (s, 3 H), 2.92 (s, 3 H), 4.41 (s, 2 H), 4.64 (s, 2 H) ), 7.13-7.20 (m, 3H), 7.17 (t, J = 74.0 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (s, 1H), 8.19 (d, J = 4.9 Hz, 1H) , 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.52 (s, 1H), 10.55 (s, 1H) Example 14 N- (4-tert-butylphenyl) -2- (2-diethylaminopyridin-4-ylmethylthio) benzamide (compound No. 14-1) Triethylamine (6lDL, 0.44 mmol) is added to a solution of 4-chloromethyl-2-dimethylaminopyridine. (36 mg, 0.21 mmol) and N- (4-tert-butylphenyl) -2-mercaptobenzamide (36 mg, 0.13 mmol) in 1.0 ml of N, N-dimethylformamide at room temperature and the mixture is stirred for 68 hours. The mixture is diluted with 30 ml of ethyl acetate, the whole is washed with 30 ml of a saturated aqueous solution of sodium acid carbonate and 30 ml of brine, successively, and dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and the resulting residue is purified by silica gel column chromatography to provide 19 mg of the objective compound as a light yellow oil. (Performance 22% ' NMR XH (400 MHz, DMSO-d6) d 1.27 (s, 9H), 2.95 (s, 6H), 4.12 (s, 2H), 6.55 (dd, J = 5.1, 1.2 Hz, 1H), 6.58 (s, 1H), 7.29 (m, 1H), 7.35 (d, J = 8.8 Hz, 2H), 7.42 '(m, 1H), 7. 48-7.51 (m, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.95 (dd, J = 5.1, 0.7 Hz, 1H), 10.27 (s, 1H) As described in the following, they are obtained the compounds (No. 14-2) using the corresponding compounds that are selected from the reference compound (No. 10-1), commercially available compounds or known compounds, according to the method of synthesis of the compounds (No. ). 2 ^ (2-dimethylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (compound No. 14-2) XH NMR (500 MHz, DMSO-dg) d 2.28 (s, 6H) ), 2.96 (s, 6H), 4.35 (s, 2H), 6.55 (dd, J = 5.2, 1.2"Hz, 1H), 6.60 (s, 2H), 6.62 (s, 1H), 6.83 (s, 1H), 7.23 (dd, J = 7.6, 4.9 Hz, 1H), 7.60 (dd, J = 7.6, 1.8 Hz, 1H), 7.96 (d, J = 5.2 Hz, 1H), 8.53 (dd, J = 4.9, 1.8 Hz, 1H), 9.78 (s, 1 'H) Example 15 2- (2-Acetylaminopyridin-4-ylmethylsulfinyl) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide (compound No. 15-1). M-chloroperbenzoic acid (75%, 60 mg, 0.26 mmol) is added to a solution of 2- (2-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (Compound No. 4-1, 60 mg, 0.15 mmoles) in 3 ml of methylene chloride under cooling with ice and the mixture is stirred for 1 hour. The reaction mixture is diluted with 30 ml of ethyl acetate, the whole is washed twice with 10 ml of a saturated aqueous solution of sodium carbonate and 10 ml of brine and dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and the precipitated solid is filtered off with ethyl acetate to provide 30 mg of the objective compound as a colorless solid. (Return 48%) XH NMR (400 MHz, DMSO-dg) d2.08 (s, 3'H), 2.29 (s, 6H), 4.20 (d, J = 12.2 Hz, 1H), 4.48 (d, J = 12.2 Hz, 1H ), 6.80 (s, 1H), 6.94 (dd, J = 4.9, 1.7 Hz, 1H), 7.36 (s, 2H), 7.74 (dd, J = 7.8, 4.9 Hz, 1H), 8.05 (s, 1H) , 8.23 (d, J = 4.9 Hz, 1H), 8.29 (dd, J = 7.8, 1.5 Hz, 1H), 8.86 (dd, J = 4.9, 1.5 Hz, 1H), 10.49 (s, 1H), 10.56 ( s, 1H) Example 16 N- (4-tert-butylphenyl) -2- (2-chloroacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 16-1) N- (4-tert-butylphenyl) -2- (2-hydroxyacetylaminopyridin) is suspended. -4-ylmethylthio) pyridine-3-carboxamide (compound No. 12-8, 250 mg, 0.55 mmole) in 5.0 ml of anhydrous dichloromethane, under ice cooling and thionyl chloride (80DL, 1.1 mmole) is added thereto. The mixture is stirred for 6 hours at room temperature and the solvent is evaporated under reduced pressure. The resulting solid is filtered off with ethyl acetate and washed with diethylether to give 270 mg of the objective compound, quantitatively, as a light yellow solid.

NMR XH (400 MHz, DMSO-dg) d 1.27 (s, 9H), 4.37 (s, 2H), 4.45 (s, 2H), 7.27 (d, J = 5.4 Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.36 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 8.8 Hz, 2H), 7.97 (d, J = 7.6 Hz, 1H), 8.09 (s, 1H) , 8.24 (d, J = 5.4 Hz, 1H), 8.58 (dd, J = 4.8, 1.7 Hz, 1H), 10.43 (s, 1H), 11.19 (s, 1H) As described in the following, the compounds (No. 16-2-9) using the corresponding compounds that are selected from the compounds (No. 12-1-16), commercially available compounds or known compounds, according to the method of synthesis of the compound (No. -1) . 2- (2-Chloroacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 16-2) XH NMR (400 MHz, DMSO-dg) d 4.32 (s, 2H), 4.43 (s, 2H), 7.17 (dd, J = 5.1, 1.7 Hz, 1H), 7.31 (dd, J = 7.8, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.8, 1.7 Hz, 1H), 8.15 (s, 1H), 8.21 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H ), 10.66 (s, 1H), 10.75 (s, 1H) 2- (2-chloroacetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridine-3-carboxamide (Compound No. 16-3) XH-NMR ( 400 MHz, DMSO-dg) d 4.32 (s, 2H), 4.43 (s, 2H), 7.17 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.15 (s, 1H), 8.21 (dd, J = 5.1, 1.5 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.60 (s, 1H), 10.75 (s, 1H) 2- (2-chloroacetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (compound No. 16-4) XH NMR (400 MHz, DMSO-dβ) d 2.25 (s, 6H), 4.32 (sr 2H), 4.42 (s, 2H) , 6.76 (s, 1H), 7.17 (dd, J = 5.1, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.93 (dd, J = 7.6 , 1.7 Hz, 1H), 8.15 (s, 1H), 8.21 (dd, J = 5.1, 0.7 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.30 (s, 1H), 10.75 (s, 1H) 2- (2-Chloroacetylaminopyridin-4-ylmethylthio) -N- (4-difluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 16-5) XH NMR (400 MHz, DMSO-dg) d 4.32 (s, 2H), 4.43 (s, 2H), 7.17 (t, J = 74.2 Hz, 1H), 7.17-7.19 (m, 3H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.73 (d, J = 9.0 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.15 (s, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.8, 1.7 Hz, 1H), 10.55 (s, 1H), 10.75 (s, 1H) 2- (2-chloroacetylaminopyridin-4-methylmethyl) -N- (3-methylphenyl) ) pyridine-3-carboxamide (compound No. 16-6) XH NMR (400 MHz, DMSO-dg) d 2.30 (s, 3?), 4.32 (s, 2H), 4.42 (s, 2H), 6.93 (d, J = 7.8 Hz, 1H), 7.17 (dd, J = 5.1, 1.3 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.29 ( dd, J = 7. 7, 4.9 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7. 95 (dd, J = 7.7, 1.6 Hz, 1H), 8.15 (s, 1H), 8.22 (d, J = . 1 Hz, 1H), 8.58 (dd, J = 4.9, 1.6 Hz, 1H), 10.38 (s, 1H), . 75 (s, 1H) 2- (2-chloroacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethylphenyl) pyridin-3-carboxamide (Compound No. 16-7) XH NMR (400 MHz, DMSO-dg) d 4.32 (s, 2H), 4.44 (s, 2H), 7.17 (d, J = 5.1, 1.0 Hz, 1H), 7.32 (dd, J = 7.7, 4.9 Hz, 1H), 7.73 (d, J = 8.5 Hz, 2H), 7.92 (d, J = 8.5 Hz, 2H), 8.02 (dd, J = 7.7, 1.7 Hz, 1H), 8.15 (s, 1H), 8.22 (d, J = 5.1 Hz, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.75 (s, 1H), 10.82 (s, 1H) 2- (2-chloroacetylaminopyridin-4-ylmethylthio) -N- (3-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No. 16-8) XH NMR (400 MHz, DMSO-dg) d 4.32 (s, 2H), 4.44 (s, 2H), 7.18 (d, J = 5.1, 1.2 Hz, 1H), 7.33 (dd, J = 7.6, 4.8 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.61 (t, J = 8.1 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 8.04 (dd, "J = 7.6, 1.7 Hz, 1H), 8.16 (s, 1H), 8.19 (s, 1H), 8.22 (d, J = 5.1 Hz, 1H), 8. 62 (dd, J = 4.8, 1.7 Hz, 1H), 10.76 (s, 1H), 10.80 (s, 1H) 2- (2-chloroacetylaminopyridin-4-ylmethylthio) -N- (3-isopropylphenyl) pyridine-3-carboxamide (compound? O. 16-9) RM? XH (500 MHz, DMSO-dg) d 1.20 (d, J = 6.7 Hz, 6H), 2.87 (m, 1H), 4.32 (s, 2H), 4.42 (s, 2H), 7.00 (d, J = 7. 6 Hz, 1H), 7.17 (dd, J = 5.0, 1.5 Hz, 1H), 7.24-7.30 (m, 2H), 7.51 (d, J = 7.6 Hz, 1H), 7.59 (s, 1H), 7.96 ( dd, J = 7. 6, 1.5 Hz, 1H), 8.15 (s, 1H), 8.21 (dd, J = 5.0, 0.6 Hz, 1H), 8.58 (dd, J = '4.9, 1.5 Hz, 1H), 10.39 (s, 1H), 10.75 (s, 1H) Example 17 N- (4-tert-butylphenyl) -2- (2-morpholine-acetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 17-1) N- (4-tert-butylphenyl) -2- (2-chloroacetylaminopyridine is suspended. -4-ylmethylthio) pyridin-3-carboxamide (compound No. 16-1, 50 mg, 0.11 mmol) in 1.0 ml of morpholine and the mixture is stirred for 2 hours at 80 D in a sealed tube. 50 ml of ethyl acetate is added to the reaction mixture, the whole is washed with 50 ml of water and 50 ml of brine, and dried over anhydrous sodium sulfate. The solvent is evaporated under reduced pressure, the resulting solid is filtered off with diethyl ether and dried under reduced pressure to give 17 mg of the objective compound as a light yellow solid.

(Yield 32%) X H NMR (500 MHz, CDCl 3) d 1.32 (s, 9 H), 2.60 (t, J = 4.6 Hz, 4 H), 3.14 (s, 2 H), 3.78 (t, J = 4.6 Hz, 4 H), 4.51 (s) , 2H), 7.10 (dd, J = 5.2, 1.5 Hz, 1H), 7.13 (dd, J- = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 8.7 Hz, 2H), 7.56 (d, J = 8.7 Hz, 2H), 7.87 (d, J = 7.6 Hz, 1H), 8.11 (broad s, 1H), 8.18 - (d, J = 5.2 Hz, 1H), 8.29 (s, 1H), 8.54 (dd) , J = 4.9, 1.7 Hz, 1H), 9.48 (s, 1H) As described in the following, the compounds (No. 17-2-88) are obtained using the corresponding compounds that are selected from the compounds (No. 16-1-9), commercially available compounds or known compounds, according to the method of synthesis of the compounds (No. 17-1). 2- (2-isopropylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3 -carboxamide * (compound No. 17-2) XH NMR (400 MHz, DMSO-dg) d 0.99 (d, J = 6.3 Hz, 6H), 2.71 (m, 1H), 3.27 (s, 2H), 4.43 (s, 2H) '7.14 (dd, J = 5.2, 1.6 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.17-8.20 (m, 2H ), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.12 (s, 1H), 10.66 (s, 1H) N- (3, 5-dimethylphenyl) -2- (2-morpholine-acetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 17-3) XH NMR (400 MHz, CDC13) d 2.32 (s, 6H), 2.60 (t, J = 4.6 Hz, 4H), 3.14 (s, 2H), 3.78 (t, J = 4.6 Hz, 4H), 4.51 (S, 2H), 6.81 (s, 1H), 7.10 (dd, J = 5.1, 1.5 Hz , 1H), 7.13 (dd, J = 7.6, 4.9 Hz, 1H), 7.27 (s, 2H), 7.67 (m, 1H), 7.87 (dd, J = 7.6, 1.7 Hz, 1H), 8.19 (d, J 5.1 Hz, 1H), 8.30 (s, 1H), 8.55 (dd, J = 4.9, 1.7 Hz, 1H), 9.48 (s, 1H) 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N- (3 , 5-dimethylphenyl) pyridine-3-carboxamide (compound No. 17-4) '' NMR XH (400 MHz, CDC13) d 2.32 (s, 6H), 2.36 (s, 6H), 3.0 * s, 2H), 4.51 (s, 2H), 6.80 (s, 1H), 7.08 (dd, J = 5.2, 10Hz, 1H), 7.12 (dd, J = 7.5, 4.8 Hz, 1H), 7.27 (s, 2H? '7.86 (dd, J = 7.5, 1.8 Hz, 1H), 8.12 (s, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.29 (s, 1H), 8.53 (dd, J = 4.8, 1.8 Hz, 1H), 9.64 (s, 1H) 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-5) XH NMR (500 MHz, CDCl3 ) d 2.36 (s, 6H), 3.07 (s, 2H), 4.53 (S, 2H), 7.07 (dd, J = 5.2, 1.5 Hz, 1H), 7.15 (dd, J = 7.6, 4.9 Hz, 1H) , 7.21 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.88 (dd, J = 7.6, 1.9 Hz, 1H), 8.18 (dd, J = 5.2, 0.6 Hz, 1H), 8.28 (d, J = 0.6 Hz, 1H), 8.44 (s, 1H), 8.54 ( dd, J = 4.9, 1.9 Hz, 1H), 9.66 (s, 1H) 2- (2-morpholinoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 17-6) NMR XH (500 MHz, CDCl3) d 2.60 (t, J = 4.6 Hz, 4H), 3.13 (s, 2H), 3.78 '(t, J = 4.6 Hz, 4H), 4.53 (s, 2H), 7.09 ( dd, J = 5.2, 1.8 Hz, 1H), 7.15 (dd, J = 7.6, 4.9 Hz, 1H), 7.22 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 8.3 Hz, 2H), 7.89 (dd, J = 7.6, 1.5 Hz, 1H), 8.19 (d, J = 5.2 Hz, 1H), 8.28 (s, 1H), 8.36 (s, 1H), 8.54 (dd, J = 4.9, 1.5 Hz, 1H), 9.50 (s, 1H) N- (4-tert-butylphenyl) -2- (2-cyclopropylaminoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 17-7) XH-NMR (500 MHz, CDCl3 ) d 0.46-0.49 (m, 4H), 1.32 (s, 9H), 2.15 (s broad, 1H), 2.2.7 (m, 1H), 3.49 (s, 2H), 4. 51 (s, 2H), 7.07 (dd, J = 4.9, 1.4 Hz, 1H), 7.13 (dd, J = 7. 3, 4.9 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 7.3 Hz, 1H), 8X15-8.17 (m, 2H), 8. 28 (s, 1H), 8.54 (dd, J = 4.9, 1.8 Hz, 1H), 9.41 (s, 1H) N- (4-tert-butylphenyl) -2- [2- (N-methyl-N- (l- methylpiperidin-4-yl) amino) acetylaminopyridin-4-ylmethylthio] pyridyl-3-carboxamide (compound No. 17-8) RM? XH (500 MHz, CDCl 3) d 1.26 (s, 9H), 1.77-1.80 (m, 2H), 1.86-2.01 (m, 4H), 2.26 (s, 3H), 2.37 (s, 3H), 2.80, 2.91 (m, 3H), 3.17 (s, 2H), 4.51 (s, 2H) ), 7.07 (dd, J = 5.2, 1.8 Hz, 1H), 7.13 (dd, J = 7.5, 4.9 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz , 2H), 7.87 (d, J = 7.5 Hz, 1H), 8.17 (s, 1H), 8.17 (dd, J = 5.2, 0.8 Hz, 1H), 8. 29 (d, J = 0.8 Hz, 1H), 8.54 (dd, J = 4.9, 1.8 Hz, 1H), 9.75 (s, 1H)? - (4-tert-butylphenyl) -2- [2- (2-methylthioethyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (compound? o. 17-9) XH NMR (400 MHz, CDC13) d 1.31 (s, 9H), 2.10 (s, 3H), 2.68 (t, J = 6.1 Hz, 2H), 2.86 (t, J = 6.1 Hz, 2H), 3.40 (s, 2H), 4.51 (s, 2H), 7.08 (dd, J = 5.1, 1.5 Hz, 1H), 7.13 (dd, J = 7.6, 4.9 Hz, 1H), 7.38 (d, J = 8.7 Hz, 2H), 7.56 (d, J = 8.7 Hz, 2H), 7.87 (dd, J = 7.6, 1.7 Hz, 1H), 8.17- 8.18 (m, 2H), 8.29 (s, 1H), 8.53 (dd, J = 4.9, 1.7 Hz, 1H), 9.75 (s, 1H) 2- [2- (2-dimethylaminoethyl) -iminoacetylaminopyridin-4-ylmethylthio ] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-10) XH NMR (400 MHz, CDCl3) d 2.22 (s, 6H), 2.41-2.44 (m, 2H), 2.69-2.73 (m, 2H), 3.38 (s, 2H), 4.53 (s, 2H), 7.06 (dd, J = 5.1, 1.7 Hz, 1H), 7.14 (dd, J = '7.7, 4.9 Hz, 1H), 7.22 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.5 Hz, 2H), 7.87 (dd, J = 7.7, 1.8 Hz, 1H), 8.18 (dd, J = 5.1 , 0.7 Hz, 1H), 8.28 (d, J = 0.7 Hz, 1H), 8.51 (s, 1H), 8.53 (dd, J = 4.9, 1.8 Hz, 1H), 9.93 (s, 1H) 2- [2 - (2-morpholinethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-11) XH NMR (400 MHz, CDCl3) d 2.41-2.43 (m, 4H) , 2.48-2.51 (m, 2H), 2.73-2.76 (m, 2H), 3.38 (s, 2H), 3.63-3.66 (m, 4H), 4.53 (s, 2H), 7.06 (dd, J = 5.1, 1.7 Hz, 1H), 7.15 (dd, J = 7.6, 4.9 Hz, 1H), 7.21 (d, J = 9.0 Hz, 2H), 7.70 (d, J = 9.0 Hz, 2H), 7.86 (dd, J = 7.6, 1.7 Hz, 1H), 8.17 (dd, J = 5.1, 0.9 Hz, 1H), 8.29 (d, J = 0.9 Hz, 1H), 8.50 (s, 1H), 8.55 (dd, J = 4.9, 1.7 Hz, 1H), 9.84 (s, 1H) 2- [2- (N-methyl-N- (1-methylpiperidin-4-yl) amino) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine- 3 -carboxamide (compound No. 17-12) XH NMR (400 MHz, CDCl3) d 1.54-1.65 (m, 2H), 1.76-1.79 (m, 2H), 1.88-1.96 (m, 2H), 2.26 (s) , 3H), 2.37 (s, 3H), 2.39 (m, 1H), 2.88-2.92 (m, 2H), 3.16 (s, 2H), 4.53 (s, 2H), 7.06 (dd, J = 5.1, 1.5 Hz, 1H), 7.14 (dd, J = 7.6, 4.9 Hz, 1H), 7.22 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.88 ( dd, J = 7.6, 1.7 Hz, 1H), 8.17 (d, J = 5.1 Hz, 1H), 8.28 (S, 1H), 8.48 (s, 1H), 8.54 (dd, J = '4.9, 1.7 Hz, 1H), 9.76 (s, 1H) 2- [2- (3-methoxypropyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-13) XH-NMR (400 MHz, DMSO-dg) d 1.60-1.67 (m, 2H), 2.55 (t, J = 7.0 Hz, 2H), 3.20 (s, 3H), 3.26 (s, 2H), 3.37 (t, J = 6.3 Hz , 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.7, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H) , 7.81 (d, J = 8.8 Hz, 2H), 7.99 (d, J = 7.7, 1.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.21 (s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.08 (s, 1H), 10.66 (s, 1H) 2- [2- (3-hydroxypropyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3 -carboxamide (compound No. 17-14) XH NMR (500 MHz, DMSO-dg) d 1.53-1.59 (m, 2H), 2.57 (t, J = 6.9 Hz, 2H), 3.26 (s, 2H), 3.46 (t, J = 6.3 Hz, 2H), 4.41 (broad s, 1H), 4.42 (s, 2H), 7.14 (dd, J = 5.2, 1.5 Hz, 1H), 7.31 ( dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (d, J = '5.2 Hz, 1H), 8.21 (s, 1H), 8.60 (dd, J = 4.9 , 1.8 Hz, 1H), 10.08 (s, 1H), 10.66 (s, 1H) 2- [2- (3-tetrahydropyran-4-yl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine- 3-carboxamide (compound No. 17-15) XH NMR (400 MHz, DMSO-dg) d 1.20-1.30 (m, 2H), 1.72-1.75 (m, 2H), 2.59 (m, 1H), 3.22-3.32 (m, 4H), 3.79-3.82 (m, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 9.0 Hz, 2H), 7.81 (d, J = 9.0 Hz, 2H), 7.99 (d, J = 7.6, 1.7 Hz, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.11 (broad s, 1H), 10.66 (s, 1H) 2- [2- (4-hydroxypiperidin-1-yl) acetylaminopyridin -4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-16) XH NMR (400 MHz, DMSO-dg) d 1. 2-1.47 (m, 2H), 1.72- 1.75 (, 2H), 2.23-2.28 (m, 2H), 2.71-2.75 (m, 2H), 3.11 (s, 2H), 3.47 (m, 1H), 4.42 (s, 2H), 4.59 (d, J = 4.2 Hz, 1H), 7.15 (d, J = 6.6 Hz, 1H), 7.31 (d, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.19 (m, 2H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.82 (s, 1H), 10.66 (s, 1H) 2- [2- (1 ~ 4-trans-4-hydroxycyclohexan-1-yl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3 - carboxamide (compound No. 17-17) XH NMR (500 MHz, DMSO-dg) dl ".00-1.15 (m, 4H), 1. 74-1.82 (m, 4H), 2.31 (m, 1H), 3.27 (s, 2H), 3.34 (m, 1H), 4.42 (s, 2H), 4.47 (d, J = 4.6 Hz, 1H), 7.14 (d, J = 5.2, 1.5 Hz, 1H), 7.31 (d, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.81 (d, J = 8.2 Hz, 2H) , 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.17-8.20 (m, 2H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.8 (s, 1H), 10.65 (s, 1 H) 2- [2- (4-ethoxycarbobilpiperidin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-18) XH NMR (500 MHz, DMSO -dg) d 1.17 (t, J = 7.0 Hz, 3H), 1.57-1.66 (m, 2H), 1.80-1.84 (m, 2H), 2.20-2.37 (m, 3H), 2.78-2.83 (m, 2H), 3.13 (s, 2H), 4.07 (c, J = 7.0 Hz, 2H), 4.42 (s, 2H), 7.15 (d, J = 5.2, 1.2 Hz, 1H), 7.31 (d, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 2H), 7.81 (d, J = 8.6 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (s, 1H), 8.19 (d, J = 1.8 Hz, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 9.84 (s, 1H), 10.66 (s, 1H) 2- (2-diethylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3- carboxamide (compound No. 17-19) XH NMR (400 MHz, DMSO-dg) d 1.00 (t, J = 7.1 Hz, 6H), 2.59 (c, J = 7.1 Hz, 4H), 3.16 (s, 2H) , 4.43 (s, 2H), 7.16 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.8, 4.9 Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.81 ( d, J = 8.9 Hz, 2H), 7.99 (dd, J = 7.8, 1.7 Hz, 1H), 8.17-8? 9 (m, 2H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.82 (s, 1H), 10.66 (s, 1H) 2- [2- (pyrrolidin-1-yl) acetylaminopyridin-4-ylmethylthiol-N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-20)H-NMR (500 MHz, DMSO-dg) d 1.71-1.77 (m, 4H), 2. 55-2.59 (m, 4H), 3.27 (s, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.2, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H) , 7.37 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.6 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H) , 8.18 (s, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 9.81 (s, 1H), 10.66 (s, 1H) N- (4-chlorophenyl) -2- (2-dimethylaminoacetylaminopyridin- 4-ylmethylthio) pyridin-3-carboxamide (compound No. 17-21.) XH NMR (400 MHz, DMSO-dg) d 2.28 (s, 6H), 3.09 (s, 2H), 4.42 (s, 2H), 7.14 (d, J = 6.6 Hz, 1H), 7.30 (dd, J = 7.7, 4.8 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.7, 1.6 Hz, 1H), 8.17 (s, 1H), 8.19 (s, 1H), 8.59 (dd, J = 4.8, 1.6 Hz, 1H), 9.81 (s, 1H), 10.60 (s, 1H) N- (4-chlorophenyl) -2- (2-morpholinoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 17-22) XH-NMR (500 MHz, DMSO, d6) d 2.45- 2.55 (m, 4H), 3.16 (s, 2H), 3.61 (t, J = 4.9 Hz, 4H), 4.42 (s, 2H), 7.15 (d, J = 4.9 Hz, 1H), 7.30 (dd, J = 7.6, 4 .9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.98 (dd, J = 7.6, 1.5 Hz, 1H), 8.19 (s, 1H) ), 8.19 (d ", J = 4.9 Hz, 1H), 8.59 (dd, J = 4.9, 1.5 Hz, 1H), 9.89 (s, 1H), 10.59 (s, 1H) N- (4-chlorophenyl) - 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 17-23) NMR-XH (400 MHz, DMSO-d6) d 2.13 (s, 6H), 2.31 ( t, J = 6.1 Hz, 2H), 2.60 (t, J = 6.1 Hz, 2H), 3.30 (s, 2H), 4.42 (s, 2H), 7.13 (d, J = 5.1 Hz, 1H), 7.30 (dd, J = 7.6, 4. 9 Hz, 1H), 7.41 (d, J = 9.0 Hz, 2H), 7.72 (d, J = 9.0 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.25 (broad s, 1H), 10.60 (s, 1H) N- (4-chlorophenyl) -2 - [2- (pyridin-2-yl) methylaminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 17-24) XH NMR (500 MHz, DMSO-dg) d 3.36 (s, 2H), 3.84 ( s, 2H), 4.42 (s, 2H), 7.13 (d, J = 4.9 Hz, 1H), 7.24 (m, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.40-7.44. (m, 3H), 7.71-7.78 (, 3H), 7.98 (dd, J = 7.6, 1.8 Hz, 1H), 8.17-8.20 (m, 2H), 8.50 (d, J = 4.9 Hz, 1H), 8.59 (dd, J = 4.9, 1.8 Hz, 1H), 10.20 (s, 1H), 10.59 (s, 1H) N- (4-chlorophenyl) -2- [2- (pyridinium-1-yl) acetylaminopyridine- bromide 4-ylmethylthio] pyridin-3-carboxamide (Compound No. 17-25) XH NMR (400 MHz, DMSO-d6) d 4.40 (s, 2H), 5.70 (s, 2H), 7.20 (d, J = 5.1 Hz , 1H), 7.28 (dd, "J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 8.01 (dd, J = 7.6, 1.5 Hz, 1H), 8.07 (s, 1H), 8.19-8.27 (m, 3H), 8.55 (dd, J = 4.9, 1.5 Hz, 1H), 8.69 (t, 'J = 7.7 Hz, 1H), 9.06 (d, J = 5.6 Hz, 2H), 10.68 (s, 1H), -11.27 (s, 1H) 2- (2-aminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 17-26) ) NMR XH (400 MHz, DMSO-dg) d 3.27 (s, 2H), 4.42 (s, 2H), 7.13 (dd, J = 5.2, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz , 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (dd, J = 5.2, 0.8 Hz, 1H), 8.21 (s, '1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.66 (s, 1H) 2- (2-methylaminoacetylaminopyridin-4-ylmethylthio) -N- (4 -trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 17-27) XH NMR (400 MHz, DMSO-dg) d 2.29 (s, 3H), 3.24 (s, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.7, 4.8 Hz, 1H), 7.37 (d, J = 9.0 Hz, 2H), 7.80 (d, J = 9.0 Hz, 2H), 7.99 (dd, J = 7.7, 1.6 Hz, 1H) , 8.18 (d, J = 5.1 Hz, 1H), 8.21 (s, 1H), 8.60 (dd, J = 4.8, 1.6 Hz, 1H), 10.66 (s, 1H) 2- [2- (N- (2-dimethylaminoethyl) -N-methylamino) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide * ( Compound No, 17-28) XH NMR (500 MHz, DMSO-dg) d 2.13 (s, 6H), 2.33 (s, 3H), 2.35 (t, J = 6.4 Hz, 2H), 2.55 (t, J = 6.4 Hz, 2H), 3.17 (s, 2H), 4.42 (s, 2H), 7.12 (d, J = 5.0 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.80 (d, J = 8.7 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.21 (s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.37 (s, 1H), 10.65 (s, 1H) 2- [2- (N- (2-diethylaminoethyl) -N-ethylamino) acetylaminopyridine- 4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-29) XH NMR (400 MHz, DMSO-dg) d 0.91 (t, J = 7.2 Hz, 6H), 0.98 (t, J = 7.1 Hz, 3H), 2.43-2.51 (m, 6H), 2.61 (c, J = 7.2 Hz, 4H), 3.20 (s, 2H), 4.42 (s, 2H), 7.12 (d, J = 5.1 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 ( d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.20 ( s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.40 (s, 1H), 10.66 (s, 1H) 2- [2- (3-dimethylaminopropyl) aminoacetylamino] pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-30) XH NMR (500 MHz, DMSO-dg) d 1.50-1.56 (m, 2H), 2. 09 (s, 6H), 2.23 (t, J = 7.0 Hz, 2H), 2.45-2.50 (m, 2H), 3.26 (s, 2H), 3.30 (s broad, 1H), 4.42 (s, 2H), 7.13 (d, J = 5.2, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, '4.9 Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.20 (s, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.09 (s, 1H, 10.66 (s, 1H) 2- [2- (2-hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-31) NMR XH (500 MHz, DMSO-dg) d 2.60 (t, J = 5.7 Hz, 2H), 3.31 (s, 2H), 3.43-3.47 (m, 2H), 4.42 (s, 2H), 4.57 (t, J) = 5.3 Hz, 1H), 7.14 (d, J = 5.0, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 8.7 Hz, 2H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.21 (s, 1H), 8.60 (dd, J = 4.-9, 1.8 Hz, 1H), 10.12 (s broad, 1H), 10.66 (s, 1H) 2- [2- (2-ethoxyethyl) aminoacetylaminopyridin-4-ylmethylthio-N- (4-1-trifluoromethoxy-phenyl) -pyridine-3-carboxamide (compound No 17-32) XH NMR (400 MHz, DMSO-dg) d 1.08 (t, J = 7.0 Hz, 3H), 2.68 (t, J = 5.5 Hz, 2H), 3.30 (s, 2H), 3.36-3.42 (m, 4H), 4.42 (s, 2H), 7.13 (d, J = 5.1 Hz, 1H), 7.31 (dd, J = 7. 7, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, - J = 8. 8 Hz, 2H), 7.99 (d, J = 7.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.21 (s, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H) , 10.12 (broad s, 1H), 10.66 (s, 1H) 2- [2- (2- (2-hydroxyethoxy) ethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide ( Compound No. 17-33) XH NMR (400 MHz, DMSO-dg) d 2.69 (t, 'J = 5.2 Hz, 2H), 3.30 (s, 2H), 3.40 (t, J = 5.2 Hz, 2H), 3.44-3.49 (m, 4H), 4.42 (s, 2H), 4.66 (s broad, 1H), 7.14 (dd, J = 5.0, 1. 5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8. 9 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.17 (d, J = 5.0 Hz, 1H), 8.22 (s, 1H) , 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 10.13 (broad s, 1H), 10.66 (s, 1H) 2 - [2- (piperazin-1-yl) acetylaminopyridin-4-methylmethyl] -N- (4-trifluoromethyl enyl) pyridin-3-carboxamide (compound No. 17-34) XH NMR (500 MHz, CDCl 3) d 2. 57 (s broad, 4H), 2. 95-2. 98 (m, 4H), 3. 11 (s, 2H), 4. 53 (s, 2H), 7. 08 (d, J = 5.2, 1.8 Hz, 1H), 7.14 (dd, J = 7.6, 4.9 Hz, 1H), 7.22 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 7.88 (dd, J = 7.6, 1.7 Hz, 1H), 8.19 (dd, J = 5.2, 0.6 Hz, 1H), 8.28 (d, J = 0.6 Hz, 1H), 8.41 (broad s, 1H), 8.54 (dd, J = 4.9, 1.7 Hz, 1H), 9.56 (s, 1H) N- (4-difluoromethoxyphenyl) -2- (2-dimethylaminoacetylaminopyridin-4-monohydrochloride. ylmethylthio) pyridine-3-carboxamide (compound No. 17-35) XH NMR (400 MHz, DMSO-dg) d 2.86 (s, 6H), 4.18 (s, 2H), 4.44 (s, 2H), 7.18 (t , J = 74.2 Hz, 1H), 7.18-7.24 (m, 3H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.75 (d, J = 9.1 Hz, 2H), 8.03 (dd, J = 7.6, 1.8 Hz, 1H), 8.15 (s, 1H), 8.25 (d, J = 5.1 Hz, 1H), 8.59 (dd, J = 4.9, 1.8 Hz, 1H), 10.02 (s, 1H), 10.63 ( s, 1H), 11.20 (s, 1H) 2- [2- (2-acetylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-36) XH NMR (500 MHz, DMSO-dg) d 1.79 (s, 3H), 2.57 (t, J = 6.1 Hz, 2H), 3.11 (m, 2H), 3.29 (s, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.0, 1, 5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.79-7.84 (m, 3H), 7.99 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.20 (s, 1H), 8.60 (dd, J = 4.9, 1.8 Hz, 1H), 10.08 (s, 1H), 10.66 (s, 1H) N- (4-chlorophenyl) -2- [2- (2-hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 17-37) H-NMR (500 MHz, DMSO-dg) d 2.60 (t, J = 5.5 Hz, 2H), 3.30 (s, 2H), 3.44-3.47 (m, 2H), 4.42 (s, 2H), 4.57 (t, J = 5.2 Hz, 1H), 7.13 (d, J = 4.9 Hz, 1H), 7.30 (dd, J = 7.5, 4.9 Hz, 1H), 7.41 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8. 7 Hz, 2H), 7.98 (d, J = 7.5 Hz, 1H), 8.18 (d, J = 4.9 Hz, , 1H), 8.20 (s, 1H), 8.59 (d, J = 4.9 Hz, 1H), 10.13 (s, 1H), . 59 (s, 1H) N- (4-chlorophenyl) -2- [2- (3-hydroxypropyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide (Compound No. 17-38) XH NMR (500 MHz, DMSO-dg) d 1.54-1 59 (m, 2H), 2. 57 (t, J = 6.9 Hz, 2H), 3.27 (s, 2H), 3.46 (t, J = 6.3 Hz, 2H), 4.42 (s, 2H), 7.14 (d, J = 5.0 Hz, 1H), 7.30 (dd, J = 7.5, 5.0 Hz, 1H), 7.41 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 7.98 (d, J = 7.5 Hz, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.20 (s, 1H), 8.59 (d, J = 5.0 Hz, 1H), 10.07 (s, 1H), 10.59 (s, 1H) N- (4-chlorophenyl) -2- [2- (N- (2-hydroxyethyl) -N-methylamino) acetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 17-39) XH NMR (500 MHz, DMSO-dg) d 2.31 (s, 3H), '2.54 (t, J = 5.7 Hz, 2H), 3.19 (s, 2H), 3.46-3.51 (m, 2H), 4.42 (s, 2H), 4.63 (t, J = 5.2 Hz, 1H), 7.14 (dd, J = 5.0 , 1.5 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.98 (m, 1H) ), 8.18 (d, J = 5.0 Hz, 1H), 8.20 (s, 1H), 8.59 (dd, J = 4.9, 1.5 Hz, 1H), 9.95 (s, 1H), 10.59 (s, 1H) N- (4-chlorophenyl) -2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide (compound No. 17-40) XH-NMR (500 MHz, DMSO-dg) d 2.43 ( s broad, 4H), 2.72 (t, J = 4.9 Hz, 4H), 3.09 (s, 2H), 4.42 (s, 2H), 7.15 (m, 1H), 7.30 (dd, J = 7.5, 4.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.98 m, 1H), 8.18-8.19 (m, 2H), 8.59 (dd, J = 4.9, 1.5 Hz, 1H), 9.81 (s, 1H), 10.59 (s, 1H) 2- [2- (2-acetylaminoethyl) aminoacetylaminopyridin'-4-ylmethylthio] -N- (4-chlorophenyl) pyridin-3-carboxamide ( Compound No. 17-41) XH NMR (500 MHz, DMSO-dg) d 1.79 (s, 3H), 2.57 (t, J = 6.4 Hz, 2H), 3.09, 3.13 (m, 2H), 3.29 (d, J = 2.4 Hz, 2H), 4.42 (s, 2H), 7.14 (d, J = 5.2 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.84 (m, 1H), 7.98 (d, J = 7.6 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.20 (s, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.08 (s, 1H), 10.59 (s, 1H) N- (4-chlorophenyl) -2- [2- (3-dimethylaminopropyl) aminoacetylaminopyridin-4-ylmethylthio ] pyridine-3-carboxamide (compound No. 17-42) XH-NMR (500 MHz, DMSO-d) d 1.51-1.57 (m, 2H), 2.10 (s, 6H), 2.25 (t, J = 7.0 Hz, 2H), 2.52-2.54 (m, 2H), 3.26 (s, 2H), 4.42 (s, 2H), 7.13 (dd, J = 5.2, 1.5 Hz, 1H), 7.30 (dd, J = 7.5, 4.7 Hz , 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.73 (d, J = 8.9 Hz, 2H), 7.98 (d, J = 7.5, 1.7 Hz, 1H), 8.18 (d, J = 5.2 Hz , 1H), 8.20 (s, 1H), 8.59 (dd, J = 4.7, 1.7 Hz, 1H), 10.09 (s, 1H), 10.59 (s, 1H) 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) monochlorohydrate ) -N- (3-methylphenyl) pyridine-3-carboxamide (compound No. 17-43) XH NMR (400 MHz, DMSO-dg) d 2.30 (s, 3H), 2.86 ( s, 6H), 4.17 (s, 2H), 4.44 (s, 2H), 6.94 (d, J = 7.7 Hz, 1H), 7.20-7.25 (m, 2H), 7.30 (dd, J = 7.6, 4.9 Hz , ÍH), 7.47 (d, J = 7.7 Hz, 1H), 7.57 (s, 1H), 7.99 (dd, J = 7.6, 1.6 Hz, 1H), 8.15 (s, 1H), 8.25 (d, J = 5.4 Hz, 1H), 8.58 (dd, J = 4.9, 1.6 Hz, 1H), 9.97 (s, 1H), 10.43 (s, 1H), 11.15 (s, 1H) 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthiol-N- (3-methylphenyl) pyridine-3-carboxamide (compound No. 17-44) XH-NMR (400 MHz, DMSO-dg) d 2.29 (s, 3H), 2.30 (s, 6H) , 2.48-2.50 (m, 2H), 2.69 (t, J = 6.3 Hz, 2H), 3.36-3.38 (m, 2H), 4.41 (s, 2H), 6.94 (d, J = 6.6 Hz, 1H), 7.12-7.31 (m, 3H), 7.45 (d, J = 7, 3 Hz, 1H), 7.56 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 8.18-8.20 (m, 2H) , 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.31 (s, 1H), 10.39 (s, 1H) N- (3-methylphenyl) -2- [2- (piperazin-1-yl) acetylaminopyridin- 4-ylmethyl-thio] pyridin-3-carboxamide (Compound No. 17-45) XH NMR (400 MHz, DMSO-dg) d 2.30 (s, 3H), 2.46-2.50 (m, 4H), 2.80 (t, J = 4.6 Hz, 4H), 3.14 (s, 2H), 4.41 (s, 2H), 6.93 (d, J = 7.9 Hz, 1H), 7.15 (d, J = 6.1 Hz , 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.56 (s, 1H), 7.96 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.20 (m, 2H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 9.87 (s, 1H), 10.41 (s, 1H) 2 - [2- (2-hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (3-methylphenyl) pyridine-3-carboxamide (Compound No. 17-46) XH-NMR (400 MHz, DMSO-d6) d 2.30 (s) , 3H), 2.60 (t, J = 5.6 Hz, 2H), 3.30-3.32 (m, 2H), 3.43-3.47 (m, 2H), 4.41 (s, 2H), 4.58 (t, J = 5.2 Hz, 1H), 6.93 (d, J = 7.8 Hz, 1H), 7.13 (dd, J = 5.1, 1.5 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.94 (dd, J = 7.6, 1.6 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 8.58 (dd, J = 4.9, 1.6 Hz, 1H), 10.14 (s, 1 H), 10.38 (s, 1H) N- (4-difluoromethoxyphenyl) -2- [2- (2 -dimethylaminoethyl) aminoacetylaminopyridin-4-i lmethylthio] pyridin-3-carboxamide (compound No. 17-47) XH NMR (400 MHz, DMSO-dg) d 2.13 (s, 6H), 2.31 (t, J = 6.2 Hz, 2H), 2.60 (t, J = 6.2 Hz, 2H), 3.30 (s, 2H), 4.41 (s, 2H), 7.12 (dd, J = 5.1, 1.5 Hz, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.18 (t , J = 74.3 Hz, 1H), 7.30 (dd, J = 7.6, 4.8 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 -8.20 (m, 2H), 8.59 (dd, J = 4.8, 1.7 Hz, 1H), 10.25 (s, 1H), 10.54 (s, 1H) N- (4-difluoromethoxyphenyl) -2- [2- (2 -hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 17-48) XH NMR (400 MHz, DMSO-dg) d 2.60 (t, J = 5.6 Hz, 2H), 3.31 (s, 2H ), 3.44, 3.48 (m, 2H), 4-.42 (s, 2H), 4.58 (t, J = 5.2 Hz, 1H), 7.14 (dd, J = 5.1, 1.7 Hz, 1H), 7.17 (t , J = 74.2 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.97 (dd) , J = 7, 6, 1.7 Hz, 1H), 8.18-8.21 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.13 (s, 1H), 10.55 (s, 1H) 2 - [2- (2-acetyl minoethyl) aminoacetylaminopyridin-4-ylmethylthiol-N- (4-difluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-49) XH-NMR (400 MHz, DMSO-dg) d 1.79 (s, 3H), 2.57 (t, J = 6.4 Hz, 2H), 3.09, 3.13 (m, 2H), 3.29 (s, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.18 (t, J) = 74.2 Hz, 1H), 7.18 (d, J = 9.0 Hz, 2H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.72 (d, J = 9.0 Hz, 2H), 7.84 (s, 1H) ), 7.97 '(dd, J = 7.6, 1.6 Hz, 1H), 8.18-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.6 Hz, 1H), 10.08 (s, 1H), 10.55 (s) , 1H) N- (-difluoromethoxyphenyl) -2- [2- (N- (2-dimethylaminoethyl) -N-methylamino) acetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 17-50) XH NMR ( 400 MHz, DMSO-dg) d 2.14 (s, 6H), 2.33 (s, 3H), 2.36 (t, J = 6.4 Hz, 2H), 2.56 (t, J = 6.4 Hz, 2H), 3.17 (s, 2H), 4.41 (s, 2H), 7.13 (dd, J = 5.1, 1.1 Hz, 1H), 7.17 (t, J = 74.2 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.30 ( dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.79 (dd, J = 7.6, 1.7 Hz, 1H), 8.1 8-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.38 (s, 1H), 10.55 (s, "1H) 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N - (4-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No. 17-51) XH-NMR (500 MHz, DMSO-dg) d 2.28 (s, 6H), 3.09 (s, 2H), 4.43 (s, 2H) , 7.15 (dd, J = 5.2, 1.5 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.91 (d, J = 8.7 Hz, 2H), 8.02 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.18 (s, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 9.81 (s, 1H), 10.81 (s, 1H) 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No 17-52) XH NMR (400 MHz, DMSO-dg) d 2.12 (s, 6H), 2.30 (t, J = 6.1 Hz, 2H), 2.59 (t, J = 6.1 Hz, 2H), 3.30 (s) , 2H), 4.43 (s, 2H), 7.13 (d, J = 5.2, 1.5 Hz, 1H), 7.31 (dd, J = 7.7, 4.9 Hz, 1H), 7.73 (d, J = 8.7 Hz, 2H) , 7.91 (d, J = 8. 7 Hz, 2H), 8.02 (dd, J = 7.7, 1.7 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.21 (s, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.26 (s broad, 1H), 10.82 (s, 1H) 2- [2- (2-hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethylphenyl) pyridine-3-carboxamide (Compound No. 17-53) XH NMR (500 MHz, DMSO-dg) d 2.60 (t, J = 5.5 Hz, 2H), 3.30 (S, 2H), 3.43-3.47 (m, 2H), 4.43 (s, 2H), 4.57 (t, J = 5.2 Hz, 1H), 7.14 (dd, J = 5.2, '1.5 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 8.7 Hz, 2H), 8.02 (dd, J = 7.6, 1.8 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.21 (s, 1H), 8.61 ( dd, = 4.9, 1.8 Hz, 1H), 10.22 (broad s, 1H), 10.82 (s, 1H) 2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethylphenyl) ) pyridin-3-carboxamide (compound No. 17-54) XH NMR (400 MHz, DMSO-dg) d 2.43 (broad s, 4H), 2. 70, 2.73 (m, 4H), 3.10 (s, 2H), 4.43 (s, 2H), 7.15 (d, J = 5.5 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J =. 8. 8 Hz, 2H), 7.91 (d, J = 8.8 Hz, 2H), 8.02 (dd, J = 7.6, 1.7 Hz, 1H), 8.19 (d, J, = 5.5 Hz, 1H), 8.20 (s, 1H) ), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 9.82 (broad s, 1H), I0.82 (s, 1H) 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N- (3-trifluoromethylphenyl) ) pyridine-3-carboxamide (compound No. 17-55) RM? XH (400 MHz, DMSO-dg) d 2.28 (s, 6H), 3.09 (s, 2H), 4.43 (s, 2H), 7.15 (dd, J = 5.1, 1.7 Hz, 1H), 7.32 (dd, J = 7.6, 4.9 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.91 (d, J = 7.8 Hz, 1H), 8.03 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (s, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.19 (s, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 9.81 (s, 1H), 10.79 (s, 1H) 2- [2- (2-dimethylaminoethyl) aminoacetylaminspyridin-4-ylmethylthio] -? - (3-trifluoromethylphenyl) pyridin-3-carboxamide (compound? 17-56) RM? XH (400 MHz, DMSO-dg) d 2.13 (s, 6H), 2.31 (t, J = 6.2 Hz, 2H), 2.59 (t, J = 6.2 Hz, 2H), 3.30 (s, 2H), 4.43 ( s, 2H), 7.13 (dd, J = 5.1, 1.5 Hz, 1H), 7.32 (dd, J = 7.7, 4.9 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 8.03 (dd, J = 7.7, 1.7 Hz, 1H), 8.18 (s, 1H), 8.18 (d, J = 5.1 Hz, 1H ), 8.21 (s, 1H), 8.61 (dd, J = 4.9, 1.7 Hz, 1H), 10.26 (broad s, 1H), 10.79 (s, 1H) 2- [2- (piperazin-1-yl) monohydrochloride ) acetylaminopyridin-4-ylmethylthio] -? - (3-trifluoromethylphenyl) pyridine-3-carboxamide (compound? o. 17-57) RM? XH (400 MHz, DMSO-dg) d 3.40 (broad s, 4H), 3.49 (s broad, 4H), 4.14 (broad s, 2H), 4.45 (s, 2H), 7.26 (d, J = 5.0 Hz, 1H), 7.33 (dd, J = 7.6, 4.9 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 8.10 (dd, J = 7.6, 1.5 Hz, 1H), 8.18 (broad s, 1H), 8.22 (s, 1H), 8.27 (d, J = 5.0 Hz, 1H), 8.61 (dd, J = 4.9, 1.5 Hz, 1H), 9.70 (broad s, 2H), 10.91 (s, 1H), 11.08 (s, 1H) 2- [2- (4- (2-hydroxyethyl) piperazin-1-yl) acetylaminopyridine- 4-ylmethylthio] -N- (4-trifluoroethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-58) XH-NMR (400 MHz, DMSO-dg) d 2.38 (t, J = 6.3 Hz, 2H), 2.45 (broad s, 8H), 3.13 (s, 2H), 3.32-3.50 (m, 2H), 4.38 (t, J = 5.4 Hz, 1H), 4.42 (s, 2H), 7.15 (d, J = 5.1 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 '(d, J = 8.9 Hz, 2H), 7.80 (d, J = 8.9 Hz, 2H), 7.99 (dd) , J = 7.6, 1.5 Hz, 1H), 8.18-8.19 (m, 2H), 8.60 (dd, J = 4.9, 1.5 Hz, 1H), 9.81 (s, 1H), 10.66 (s, 1H) 2- [ 2- (4-acetylpiperazin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-59) XH NMR (400 MHz, DMSO-dg) d 1.99 (s, 3H), 2.46- 2.53 (m, 4H), 3.20 (s, 2H), 3.45-3.47 (m, 4H), 4.43 (s, 2H), 7.15 (dd, J = 5.4, 1.2 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = '8.8 Hz, 2H), 7.99 ( dd, J = 7.6, 1.6 Hz, 1H), 8.18-8.20 (m, 2H), 8.60 (dd, J = 4.9, 1.6 Hz, 1H), 9.94 (s, 1H), 10.66 (s, 1H) 2- [2- (2-Hydroxyethyl) aminoacetylaminopyridin-4-methylmethyl] -N- (3-isopropylphenyl) pyridine-3-carboxamide (Compound No. 17-60) XH NMR (500 MHz, DMS0-d6) d 1.20 (d, J = 7.1 Hz, 6H), 2.60 (broad s, 2H), 2.86 (m, 1H), 3.30 (s, 2H), 3.45 (t, J = 5.5 Hz, 2H), 4.41 (s, 2H), 7.00 (d, J = 7.8 Hz, 1H), 7.14 (m, 1H), 7.23-7.30 (m, 2H), 7.51 (d, J = 8.5 Hz, 1H), 7.59 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 5.4 Hz, 1H), 8.20 (s, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.15 (s, 1H), 10.39 (s, 1 H) 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (3-isopropylphenyl) pyridin-3-carboxamide (Compound No. 17-61) 'XH NMR ( 400 MHz, CDCl3) d 1.25 (d, J = 6.8 Hz, 6H), 2.23 (s, 6H), 2.43 (t, J = 5.7 Hz, 2H), 2.71 (t, J = 5.7 Hz, 2H), 2.91 (m, 1H), 3.32 (m, 1H), 3.38 (s, 2H), 4.50 (s, 2H), 7.03 (d, J = 7.6 Hz, 1H), 7.07 (d, J = 5.0 Hz, 1H) , 7.11 (dd, J = 7.6, 4.9 Hz, 1H), 7.27 (m, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.52 (s, 1H), 7.86 (d, J = 7.3 Hz, 1H), 8.17 (d, J = 5.0 Hz, 1H), 8.29 (m, 2H), 8.52 (m, 1H), 9.89 (s, 1H) 2- [2- (4-methylpiperazin-1-yl) acetylaminopyridin -4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 17-62) XH NMR (400 MHz, CDCl3) d 2.38 (s, 3H), 2.61-2.69. (M, 8H ), 3.15 (s, 2H), 4.53 (s, 2H), 7.08 (dd, J = 5.1, 1.1 Hz, 1H), 7.15 (dd, J = 7.6, 4.8 Hz, 1H), 7.22 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.88 (dd, J = 7.6, 1.7 Hz, 1H), 8.19 (d, J = 5.1 Hz, 1H), 8.28 (s, 1H) , 8.39 (s, 1H), 8.54 (dd, J = 4.8, 1.7 Hz, 1H), 9.50 (s, 1H) N- (4-chlorophenyl) -2- [2- (2-propin-1-yl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carbox amide (compound No. 17-63) XH NMR (400 MHz, DMSO-dg) d 2.80 (broad s, 1H), 3.10 (t, J = 2.4 Hz, 1H), 3.30-3.40 (m, 4H), 4.42 (s, 2H), 7.12 (d, J = 5.1 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.17-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.04 (s, 1H), 10.60 (s, 1H) N- (4-chlorophenyl) -2- [2- (4- (2-hydroxyethyl) piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide (Compound No. 17- 64) XH NMR (400 MHz, DMSO-d6) d 2.39 (t, J = 6.3 Hz, 2H), 2.40-2.60 (m, 8H), 3.13 (s, 2H), 3.45-3.49 (m, 2H), 4.38 (t, J = 5.1 Hz, 1H), 4.42 (s, 2H), 7.15 (d, J = 5.9 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.98 (m, 1H), 8.18 (s, 1H), 8.19 (d, J = 5.9 Hz, 1H), 8.59 (dd, J = 4.9, 1.5 Hz, 1H), 9.81 (s, 1H), 10.60 (s, 1H) N- (4-difluoromethoxyphenyl) -2- [2- (N- (2-hydroxyethyl) -N-methylamino) acetylaminopyridine- 4-ylmethylthio] p iridin-3-carboxamide (compound No. 17-65) XH NMR (400 MHz, DMSO-dg) d 2.31 (s, 3H), 2.54 (t, J = 5.8 Hz, 2H), 3.19 (s, 2H), 3.47-3.51 (m, 2H), 4.42 (s, 2H), 4.63 (t, J = 5.3 Hz, 1H), 7.14 (dd, J = 5.0 , 1.5 Hz, 1H), 7.17 (d, J = 9.0 Hz, 2H), 7.17 (t, J = 74.2 Hz, 1H), 7:30 (dd, J = 7.6, 4.9 Hz, 1H), 7.72 (d, J = 9.0 Hz, 2H), 7. 97 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.41 (s, 1H), 10.54 (s, 1H) N- (4-difluoromethoxy-phenyl) -2- [2- (piperazin-1-yl) -acetylamitiopyridin-4-ylmethylthio] pyridin-3-carboxamide (compμesto No. 17-66) XH NMR (400 MHz, DMSO-dg) d 2.42 (s' broad, 4H), 2. 72 (s broad, 4H), 3.10 (s, 2H), 4.42 (s, 2H), 7.15 (m, 1H), 7.17 (t, J = 74.2 Hz, 1H), 7.18 (d, J = 8.9 Hz, 2H), 7. 30 (dd, J = 7.6, 4.9 Hz, 1H), 7.72 (d, J = 8.9 Hz, 2H), 7. 98 (d, J = 7.6 Hz, 1H), 8.18-8.19 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 9.82 (s, 1H), 10.55 (s, 1H) 2- (2-aminoacetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridine-3-carboxamide (compound No. 17-67) NMR XH (400 MHz, DMSO-ds) d 3.33-3.34 (m, 2H), 4.42 (s, 2H), 7.14 (m, 1H), 7.30 '(dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.95, 8.01"(m, 2H), 8.19 (m, 1H), 8.59 (dd, J = 4.9, 1.7 Hz , 1H), 10.64 (s, 1H) 2- (2-acetylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) pyridine-3-carboxamide (Compound No. 17-68) XH NMR (400 MHz, DMSO- dg) d 1.87 (s, 3H), 3.89 (d, J = 5.9 Hz, 2H), 4.41 (s, 2H), 7.12 (dd, J = 5.1, 1.2 Hz, 1H), 7.29 (dd, J = 7.6 , 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.13-8.19 (m , 3H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.39 (s, 1H), 10.60 (s, 1H) N- (4-difluoromethoxyphenyl) -2- (2-phthaloylaminoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (compound No. 17-69) XH-NMR (400 MHz, DMSO-dg) d 4.39 (s, 2H), 4.49 (s, 2H), 7.15-7.19 (m, 3H), 7.18 (t , J = 74.2 Hz, 1H), 7.27 (dd, J = 7.6, 4.9 Hz, 1H), 7.70 (d, J = 9.0 Hz ', 2H), 7.83-7.95 (m, 5H), 8.0 6 (s, 1H), 8.22 (d, J = 5.1- Hz, 1H), 8.55 (dd, J = 4.9, 1.7 Hz, 1H), 10.52 (s, 1H), 10.90 (s, 1H) N- ( 4-difluoromethoxyphenyl) -2- [2- (4-methylpiperazin-1-yl) acetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide (compound No. 17-70) XH-NMR (400 MHz, DMSO-dg) d 2.17 (s, 3H), 2.36 (s broad, 4H), 2.51 (s broad, 4H), 3.14 (s, 2H), 4.42 (s, 2H), 7.14-7.19 (m, 3H), 7.18 (t, J = 74.2 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.73 (d, J = 9.0 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.19 (, 2H), 8.59 '(dd, J = 4. 9, 1.7 Hz, 1H), 9.82 (s, 1H), 10.54 (s, 1H) N- (4-difluoromethoxyphenyl) -2- (2-isopropylaminoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 17 -71) XH NMR (400 MHz, DMSO-dg) d 0.99 (d, J = 6.1 Hz, 6H), 2.72 (m, 1H), 3.26 (s, 2H), 4.42 (s, 2H), 7.14 (dd, J = 5.1, 1.5 Hz, 1H), 7.17 (t, J = 74.2 Hz, 1H), 7.18 (d, J = 9. 0 Hz, 2H), 7.30 (dd, J = 7.6, 4.9 Hz. 1H), 7.72 (d, J = 9. 0 Hz, 2H), 7.97 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.20 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.10 (s, 1H), 10.54 (s, 1H) 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridin-3-carboxamide (Compound No. 17-72) XH-NMR (400 MHz, DMSO-d6) d 2.15 (s, 6H), 2.25 (s, 6H), 2.33 (t, J = 6.1 Hz, 2H), 2.61 (t, J = 6.1 Hz, 2H), 3.31 (s, '2H), 4.41 (s, 2H),' 6.76 (s, 1H), 7.13 (dd, J = . 1, 1.5 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 8.18-8.20 (m, 2H), 8. 57 (dd, J = 4.9, 1.7 Hz, 1H), 10.26 (s, 1H), 10.29 (s, 1 H) N- (3-5-dimethylphenyl) -2- (2-isopropylaminoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 17-73) XH NMR (400 MHz, DMSO-dg) d 0.99 (d , J = 6.1 Hz, 6H), 2.25 (s, 6H), 2.73 (m, 1H), 3.27 (s, 2H), 4.41 (s, 2H), 6.76 (s, 1H), 7.14 (dd, J = 5.1, 1.2 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H), 7.32 (s, 2H), 7.92 (dd, J = 7.6, 1.7 Hz, 1H), 8.16-8.20 (s, 2H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.12 (s, 1H), 10.30 (s), 1 H) 2- [2- (2-propen-l-yl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-74) XH NMR (400 MHz, DMSO-dg) d 3.18 (d, J = 5.4 Hz, 2H), 3.27 (s, 2H), 4.42 (s, 2H), 5.07 (d, J = 10.0 Hz, 1H), 5.17 (d, J = 17.1 Hz, 1H), 5.83 (m, 1H), 7.14 (d, J = 5.0 Hz, 1H), 7.31 (dd, J = 7.7, 4.9 Hz, 1H), 7.37 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 8.7 Hz, 2H), 7.99"(d, J = 7.7 Hz, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.20 (s, 1H), 8.60 (d, J = 4.9 Hz, 1H), 10.09 (s broad, 1H), 10.66 (s, 1H) 2- [2- (2-methylaziridin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine- 3-carboxamide (compound No. 17-75) XH NMR (400 MHz, DMSO-d6) d 1.13 (d, J = 5.4 Hz, 3H), 1.45 (d, J = 6.3 Hz, 1H), 1.54 (d, J = 3.7 Hz, 1H), 1.63 (m, 1H), 3.01 (d, J = 15.9 Hz, 1H), 3.10 (d, J = 15.9 Hz, 1H), 4.43 (s, 2H), 7.16 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.20 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.83 (S , 1H), 10.66 (s, 1H) 2- [2- (N-ethyl-N-methylaminoacetylamino) pyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-76 ) NMR XH (400 MHz, DMSO-dg) d 1.02 (t, J = 7.1 Hz, 3H) -, 2.28 (s, 3H), 2.49-2.51 (m, 2H), 3.13 (s, 2H), 4.43 ( s, 2H), 7.15 (dd, J = 5.1, 1.5 Hz, 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.19 (s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.80 (s, 1H), 10.66 (s, 1H) 2- [2- (azetidin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide ( compound No. 17-77) 'NMR XH (400 MHz, DMSO-dg) d 1.99-2.06 (m, 2H), 3.21 (s, 2H), 3.28 (t, J = 7.0 Hz, 4H), 4.42 (' s, 2H), 7.14 (d, J = 5.1 Hz, 1H), 7.30 (dd, J = 7.6, 4.9-Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.80 (d, J = 8.9 Hz, 2H ), 7.99 (d, J = 7.6 Hz, 1H), 8.15 (s, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.81 (s) , 1H), 10.66 (s, 1H) 2- [2- (2- (pyrrolidin-1-yl) ethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-78) XH NMR (400 MHz, DMSO-dg) d 1.65-1.67 (m, 4H), 2.41-2.48 (m, 6H), 2.63 (t, J = 6.2 Hz, 2H), 3.32 (s, 2H) ), 4.42 (s, 2H), 7.13 (dd, J = 5.1, 1.5 Hz, 1H), 7.30 '(dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.6, 1.6 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.20 (s, 1H), 8.60 (dd, J = 4.9, 1.6 Hz, 1H), 10.23 (s, 1H), 10.66 (s, 1H) N- (4-chlorophenyl) -2- [2- (2- (pyrrolidin-1-yl) ethyl) aminoacetylaminopyridin-4 -ylmethylthio] pyridine-3-carboxamide (compound No. 17-79) XH-NMR (500 MHz, DMSO-dg) d 1.65-1.66 (m, 4H), 2.42-2.45 (m, 4H), 2.47-2.52 (m , 2H), 2.62, 2.64 (m, 2H), 3.29 (s, 2H), 4.42 (s, 2H), 7.12 (dd, J = 5.2, 1.7 Hz, 1H), 7.30 (dd, J = 7.6, 4.9Hz, 1H), 7, 41 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 7.98 (dd, J = 7.6, "1.7 Hz, 1H), 8.18 (d, J = 5.2 Hz, 1H), 8.20 (s, 1H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 10.22 (s, 1H), 10.59 (s, 1H) 2- [2- (l- 4-dihydro-4-oxopyridin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxy-phenyl) -pyridine-3-carboxamide (Compound No. 17-80) XH-NMR (400 MHz, DMSO-dg) d 4.41 (s, 2H), 4.82 (s, 2H), 6.06 (d, J = 7.6 Hz, 2H), 7.16 (d, J = 5.1 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H ), 7.37 (d, J = 8.9 Hz, 2H), 7.58 (d, J = 7.6 Hz, 2H), 7.80 (d, J = 8.9 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H ), 8.11 (s, 1H), 8.22 (d, J = 5.1 Hz, 1H), 8.58 (dd, J = 4.9, 1.7 Hz, 1H), 10.65 (s, 1H), 10.83 (s, 1H) N- (4-chlorophenyl) -2- [2- (4-methylpiperazin-1-yl) acetylaminopyridin-4-ylmethylthiopyridine-3-carboxamide (Compound No. 17-81) XH-NMR (400 MHz, DMSO-dg) d 2.17 ( s, 3H), 2.35 (s broad, 6H), 3.14 (s, 2H), 3.32 (s, 2H), 4.42 (s, 2H), 7.15 (d, J = 6.3 Hz, 1H), 7.30 (dd, J = 7.6, 4 .9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, .2H), 7.98 (dd, J = 7.6, 1.6 Hz, 1H), 8.18-8.19 (m, 2H ), 8.59 (dd, J = 4.9, 1.6 Hz, 1H), 9.82 (s, 1H), 10.60 (s, 1H) 2- [2- (imidazol-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (compound No. 17-82) XH-NMR (400 MHz, DMSO-dg) d 4.41"(s, 2H), 4.94 (s, 2H), 6.88 (d, J = 1.0 Hz, 1H), 7.15-7.16 (m, 2H), 7.29 (dd, J = 7.6, 4.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.62 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.98 (dd, J = 7.6, 1.7 Hz, 1H), 8.11 (s, 1H), 8.22 (d, J = 5.1 Hz, 1H ), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.65 (s, 1H), 10.78 (s, 1H) N- (4-chlorophenyl) -2- [2- (azetidin-1-yl) acetylaminopyridine -4-ylmethylthio] pyridin-3-carboxamide (Compound No. 17-83) XH NMR (400 MHz, DMSO-dg) d 1.90-2.08 (m, 2H), 3.21 (s, 2H), 3.25-3.34 (m , 4H), 4.41 (s, 2H), 7.14 (d, J = 5.1 Hz, 1H), 7.30 (dd, J = 7.6, 4.9 Hz, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.98 (m, 1H), 8.15-8.19 (m, 2H), 8.59 (dd, J = 4.9, 1.7 Hz, 1H), 9.80 (s, 1H), 10.59 ( s, 1 H) N- (3,5-dimethylphenyl) -2- [2- (3-hydroxypropyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (Compound No. 17-84) XH NMR (400 MHz, DMSO -dg) d 1.50-1.60 (m, 2H), 2. 25 (s, 6H), 2.57 (t, J = 6.8 Hz, 2H), 3.27 (s, 2H), 3.46 (t, J = 6.8 Hz, 2H), 4.40 (broad s, 1H), 4.41 (s, 2H), 6.76 '(s, 1H), 7.14 (d, J = 5.1 Hz, 1H), 7.28 (dd, J = 7.6, 4. 9 Hz, 1H), 7.32 (s, 2H), 7.93 (dd, J = 7.6, 1.7 Hz, 1H), 8. 17-8.21 (m, 2H), 8.57 (dd, J = 4.9, 1.7 Hz, 1H), 10.07 (broad s, 1H), 10.59 (s, 1H) N- (3, 5-dimethylphenyl) -2- [ 2- (2-morpholinethyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide (compound No. 17-85) XH NMR (400 MHz, DMSO-dg) d 2.25 (s, 6H), 2.30-2.40 ( m, 6H), 2.63 (t, J = 6.1 Hz, 2H), 3.30 (s, 2H), 3.54 (t, J = 4.6 Hz, 4H), 4.41 (s, 2H), 6.76 (s, 1H), 7.13 (d, J = 5.1 Hz, 1H), 7.28 (dd, J = 7.6, 4.9 Hz, 1H) , 7.32 (s, 2H), 7.93 (dd, J = 7.6, 1.7 Hz, 1H), 8.17-8.21 (m, 2H), 8. 57 (dd, J = 4.9, 1.7 Hz, 1H), 10.17 (broad s, 1H), 10.30 (s, 1H) 2- (2-ethylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 17-86) XH NMR (400 MHz, CDCl3) d 1.15 (t, J = 7.1 Hz, 3H), 2.72 (c, J = 7.1 Hz, 2H), 3.39 (s, 2H), 4.52 (s, 2H), 7.06 (d, J = 5.1 Hz, 1H), 7.13 (dd, J = 7.6, 4.9 Hz, 1H), 7.21 (d, J = 8.3 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H), 7.87 (dd, J = 7.6, 1.7 Hz, 1H), 8.18 (d, J = 5.1 Hz, 1H), 8.26 (s, 1H), 8.51-8.54 (m, 2H), 9.82 (broad s, 1H). 2- (2-Cylopropylmethoxyacetylaminopyridin-4-methylmeththio) -N- (4-trifluoromethoxy-phenyl) -pyridine-3-carboxamide (compound No. 17-87) XH-NMR (400 MHz, DMSO-dg) d 0.19-0.23 (m, 2H) ), 0. 46-0.51 (m, 2H), 1.11 (m, 1H), 3.35 (d, J = 6.8 Hz, 2H), 4. 09 (s, 2H), 4.43 (s, 2H), 7.16 (dd, J = 5.0, 1.5 Hz, 1H), 7.31 (dd, J = 7.7, 4.9 Hz, 1H), 7.37 (d, "J = 8.8 Hz, 2H), 7. 81 (d, J = 8.8 Hz, 2H), 7.99 (dd, J = 7.7, 1.7 Hz, 1H), 8. 18 (d, J = 5.0 Hz, 1H), 8.20 (s, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 9.74 (s, 1H), 10.66 (s, 1H) N- (3,5-dimethylphenyl) -2- (2-phthaloylaminoacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide (Compound No. 17-88) XH-NMR (400 MHz, DMSO-dg) d 2.24 (s, 6H), 4.38 (s, 2H), 4.50 (s, 2H), 6.74 (s, 1H), 7.15 (d, J = 5.1 Hz, 1H), 7.25 (dd, J = 7.8, 4.9 Hz, 1H), 7.30 (s) , 2H), 7.83 (s, 1H), 7.88-7.49 (m, 4H), 8.06 (s broad, 1H), 8.22 (d, J = 5.1 Hz, 1H), 8.53 (dd, J = 4.9, 1.7 Hz , 1H), 10.28 (s, 1H), 10.90 (s, 1H) EXAMPLE 18 2- (2-Aminoacetylaminopyridin-4-ylmethylthio) -N- ((4-difluoromethoxyphenyl) pyridine-3-carboxamide (Compound No. 18- 1) N- (4-difluoromethoxyphenyl) -2- (2-phthaloylaminoacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide (Compound No. 17-69, 50 mg, 0.085 mmol) and hydrazine monohydrate (42, 1, 0.42) are suspended. mmoles) in a mixture of 2.0 ml of methanol and 2.0 ml of 1,4-dioxane at room temperature, then the mixture is stirred for 1 hour at 8 [deg.] C. The mixture is diluted with 30 ml of ethyl acetate and the whole wash twice with 30 ml of brine and dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and the resulting residue is purified by silica gel column chromatography to provide 11 mg of the objective compound as a colorless solid. (Performance, 29%) NMR XH (400 MHz, DMSO-d6) d 3.30 (s, 2H), 3.41 (s, 2H), 4.43 (s, 2H), 7.14-7.20 (m, 3H), 7.18 (t, J = 74.2 Hz, 1H), 7.30 (dd, J = 7.6, 4. 9 Hz, 1H), 7.73 (d, J = 9.0 Hz, 2H), 7.84 (s, 1H), 7.98 (d, J = 7.6 Hz, 1H), 8.30 (d, J = 5.1 Hz, 1H), 8.60 (d, J = 4. 9 Hz, 1H), 10.54 (s, 1H). The chemical structures of the compounds of the present invention described above are shown below.

[Formulation Examples] Typical formulation examples of the compounds of the present invention are shown in the following. 1) Tablets (in 100 mg) Compound of the present invention 1 mg Lactose 66.4 mg Corn starch 20 mg Calcium carboxymethylcellulose 6 mg Hydroxypropyl cellulose 4 mg Magnesium stearate 0.6 mg The tablet of the formulation mentioned above is coated using 2 mg of a coating agent (for example, a conventional coating agent such as hydroxypropylmethylcellulose, macrogol or a silicone resin), whereby the desired coated tablet is obtained. In addition, a desired tablet can be obtained by appropriately changing the classes or amounts of the compound of the present invention or the additives. 2) Capsule Formulation 2 (in 150 mg) Compound of the present invention 5 mg Lactose 145 mg The capsule that is desired can be obtained by appropriately changing the mixing ratio of the compound of the present invention to lactose. 3) Ophthalmic solution - Formulation 3 (in 100 ml) Compound of the present invention 100 mg Sodium chloride 900 mg Polysorbate 80 200 mg Sodium hydroxide as long as it is sufficient Hydrochloric acid as long as it is sufficient Sterile purified water when sufficient A desired ophthalmic solution can be obtained by appropriately changing the classes or amounts of the compound of the present invention or the additives.

[Pharmacological tests] 1. Evaluation test of the inhibitory effect of angiogenesis As one of the methods widely used to evaluate the inhibitory effects of angiogenesis of drugs, it has been reported in Cancer Res., 59, 99-106 (1999) a cell proliferation inhibitory action test using a VEGF-induced HUVEC proliferation reaction evaluation system. According to the method described in the aforementioned document, the cell proliferation inhibiting action test of the compounds of the present invention is carried out, the rate of inhibition of cell proliferation is calculated and the inhibitory effect of angiogenesis of cells is evaluated. each of the compounds of the present invention using the rate obtained as an index. (Preparation of the test compound solution) Each test compound is dissolved in dimethyl sulfoxide (hereinafter abbreviated as DMSO) and the resulting solution is diluted with a commercially available phosphoric acid buffer solution. (hereinafter abbreviated as PBS), whereby a 20 μg / ml test compound solution is prepared. (Preparation of the suspension (HUVEC) HUVEC is suspended in 0.5% fetal bovine serum (hereinafter abbreviated as F12K medium containing FBS) so a HUVEC suspension is prepared. 2 x 104 cells / ml. (Preparation of the VEGF solution) VEGF is dissolved in PBS containing 0.1% bovine serum albumin and the resulting solution is diluted with the F12K medium containing 0.5% FBS, whereby a 400 ng / ml VEGF solution is prepared. (Test method and measurement method) 1) The HUVEC suspension is inoculated in an amount of 100 μl in each well of a 96-well plate coated with type I collagen (2 x 103 cells per well). 2) One day after the inoculation, the solution of the test compound is added in an amount of 5 μl per well. 3) One hour after the addition of the test compound solution, the VEGF solution is added in an amount of 5 μl per well. 4) Three days later, from the addition of the VEGF solution, the test set WST-8 is added (Dojin Chemical Co., Ltd.) in an amount of 10 μl per well. 5) After 3 hours, the plate mentioned above is attached to an absorber (Multilabel Counter ARVO) and the absorbance at 450 nm of each well suspension (hereinafter referred to as suspension of the test compound) is measured. 6) A test is carried out in the same manner as in items 1) to 5) above except that 1.0% DMSO is used instead of the test compound solution. The result is used as a control. The incubation is carried out under conditions of 37 ° C, 5% carbon dioxide and 95% oxygen in an incubator through the test stages mentioned above. (Calculation of the rate of inhibition of cell proliferation) The speed (%) of inhibition of cell proliferation is calculated, which is used as an index of an inhibiting effect of angiogenesis, according to the following calculation equation.

(Calculation equation) Rate of inhibition of cell proliferation (%) = 100 -. { (Absorbance of test compound suspension -A) / (Absorbance of control - A)} x 100 A: Absorbance of only the cell suspension (cell + medium) (Test and discussion results) As an example of the test results, Table 1 shows the speeds (%) of inhibition of cell proliferation of the test compounds (Compound 1-1, Compound 1-2, Compound 1-3, Compound 1-4, Compound 1-5, Compound 1-6, Compound 1-10, Compound 1-11, Compound 1-20, Compound 2-1 , Compound 2-2, Compound 2-3, Compound 2-4, Compound 2-5, Compound 2-6, Compound 2-7, Compound 2-24, Compound 3-1, Compound 3- 2, Compound 3-3 , Compound 3-4, Compound 3-5, Compound 3-6, Compound 3-7, Compound 3-8, Compound 3-9, Compound 3-10, Compound 3-13, Compound 3-20, Compound 3-21, Compound 3-28, Compound 4-1, Compound 4-2, Compound 4-3, Compound 4-4, Compound 4-5, Compound 4-6, Compound 4-10, Compound 4-11, Compound 4-12, Compound 4-22, Compound 4-37, Compound 4-42, Compound 4-44, Compound 4-56, Compound 4-57, Compound 5-1, Compound 5-2, Compound 5-3, Compound 6-1, Compound 8-1, Compound 9-1, Compound 9-2, Compound 9-3, Compound 9-4, Compound 10-1, Compound 11-2, Compound 12-1, Compound 12-2, Compound 12-3, Compound 12-5, Compound 12-6, Compound 12-7, Compound 12-9, Compound 12-10, Compound 12-11, Compound 12-12, Compound 12-13, Compound 12-15, Compound 12-16, Compound 13-4, Compound 13-5, Compound 13-7, Compound 17-2, Compound 17-4, Compound 17-5, Compound 17-6, Compound 17-10, Compound 17-11, Compound 17-14, Compound 17-23, Compound 17-26, Compound 17-28, Compound 17-31, Compound 17-34, Compound 17-35, Compound 17-36, Compound 17-40, "Compound 17-46, Compound 17-47 , Compound 17-48, Compound 17-49, C Compound 17-50, Compound 17-52, Compound 17-58, Compound 17-66, Compound 17-71, Compound 17-72, Compound 17-73, Compound 17-84, Compound 17-85, Compound 17-86 and Compound 18-1).

Table 1 As shown in Table 1, the compounds of the present invention exhibit an excellent cell proliferation inhibiting action. Accordingly, the compounds of the present invention have an excellent angiogenesis inhibiting effect. 2. Anticancer Effect Evaluation Test As one of the methods widely used to evaluate anticancer effects of drugs, a test of tumor growth inhibitory action using one of the following methods has been reported in Cancer Res., 59, 5209-5218 (1999). cancer models in mice. According to the method described in the aforementioned document, a tumor growth inhibitory action test of the compounds of the present invention is performed, the tumor tissue weight inhibition rate is calculated, and the anticarcinogenic effect is evaluated. of each of the compounds of the present invention using the rate obtained as an index. (Preparation of the suspension of the test compound) A 1% aqueous solution of methylcellulose is added to each test compound to suspend it with a sonicator, whereby a suspension of test compound of 10 mg / ml is prepared. (Preparation of B16 cell suspension) Physiological saline is added to B16 cells, whereby a suspension of B16 cells of 3.3 x 10 7 cells / ml is prepared. (Test method and measurement method) 1) The back of each mouse is shaved (female, 6 weeks of age, C57BL / 6N mice) using an epilator under nembutal anesthesia. 2) Several days after depilation, 300 μl of a suspension of B16 cells is injected intradermally in the back of the mouse, under anesthesia with Nembutal. 3) From the day of injection of B16 cells (ie, on day 0) to day 10, a suspension of the test compound (100 mg / kg / day) is administered orally, once a day, consecutively. ). 4) Days after the injection of the cells, the mice are killed with gaseous C02. 5) The tumor tissue is removed from the mouse and the weight of the tumor tissue is measured with an electronic balance. 6) A test is performed in the same manner as in items 1) to 5), except that a 1% aqueous solution of methylcellulose is used instead of the suspension of the test compound, and the result is used as a control. (Calculation of inhibition rates in tumor tissue weight) A tumor tissue weight inhibition rate (the average of 9 mice per group), which is used as an anticancer effect index, is calculated according to the following calculation equation. (Calculation equation) Rate (%) of tumor tissue weight inhibition = 100 - (Mx / Mo) x 100 Mo: Weight of tumor tissue of the control group Mx: Weight of the tumor tissue of the test compound solution of the administration group (Test results and discussion) As an example of the test results, Table 2 shows the rates (%) of tumor tissue weight inhibition of the test compounds (Compound 1-4, Compound 1- 6, Compound 3-1, Compound 3-2, Compound 3-6, Compound 3-8, Compound 3-10, Compound 3-20, Compound 4-1, Compound 4-2, Compound 4-10, Compound 4- 11, Compound 4-14, Compound 4-16, Compound 4-20, Compound 4-43, Compound 4-56, Compound 4-59, Compound 9-1, Compound 10-1, Compound 10-2, Compound 11- 2, Compound 12-1, Compound 12-2, Compound 12-3, Compound 12-5, Compound 12-7, Compound 12-9, Compound 12-11, Compound 12-12, Compound 12-15, Compound 13- 7, Compound 17-2, Compound 17-5, Compound 17-10, Compound 17-11, Co Item 17-14, Compound 17-23 and Compound 17-35). Table 2 As shown in Table 2, the compounds of the present invention show an excellent tumor growth inhibitory action. Accordingly, the compounds of the present invention have an excellent anticancer effect. 3. Evaluation test of the antiarthritic effect As one of the widely used methods for evaluating antiarthritic effects of drugs, the test for the inhibitory action of edema of the paw plant using models of adjuvant arthritis in rats is known. Consequently, an inhibitory action test of edema of the paw of the compounds of the present invention is performed, the rate of inhibition of edema of the plant of the paw is calculated and the antiartritic effect of each of the compounds of the paw is evaluated. the present invention using the rate obtained as an index. (Preparation of the suspension of the test compound) An aqueous solution of methyl cellulose 1% is added to each test compound to suspend it, whereby a suspension of a compound of 2 mg / ml is prepared. (Preparation of adjuvant) Liquid paraffin is added to Mycobacterium butyricum to suspend it, so 6 mg / ml of adjuvant is prepared.

.- (Experiment method) 1) 0.1 ml of adjuvant is injected subcutaneously into the sole of the plant of the left hind leg of each rat (male, 9 weeks old, Lewis rat) to induce arthritis. 2) From the day of adjuvant injection (ie, on day 0) to day 20, the suspension of the test compound (10 mg / kg / day) is orally administered once a day, consecutively. 3) On the day of injection of the * adjuvant, the day 1, day 4, day 7, day 11, day 14, day 18 and day 21, is measured with a plethysmometer the volume of each one of the plants of the leg, of both hind limbs. 4) A test is performed in the same manner as in items 1) to 3), except that 1% aqueous methylcellulose solution is used instead of the suspension of the test compound and the result is used as a control. (Evaluation method) The rate of inhibition of edema in each plant of the leg of the edema generated in the plant of the paw in the plant of the leg not treated with adjuvant is calculated. (secondary inflammation in the paw plant) in each test compound administration group with respect to edema of the paw plant in a secondary inflammation in the paw plant in a control group, and the antiarthritic effect of each of the compounds of the present invention using the rate obtained as an index. (Calculation of the rate of inhibition of edema of the paw plant) The rate of edema in the paw plant is calculated according to the following calculation equation 1 and then calculated, according to the calculation equation 2 the rate of inhibition of edema in the paw plant (the average of 8 rats per group), which is used as an index of the antiarthritic effect. (Calculation equation 1) Rate of edema in the paw plant (%) = (Volume in the paw plant after adjuvant / volume treatment in the paw plant before adjuvant treatment) x 100 (Equation of calculation 2) Rate of inhibition of edema in the plant of the leg (%) = 100 -. { (Sx - 100) / (So - 100)} x 100 So: Rate of edema in the plant of the leg in the control group Sx: Rate of edema in the plant of the leg of the group to which a suspension of the test compound is administered (Test and discussion results) an example of the test results, Table 3 shows that the rates of inhibition of edema in the paw plant (%) on day 21 of the test compounds (Compound 3-1, Compound 3-6, Compound 3 -8, Compound 3-10, Compound 4-1, Compound 4-10, Compound 4-11, Compound 9-1, Compound 10-1, Compound 10-2, Compound 12-1 and Compound 12-2).

Table 3 As shown in Table 3, the compounds of the present invention exhibit an excellent edema inhibitory action in the paw plant. Accordingly, the compounds of the present invention have an excellent antiarthritic effect. 4. Evaluation test for the inhibitory effect of choroidal neovascularization As one of the examples widely used to evaluate the inhibitory effects of choroidal neovascularization in medications, an incidence test of neovascularization using neovascularization, choroidal models in rats, as reported in Graefe 's Arch. Cli. Exp. Ophthalmol., 235, 313-319 (1997). According to the method described in the aforementioned document, an incidence test of neovascularization of the compounds of the present invention is performed, the proportion of the incidence rate of neovascularization of each of the compounds of the administration groups is calculated. of the present invention with respect to the incidence rate of neovascularization of a group administered vehicle (control group) and the inhibitory effect of choroidal neovascularization of each of the compounds of the present invention is evaluated using the ratio obtained as a index. (Preparation of the test compound solution) To each test compound is added a solution of aqueous methylcellulose 1% to suspend it, whereby a suspension of 6 mg / 10 ml of test compound is prepared.

(Preparation of the laser-induced choroidal neovascularization model in rats) 1) A mixed solution 7: 1 (1 ml / kg) of injection of 5% ketamine hydrochloride and an injection of 2% xylazine hydrochloride intramuscularly into rats is administered (male Brown Norway rats, 8 weeks old, weighing: 200 to 250 g) to anesthetize them systemically. 2) It is instilled in the eyes to cause mydriasis, an ophthalmic solution of tropicamide-phenylephrine hydrochloride (trade name: Mydrin-P) and then photocoagulation is performed on a Bruch membrane of each rat using a krypton laser photocoagulation apparatus. Laser photocoagulation is performed with 8 points per eye that scarcely prevent thick retinal vessels in a posterior section of the ocular fundus and that focus on the deep layer of the retina. The photocoagulation conditions are adjusted to 100 μm of the spot size, an intensity of 100 mW and a duration of 0.1 sec. 3) After photocoagulation, the ocular fundus is photographed to confirm the photocoagulation sites (laser irradiation). (Test method and measurement method) 1) From the day of laser photocoagulation (ie, on day 0) to day 6, the suspension of the test compound (30 mg / kg / day) is administered orally once a day for 7 consecutive days. 2) With respect to the vehicle administration group (control group), the test is carried out in the same manner as in item 1) except that a 1% aqueous solution of methylcellulose is used instead of the suspension of the test compound and use the result as a control. (Evaluation method) 1) On day 7 after photocoagulation, 0.1 ml of a 10% fluorescein aqueous solution is injected into the tail vein of the rat and the fluorescein background photograph is taken. 2) In the fluorescein background photograph a point where no fluorescence leakage is observed is considered as negative and a point where fluorescence leakage is observed is considered positive. Photocoagulation sites where little fluorescence leakage is observed are considered as positive when two such sites are present. 3) The incidence rate of neovascularization is calculated according to equation 1 of calculation. The proportion of the neovascularization incidence rate of the group to which the test compound is administered with respect to the group to which the vehicle is administered is calculated according to equation 2 of calculation using the neovascularization incidence rate of the groups of respective administration. (Calculation equation 1) Neovascularization incidence rate (%) = (Number of sites with positive photocoagulation / number of sites with total photocoagulation) x 100 (Calculation equation 2) The ratio of the neovascularization incidence rate of the group to the that the test compound is administered with respect to that of the group to which the vehicle is administered (control group) (% control) = Ax / Ao x 100 Ao: Neovascularization incidence rate of the group to which the vehicle is administered ( control group) Ax: Neovascularization incidence rate of the group to which the test compound is administered (Test and discussion results) As an example of the test results, Table 4 shows the proportions (% control) of the rates of incidence of neovascularization of the administration groups of the test compound (Compound 1-6, Compound 3-1, Compound 3-8, Compound 3-10, Compound 4-1, Compound 4-10, Compound 4-11, Compound 4-20 , Compound 9-1, Compound 10-1, Compound 10-2, Compound 11-2, Compound 12-1, Compound 12-2, Compound 12-5, Compound 12-10 and Compound 17-5) with respect to the group of vehicle administration (control group Table 4 (The values are the average of 3 to 4 rats and 6 to 8 eyes) As shown in Table 4, the compounds of the present invention exhibit a lower neovascularization incidence rate compared to that of the vehicle and have an inhibitory effect of choroidal neovascularization.

INDUSTRIAL APPLICABILITY The novel cyclic compound according to the present invention has an excellent inhibitory effect of cell proliferation, a tumor growth inhibitory effect, an inhibitory effect of edema on the paw plant or an inhibitory effect of choroidal neovascularization and is useful as a therapeutic agent for a disease in which cell angiogenesis or hyperpermeability is involved, for example cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, prematurity retinopathy, retinal vein occlusion, polypoid choroidal angiopathy, edema macular diabetic, psoriasis vulgaris, atherosclerosis or similar.

Claims

1. Compound represented by the following general formula (1) (wherein ring A represents a benzene ring or an aromatic five-membered heterocyclic ring or an aromatic six-membered heterocyclic ring which may be fused to a cycloalkane ring; R1 and R2, which are the same or different, represent an atom of hydrogen, a hydroxy group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a heterocyclic ring substituted or unsubstituted, an amino group, a substituted or unsubstituted alkylamino group, a substituted or unsubstituted arylamino group or a substituted or unsubstituted acyl group; R1 and R2 can be joined to form a substituted or unsubstituted heterocyclic ring; R3 and R4, which are the same or different, represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a hydrocarbonyl group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted arylcarbonyl group or Z-R5; R3 and R4 together can form a substituted or unsubstituted heterocyclic ring; Z represents CO, CS, C0B20, CSB0, C0NB2Rs, CSB2NR6, CONB2R6S02, CSB2NRsS02 or S02; Rs represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a heterocyclic ring substituted or unsubstituted, a carboxy group or an ester thereof or an amide thereof, a hydrocarbonyl group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted arylcarbonyl group, or a substituted or unsubstituted heterocyclic carbonyl group; R5 and R6 together can form a substituted or unsubstituted heterocyclic ring; R6 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; X and Y, which are the same or different, represent one or a plurality of groups selected from a hydrogen atom, a halogen atom, a hydroxy group, a substituted or unsubstituted alkoxy group, a substituted aryloxy group * substituted, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylamino group, a substituted or unsubstituted arylamino group, a mercapto group, a group unsubstituted or substituted alkylthio, a substituted or unsubstituted arylthio group, a carboxy group or an ester thereof, or an amide thereof, a cyano group and a nitro group; B1 represents an alkylene group; B2 represents a single bond or an alkylene group; p represents 0, 1 or 2; and q represents 0 or 1), or a salt thereof,

2. Compound represented by the following general formula (1): wherein ring A represents a benzene ring, a thiophene ring or a pyridine ring; R1 represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic ring; or in the case where R1 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from an aryl group, a hydroxyaryl group and an alkoxyaryl group; in the case where R1 is an aryl group, the aryl group may have one or a plurality of substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, a halogenoalkoxy group, a hydrocarbonyloxy group, an alkylcarbonyloxy group , an arylcarbonyloxy group, an alkyl group, a halogenoalkyl group and an aryl group; R2 represents a hydrogen atom, an alkyl group or an aryl group; or in the case where R2 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a carboxy group, an alkoxycarbonyl group and an aryloxycarbonyl group; R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring or Z-R5; or in the case where R3 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a hydroxy group, an alkoxy group, an aryloxy group, an amino group, an alkylamino group and an arylamino group; in the case where R3- * is a heterocyclic ring, the heterocyclic ring may have one or a plurality of cyano groups as substituents; R3 and R4 can be joined to form a heterocyclic ring; in the case where R3 and R4 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, a hydroxyalkyl group , an alkoxyalkyl group, an aryloxyalkyl group, an aryl group, an amino group, an alkylamino group, an arylamino group, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a hydrocarbonyl group, an alkylcarbonyl group, an arylcarbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group and an arylaminocarbonyl group, furthermore, the heterocyclic ring may have a carbonyl group in the ring; R4 represents a hydrogen atom, an alkyl group, an aryl group, a hydrocarbonyl group, an alkylcarbonyl group or an arylcarbonyl group; in the case where R 4 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of alkylcarbonyloxy groups as substituents; Z represents CO, CS, C0-B2-0, CS-B2-0, CO-B2-NR6, CS-B2-NR6, CO-B2-? ReS02, CS-B2-? RsS02 or S02; R5 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a hydrocarbyl group, a alkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, an aminocarbonyl group, an alkylaminocarbonyl group or an arylaminocarbonyl group; in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, a hydroxyalkoxy group, an alkoxyalkoxy group, an aryloxyalkoxy group , a cycloalkyl group, an aryl group, a heterocyclic ring, a carboxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a hydrocarbyl group, an alkylcarbonyl group, an arylcarbonyl group, an amino group, an alkylamino group, an arylamino group, an alkoxycarbonylamino group, an aryloxycarbonylamino group, a hydrocarbylamino group, a group alkylcarbonylamino, an arylcarbonylamino group, a mercapto group, an alkylthio group, an arylthio group and a cyano group; in the case where R5 is an aryl group, the aryl group may have one or a plurality of substituents of halogen atoms; in the case where R5 is a heterocyclic ring, the heterocyclic ring can have one or a plurality of substituents which are selected from an alkyl group and an aryl group; in the case where R5 is an alkylcarbonyl group, the alkylcarbonyl group can have one or a plurality of substituents which are selected from a carboxy group, a hydrocarbonyloxy group, an alkylcarbonyloxy group, an arylcarbonyloxy group, an amino group, an alkylamino group and an arylamino group; R5 and Re can be joined to form a heterocyclic ring; in the case where R5 and R6 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, a hydroxyalkyl group , an alkoxyalkyl group, an aryloxyalkyl group, a carbkoxy group, an alkoxycarbonyl group, an aryloxycarbonyl group, a carbonyl group, a hydrocarbonyl group, an alkylcarbonyl group and an arylcarbonyl group, furthermore, the heterocyclic ring may have a carbonyl group in the ring; Rs represents a hydrogen atom, an alkyl group or an aryl group; X and Y, which are the same or different, represent one or a plurality of groups selected from a hydrogen atom, a halogen atom and an alkyl group, B1 represents an alkylene group, B2 represents a single bond or an alkylene group, p represents 0, 1 or 2, and q represents 0 or 1), or a salt thereof

3. Compound as described in claim 2, wherein in general formula (1), ring A represents a benzene ring, a thiophene ring or a pyridine ring, R 1 represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic ring; in the case where R1 is an alkyl group, the alkyl group may have one or a plurality of alkoxyaryl groups as substituents; in the case where R1 is an aryl group, the aryl group may have one or a plurality of substituents that are selected from a halogen atom, a hydroxy group, an alkoxy group, a halogenoalkoxy group, an alkylcarbonyloxy group, an alkyl group and a halogenoalkyl group; R2 represents a hydrogen atom or an alkyl group; in the case where R2 is an alkyl group, the alkyl group may have one or a plurality of substituents that are selected from a carboxy group and an alkoxycarbonyl group; R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring or Z-R5; in the case where R3 is an alkyl group, the alkyl group may have one or a plurality of substituents that are selected from a hydroxy group and an alkylamino group; in the case where R3 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of cyano groups as substituents; R3 and R4 can be joined to form a heterocyclic ring; in the case where R3 and R4 join to form a heterocyclic ring, the heterocyclic ring can have __ one or a plurality of substituents that are selected from a hydroxy group, an alkyl group, a hydroxyalkyl group, an alkylamino group, a group alkoxycarbonyl, an alkylcarbonyl group and an alkylaminocarbonyl group, furthermore, the heterocyclic ring may have a carbonyl group in the ring; R4 represents a hydrogen atom, an alkyl group or an alkylcarbonyl group; in the case where R 4 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of alkylcarbonyloxy groups as substituents; Z represents CO, C0-B2-0, CO-B2-NR6, CS-B2-NRS, C0-B2-NR6S02 or S02; R5 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, a heterocyclic ring, an alkoxycarbonyl group, an alkylcarbonyl group, a heterocyclic carbonyl group or an alkylaminocarbonyl group; in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, an alkoxy group, a hydroxyalkoxy group, an alkoxyalkoxy group, a cycloalkyl group , a heterocyclic ring, a carboxy group, an alkoxycarbonyl group, an amino group, an alkylamino group, an alkoxycarbonylamino group, an alkylcarbonylamino group, an alkylthio group and a cyano group; in the case where R5 is an aryl group, the aryl group may have one or a plurality of halogen atoms as substituents; in the case where R5 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of alkyl groups as substitutents; in the case where R5 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of substituents which are selected from a carboxy group, an alkylcarbonyloxy group and an alkylamino group; R5 and Re can be joined to form a heterocyclic ring; in the case where R5 and R6 are joined to form a heterocyclic ring, the heterocyclic ring can have one or a plurality of substituents that are selected from a hydroxy group, an alkyl group, a hydroxyalkyl group, an alkoxycarbonyl group and a -group alkylcarbonyl, furthermore, the heterocyclic ring may have a carbonyl group in the ring; R6 represents a hydrogen atom or an alkyl group; X and Y represent a hydrogen atom, B1 represents an alkylene group; B2 represents a single bond or an alkylene group; p represents 0 or 1; and q represents 0, or a salt thereof. Compound as described in claim 2 or 3, wherein the general formula (1): ring A represents a ring 'benzene, a thiophene ring or a pyridine ring; R1 represents an aryl group or a heterocyclic ring; in the case where R1 is an aryl group, the aryl group may have one or a plurality of substituents which are selected from a halogen atom, a halogenoalkoxy group, an alkyl group and a halogenoalkyl group; R2 represents a hydrogen atom; R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group, a heterocyclic ring or Z-R5; in the case where R3 is a group, the alkyl group may have one or a plurality of alkylamino groups as substituents; in the case where R3 is a heterocyclic ring, the heterocyclic ring may have one or a plurality of cyano groups as substituents; R3 and R4 can be joined to form a heterocyclic ring; in the case where R3 and R4 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of substituents that are selected from an alkyl group and an alkylcarbonyl group; R4 represents a hydrogen atom or an alkyl group; Z represents CO, C0-B2-0, CO-B2-NRs, CO-B2-NRsS02 or S02; R? represents a hydrogen atom, an alkyl group, an aryl group, an alkylcarbonyl group or an alkylaminocarbonyl group; in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, a heterocyclic ring, an alkylamino group and an alkylcarbonylamino group; in the case where R5 is an aryl group, the aryl group may have one or a plurality of halogen atoms as substituents; in the case where R5 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of carboxy groups as substituents; R5 and Rs can be joined together to form a heterocyclic ring; in the case where R5 and R6 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of hydroxyalkyl groups as substituents; R6 represents a hydrogen atom or an alkyl group; X and Y represent a hydrogen atom; B1 represents an alkylene group; B2 represents a single bond or an alkylene group; p represents 0; and q represents 0, or a salt thereof. 5. A compound as described in any of claims 1 to 4, wherein in the general formula (1), the ring A represents a pyridine ring or a thiophene ring or a salt thereof. 6. Compound as described in claim 5, wherein in the general formula (1), the ring A represents a pyridine ring or a salt thereof. 7. Compound as described in any of claims 1 to 6, wherein in the general formula (1), a partial structure (C) is attached: and a partial structure (D) to adjacent carbon atoms in ring A, or a salt thereof. Compound as described in claim 5 or 6, wherein in the general formula (1), the partial structure (C) and the partial structure (D) are bonded to the adjacent carbon atoms in ring A, and in the positions of the carbon atoms they are in the position a and a position β with respect to a heteroatom in ring A, or a salt thereof. . Compound as described in any of claims 2 to 8, wherein in the general formula (1) R -, 3"re" "p_resen" 4t.a_ Z r, - rRv5; Z represents CO, CO-B2-0, -CO-B2-NRs or C0-B: NRbS02; R5 represents a hydrogen atom, an alkyl group, an aryl group, an alkylcarbonyl group or an alkylaminocarbonyl group; in the case where R5 is an alkyl group, the alkyl group may have one or a plurality of substituents which are selected from a halogen atom, a hydroxy group, a heterocyclic ring, an alkylamino group and an alkylcarbonylamino group; in the case where R5 is an aryl group, the aryl group can have one or a plurality of halogen atoms as substituents; in the case where R5 is an alkylcarbonyl group, the alkylcarbonyl group may have one or a plurality of carboxy groups as substituents; R5 and R6 can be joined to form a heterocyclic ring; in the case where R5 and R6 are joined to form a heterocyclic ring, the heterocyclic ring may have one or a plurality of hydroxyalkyl- groups as substituents; Re represents a hydrogen atom or an alkyl group; B2 represents a single bond or an alkylene group, or a salt thereof. 10. Compound selected from the group consisting of N- (3,5-dimethylphenyl) -2- [2- (4-methylpiperazin-1-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide 2 (2-cyclopropylaminopyridin-4) -ylmethylthio) -N (3,5-dimethylphenyl) pyridin-3-carboxamide 2 - [2- (N- (2-dimethylaminoethyl) -N-methylamino) -pyridin-4-ylmethylthio] -N (3,5-dimethylphenyl) ) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-morpholinopyridin-4-ylmethylthio) pyridin-3-carboxamide N- (3,5-dimethylphenyl) -2- [2- (piperidine- l-yl) pyridin-4-ylmethylthio] pyridine-3-carboxamide, 2 [2- [4-acetylpiperazin-1-yl) pyridin-4-ylmethylthio] -N (3,5-dimethylphenyl) pyridine-3-carboxamide N - (indan-5-yl) -2- (2-morpholinopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- [2- (4-acetylpiperazin-1-yl) pyridin-4-ylmethylthiol -? - (indan- 5-yl) pyridin-3-carboxamide? - (3,5-dimethylphenyl) -2- (2-n-pentylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine-3-carboxamide 2 (2-ester) -butoxycarbonylaminopyridin-4-methylmethyl) -N- (3-isopropylphenyl) pyridine-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (indan-5-yl) pyridin-3-carboxyamide 2- (2-tert-buttoxycarbonylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2 - . 2 - (2-tert-butoxycarbonylaminopyridin-4-methylmeththio) -N- (4-tert-butylphenyl) pyridine-3-carboxamide 2- (2-tert-butoxycarbonylaminopyridin-4-ylmethylthio) -N- (lH-indazole-6 -yl) pyridine-3-carboxamide 2- [2- (N-tert-butoxycarbonyl-N-methylamino) pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridin-3-carthoxamide 2- [2- (5-cyanothiazol-2-ylamino) pyridin-4-ylmethylthio] -? - (3, 5-dimethylphenyl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (3,5-dimethylphenyl) ) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (3-isopropylphenyl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (indan-5-yl) ) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (4-tert-butylphenyl) pyridin-3-carboxamide 2- [2-aminopyridin-4-ylmethylthio) -? - (lH-indazol-6) -yl) pyridine-3-carboxamide, N- (3, 5-dimethylphenyl) -2- (2-methylamino-pyridin-4-yl-ethylthio) pyridine-3-carboxamide? - (indan-5-yl) -2- (2 -methylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- (2-methylaminopyridin-4-ylmethyl) thio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -? - (isoquinolin-3-yl) pyridine-3-carboxamide 2- (2-aminopyridin-4-ylmethylthio) -?- (3, '5-dimethylphenyl) benzamide 2- (2-aminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) benzamide 3- (2-aminopyridin-4-ylmethylthio) -? - (3,5-dimethylphenyl) thiophene- 2-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (3,5-dimethylphenyl) pyridine-3-carboxamide? - (3,5-dimethylphenyl) -2- (2-propionylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3,5-dimethylphenyl) -2- (2-trifluoroacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3,5-dimethylphenyl) -2- (2-isobutyrylaminopyridin-4-) ilmethylthio) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-pivaloylaminopyridin-4-ylmethylthio) pyridine, 3-carboxamide? - (3,5-dimethylphenyl) -2- (2-trifluoromethanesulfonylaminopyridine- 4-ylmethylthio) pyridine-3-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) pyridine-3-carboxamide 2- [2-acetylaminopyridin-4-ylmethylthio) -? - (4- trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- [α-acetyl-β-methylamino) pyridin-4-ylmethylthio] -? (3,5-dimethylphenyl) pyridine-3-carboxamide 2- (2-a) cetylaminopyridin-4-ylmethylthio) -? - (1H-indazol-6-yl) pyridine-3-carboxamide 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (3, 5-dimethyl-4-hydroxyphenyl) pyridine- 3-carboxamide 2-2-acetylaminopyridin-4-ylmethylthio) -N- (4-chlorophenyl) benzamide 2- (2-acetylaminopyridin-4-ylmethylthio) -? - (4-tert-butylphenyl) -benzamide 3- (2-acetylaminopyridin-4) -ylmethylthio) -? - (3,5-dimethylphenyl) thiophene-2-carboxamide 3- (2-acetylaminopyridin-4-ylmethylthio) -? - (4-chlorophenyl) thiophene-2-carboxamide N- (3,5-dimethylphenyl) ) -2- [2- (N'-n-propylureido) pyridin-4-ylmethylthio] -pyridin-3-carboxamide 2- [2- (N 1 -ter-butylureido) pyridin-4-ylmethylthio] -N- (3 , 5-dimethylphenyl) -pyridin-3-carboxamide 2- [2- (N-4-chlorophenyl) -pyridin-4-ylmethylthio] -N- (3,5-dimethylphenyl) pyridine-3-carboxamide N- (3, 5 dimethylphenyl) -2- (2-formylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-phenylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide N- (3 , 5-dimethylphenyl) -2- [2- (N1-methylureido) pyridin-4-ylmethylthio] pyridin-3-carboxamide 2- [2- (N 1 -methylureido) pyridin-4-ylmethylltiol-N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (4-chlorophenyl) -2- [ 2- (N 1 -methylureido) pyridin-4-ylmethylthio] pyridin-3 -carboxamide N- (4-difluoromethoxyphenyl) -2- [2- [N 1 -methylureido) pyridin-4-methylmethyl] pyridine-3-carboxamide 2- ( 2-acetoxiacetilaminopiridin-4-ylmethylthio) -N- (3, 5-dimethylphenyl) pyridine-3-carboxamide 2- (2-acetoxiacetilaminopiridin-4-ylmethylthio) -N- (4 -trifluorometoxifenil) pyridine-3-carboxamide 2- ( 2-aminoacetylaminopyridin-4-ylmethylthi?) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide 2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (4-chlorophenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide? (3, 5-dimethyl-4-hydroxyphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- (2-hidroxiacetilaminopiridin-4-ylmethylthio) -? - (3-methylphenyl) pyridine-3-carboxamide 2- (2-hidroxiacetilaminopiridin-4-ylmethylthio) -? - (4-trifluoromethylphenyl) pyridine-3-carboxamide 2- (2 -Hydroxyacetylaminopyridin-4-ylmethylthio) -? - (isoquinolin-3-yl) pyridine-3-carboxamide? - (3-chlorophenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- (2 -hydroxyacetylaminopyridin-4-ylmethylthio) -? - (indan-5-yl) pyridine-3-carboxamide? - (3-chloro-4-trifluoromethoxyphenyl) -2- (2-hydroxyacetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- (2-hidroxiacetilaminopiridin-4-ylmethylthio) -? - (3-isopropylphenyl) pyridine-3-carboxamide - (4 -difluorometoxifenil) -2- (2-hidroxiacetilaminopiridin-4 -ilmetiltio) pyridine-3-carboxamide 2- (2-hidroxiacetilaminopiridin-4-ylmethylthio) -N- (3-trifluoromethylphenyl) pyridine-3-carboxamide 2- [2- (3-hidroxicarbonilpropioniloxi) -acetilaminopiridin-4-ilmetiltiol-N- (4-trifluoromethoxyphenyl) pyridine-3- N- (3, 5-dimethylphenyl) -2- carboxamide (2-Acetylaminopyridin -metansulfonilamino-4-ylmethylthio) pyridine-3-carboxamide 2- (2-dimetilaminocarboniloxiacetilaminopiridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-isopropilaminoacetilaminopiridin-4-ylmethylthio ) -N- (4-trifluoromethoxyphenyl) pyridine-3'-carboxamide 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N- (3, 5-dimethyl-phenyl) pyridine-3-carboxamide 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- (2-morpholineacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine- 3-carboxamide 2- [2- (2-morpholinyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (3-hydroxypropyl) aminoacetylaminopyridin-4-ylmethylthio] -N - (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (4-chlorophenyl) -2- [2- (2-dimethylaminoethyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide 2- (2-Aminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (N- (2-dimethylaminoethyl) -N-methylamino) -acetylaminopyridin-4-ylmethylthio] - N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (2-hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide 2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- (2-dimethylamino-acetylaminopyridin-4-ylmethylthio) pyridin-3-carboxamide 2- [2- (2-acetylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4 - trifluoromethoxyphenyl) pyridine-3-carboxamide N- (4-chlorophenyl) -2- [2- (piperazin-1-yl) acetyl-aminopyridin-4-ylmethylthio] pyridine-3-carboxamide 2- [2- (2 - hydroxyethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (3-methylphenyl) pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (2-hydroxyethyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide 2- [2- (2-acetylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- ( 4-difluoromethoxyphenyl) pyridine-3-carboxamide N- (4-difluoromethoxyphenyl) -2- [2- (N- (2-dimethylaminoethyl) -N-methylamino) acetylaminopyridin-4-ylmethylthio] pyridine-3-carboxamide 2- [2 - (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (4-trifluoromethylpheni) l) pyridine-3-carboxamide 2- [2- (4- (2-hydroxyethyl) piperazin-1-yl) acetyl-aminopyridin-4-ylmethylthio] -N- (4-trifluoromethoxyphenyl) -pyridine-3-carboxamide N- (4-Difluoromethoxyphenyl) -2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide N- (4-difluoromethoxyphenyl) -2- (2-isopropylamino-acetylaminopyridin-4-ylmethylthio) pyridine-3-carboxamide 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridin-4-ylmethylthio] -N- (3, 5-dimethylphenyl) pyridin-3-carboxamide N- (3,5-dimethylphenyl) -2- (2 -isopropylaminoacetyl-aminopyridin-4-ylmethylthio) pyridine-3-carboxamide N- (3, 5-dimethylphenyl) -2- [2- (3-hydroxypropyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide N- (3 , 5-dimethylphenyl) -2- [2, (2-morpholinyl) -aminoacetylaminopyridin-4-ylmethylthio] pyridin-3-carboxamide 2- (2-ethylaminoacetylaminopyridin-4-ylmethylthio) -N- (4-trifluoromethoxyphenyl) pyridine-3 -carboxamide 2- (2-aminoacetylaminopyridin-4-ylmethylthio) -N- (4-difluoromethoxyphenyl) pyridine-3 -carbox amide 2- (3-aminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridin-3-carboxamide 2- (3-acetylaminopyridin-4-ylmethylthio) -N- (3,5-dimethylphenyl) pyridine- 3-carboxamide N- (3, 5-dimethylphenyl) -2- (2-morpholineacetylamino-pyridin-4-ylmethylthio) pyridin-3-carboxamide 2- [2- (3-dimethylaminopropyl) aminoacetylamino] pyridin-4-ylmethylthio ] -N- (4-trifluoromethoxyphenyl) -pyridine-3-carboxamide 2- (2-dimethylaminoacetylaminopyridin-4-ylmethylthio) -N- (3-methylphenyl) pyridine-3-carboxamide 2- [2- (2-dimethylaminoethyl) aminoacetylaminopyridine -4-ylmethylthio] -N- (3-methylphenyl) pyridine-3-carboxamide N- (3-methylphenyl) -2- [2- (piperazin-1-yl) acetyl-aminopyridin-4-ylmethylthio] pyridin-3- carboxamide 2- [2- (piperazin-1-yl) acetylaminopyridin-4-ylmethylthio] -N, (4-trifluoromethylphenyl) pyridin-3-carboxamide, And N- (4-difluoromethoxyphenyl) -2- [2- (N- (2-hydroxyethyl) -N-methylamino) acetylaminopyridin-4-ylmethyl] pyridine-3-carboxamide, OR a salt thereof. 11. A pharmaceutical composition comprising the compound or a salt thereof as described in any of claims 1 to 10 as an active ingredient. 12. Therapeutic agent for a disease in which angiogenesis or vascular hypermeability is involved, which comprises the compound or a salt thereof as described in any of claims 1 to 10 as an active ingredient. 13. Therapeutic agent as described in claim 12, wherein the disease in which angiogenesis or increased vascular permeability is involved is cancer, rheumatoid arthritis, age-related macular degeneration, diabetic retinopathy, premature retinopathy, occlusion of the retinal vein, polypoid choroidal angiopathy, diabetic macular edema, vulgar psoriasis or atherosclerosis.